Sub-Unit Vaccines for <i>Brucella</i> by Jenner, Dominic Charles
Open Research Online
The Open University’s repository of research publications
and other research outputs
Sub-Unit Vaccines for Brucella
Thesis
How to cite:
Jenner, Dominic Charles (2009). Sub-Unit Vaccines for Brucella. PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2009 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
31 03330377 
11111111111111111111111111111111111111111 uN1 ciRcc. -i6 
Sub-Unit Vaccines for Brucella 
Dominic Charles Jenner, BSc (Hons) 
This work was completed at the Defence Science and 
Technology Laboratory, Porton Down, Salisbury, UK. 
A thesis submitted to the Open University for the 
degree of Doctor of Philosophy in the discipline of 
Infectious Disease and Vaccine Development, May 2009 
© Crown Copyright. Dstl 2009. 
ýz, *wýrs, a--, CII r-^ý 2009 
ýOkc t7 Sapp. 2v`ß 
Abstract 
Brucella species are the causative agents of brucellosis, which is regarded as the world's most 
prevalent zoonotic disease. Brucellosis is endemic to the Middle East, Mexico, Asia, South 
America and the Mediterranean and causes significant economic losses in livestock in these 
areas of the world, as well as being a reservoir for human brucellosis. Although there are live 
attenuated vaccines available for brucellosis, they have many drawbacks when used in animals, 
and are still infectious to humans. It is clear from this that there is a need for a new effective 
vaccine for brucellosis for both animal and human use. 
There are increasing instances of ATP-binding cassette (ABC) systems being identified as 
virulence factors or potential vaccine candidates. In this study inventories of all the ABC 
systems encoded by five sequenced Brucella strains were compiled. These inventories were 
compared and differences have been found that could aid in the identification of virulence 
factors of Brucella. This study also explores the potential of ATP-binding cassette transporters 
as sub-unit vaccines against Brucella melitensis 16M. Eight ABC transporter proteins (PotD, 
PotF, Cgt, CydD, LolE, FbpA, OppA and ZnuA) have been produced using recombinant protein 
technologies, and their protective efficacy was evaluated in a number of studies using the 
murine model of B. melitensis infection. Of the eight vaccine candidates selected two have 
shown potential as novel vaccines against brucellosis. PotD and PotF are putative polyamine 
binding proteins of Brucella and show protection against experimental challenge of 
approximately 1x104 CFU of B. melitensis 16M when expressed by DNA vaccines or used in a 
PotD/PotF combination vaccine. Through this work a duel adjuvant system (ISCOMs and CpG) 
has been identified as a more effective adjuvant for Brucella vaccines than others previously 
used. 
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Chapter 1- Introduction 
1.1 Brucella 
The first official isolation of Brucella was achieved by David Bruce in 1887 [34]. Earlier reports 
describe outbreaks of animal abortions of epidemic proportions that could have been attributed 
to Brucella infections [127]. There is evidence of Brucella being discovered in two thousand year 
old cheese [43] and there are suggestions that Florence Nightingale died from brucellosis 
[84,21,367]. In both animals and humans Brucella species are the causative agents of 
brucellosis, also known as Malta fever or undulant fever [67]. The bacteria are small (0.5-0.7 pm 
diameter, 0.6-1.5 pm length) non-motile, gram-negative, non-spore forming coccobacilli that are 
part of the sub-phylum a2-proteobacteria, which also includes nitrogen-fixing bacteria of the 
genus Nitrobacter, Rhizobium, Agrobacterium and Rickettsia [249]. Brucella species are 
described as facultative intracellular pathogens. There are currently nine (B. melitensis, B. suis, 
B. abortus, B. canis, B. ovis, B. neotomae, B. pinnipedialis, B. ceti and B. micron) recognised 
species of Brucella and their differences are determined by their host preferences (see section 
1.1.1). 
Growth of Brucella species can be achieved on many different types of media, such as serum 
dextrose agar (SDA), glycerol dextrose agar (GDA), Farrell's antibiotic medium or commercially 
available media such as chocolate agar (Becton Dickinson). Although Brucella species will 
growth at a range of temperatures between 20 and 40 °C their optimal growth occurs at 37°C. 
Only two Brucella species (B. abortus and B. ovis) require supplementary CO2 for optimal 
growth. Different biovars of Brucella species can be distinguished experimentally by identifying 
different growth properties including: CO2 requirement, Hydrogen Sulphide production and by 
looking at their serological properties [2041. 
1.1.1 Animal brucellosis 
In animals brucellosis is a non-lethal infection that predominantly causes infectious abortions in 
females and orchitis in males. The route of animal infection is via the mouth, eyes, nose and 
skin if open. Once inside the animal host, the Brucella are phagocytosed by macrophages and 
trafficked through the regional lymph nodes to placental trophoblasts in the females and the 
testis in males [237]. Brucella's ability to preferentially utilise erythritol rather than other carbon 
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sources was once thought to be the reason for its quick colonisation of the female reproductive 
tract in ruminants as they have high levels of erythritol in this area [96]. However, Brucella also 
colonises the reproductive tracts of rodents, which only have trace amounts of erythritol in their 
tissues [96]. 
The control of animal brucellosis is paramount in reducing the incidence of human brucellosis. 
Many areas of the world that are brucellosis-free have strict control programs and mandatory 
pasteurisation of all milk products. Successful eradication of brucellosis depends upon strong 
regulation and diagnostic testing of live stock to prevent spread and to control the disease [245]. 
1.1.1.1 Brucella melitensis 
The natural hosts of Brucella melitensis are goats and sheep, in which it causes infectious 
abortions. B. melitensis is considered the least host-specific of the Brucella species and can 
sometimes infect other animals including dogs and camels [369]. It is highly pathogenic to 
humans and is thought to be one of the world's most prevalent zoonotic diseases. B. melitensis 
was the first of the Brucella species to be isolated by David Bruce in 1887, isolated from a 
patient's splenic tissue and originally called Micrococcus melitensis [67]. In 1917 the name was 
changed to Brucella in honour of Bruce. According to the International Committee on 
Systematics of Prokaryotes - Subcommittee on the taxonomy of Brucella (ICSP) there are three 
recognised biovars of B. melitensis; B. melitensis 16M, B. melitensis 63/9 and B. melitensis 
Ether. 
1.1.1.2 Brucella suis 
There are five different biovars of Brucella suis, which are categorised according to their 
microbiological phenotypic characteristics. Brucella suis strains 1330, Thomsen, and 686 can 
cause infections in wild and domesticated swine, whereas B. suis strains 40 and 513 infect 
reindeer and murine species, respectively. In female swine B. suis causes miliary brucellosis of 
the uterus leading to infectious abortions, and spreads rapidly between animals [237]. All of the 
B. suis strains, with the exception of Thomsen, have been found to cause disease in humans, 
although to a lesser degree than B. melitensis. The first description of brucellosis in swine was 
by Traum in 1914, but it was not named as a separate species until 1931 by Huddleson [140]. 
Infection of pigs with B. suis results in an acute disease characterised by abortions, infertility, 
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orchitis, epididymitis and arthritis. B. suis also causes frequent abscesses in infected organs 
and tissues along with the onset of spondylitis [6]. 
1.1.1.3 Brucella abortus 
The natural host of Brucella abortus is cattle. In 1897 Bernhard Bang, a Danish veterinarian 
isolated Brucella abortus as the agent that caused brucellosis in cattle, bison, water buffalo and 
African buffalo. Although B abortus host preference is cattle, there have been reports of B. 
abortus infections in camels [5]. Infection with B. abortus occurs through exposure to infectious 
abortions during calving or when an abortion occurs. B. abortus is also able to infect and cause 
disease in humans although the disease caused is considered less severe than that of B. 
melitensis [237]. The geographical distribution of B. abortus is still widespread however, there 
are countries that have effectively eradicated bovine brucellosis (defined as the absence of any 
reported cased in the last five years). These countries include, Australia, Canada, Cyprus, 
Denmark, Finland, The Netherlands, New Zealand, Norway, Sweden and the United Kingdom 
[293]. It is difficult to assess the natural incubation time of B. abortus in infected cattle as it is 
not possible to determine the exact moment of infection. In female cattle the predominant 
symptom is abortion, whereas in bulls Brucella localise in the testicles causing enlargement [6]. 
1.1.1.4 Brucella canis 
The natural host species for Brucella canis is the dog. B. canis was first isolated from aborted 
pups in pregnant beagles by Carmichael in 1966 [44]. Most canine Brucella infections are 
acquired though the consumption of infected milk, or contact with infectious vaginal secretions 
and male urine or semen [346,237]. Routes of entry into the body include the genitals, the nose 
or the eyes. Infection with Brucella often results in the end of the dog's breeding career. Dogs 
infected with B. canis present with a range of symptoms including infectious abortions, 
bacteraemia, prostatitis, epididymitis, scrotal dermatitis, lymphadenitis and splenitis [6]. 
Although primarily a pathogen of the dog, B. canis can occasionally infection humans with mild 
symptoms [344,197,198]. 
1.1.1.5 Brucella ovis 
The sheep is the natural host of Brucella ovis. It predominately causes testicular complications 
such as genital lesions leading to low fertility in rams, whereas ewes appear relatively resistant, 
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although they do suffer from occasional abortions. Rams often shed Brucella in their semen 
during early infection but over time the numbers decrease [61 B. ovis was first isolated from 
sheep in New Zealand by MacFarlane et al. in 1950 [2151, and was given its name by Buddle in 
1955 [37,36]. There are no documented cases of B. ovis infections in humans. 
1.1.1.6 Brucella neotomae 
The natural host of Brucella neotomae is the wood rat. B. neotomae was first identified by 
Stoenner and Lackman in 1957 [308], and has only ever been isolated from wood rats. 
1.1.1.7 Brucella pinnipedialis and Brucella ceti 
Brucella pinnipedialis and Brucella ceti are relatively new species in the Brucella field. B. 
pinnipedialis was isolated by Ewalt et al. in 1994 from a bottlenose dolphin [97]. Its primary 
hosts are seals, sea lions, and walruses. Brucella ceti was isolated from North sea seals and 
cetacean populations in 1996 by Ross et al. [280]. There have been three reported cases of 
human infection from marine mammal Brucella species; one report was a laboratory worker with 
clinical signs of brucellosis [32], the second was two patients from Peru diagnosed with 
neurobrucellosis caused by marine mammal strains [301] and the third was from a patient in 
New Zealand infected with a Brucella strain originating from the United States of America [212]. 
1.1.1.8 Brucella microti 
Brucella microti is the most recently identified Brucella species. Originally isolated from the 
common vole Microtus arvalis [289], it has also been identified in soil samples [288] and in wild 
red foxes located in lower Austria [287]. 
1.1.2 Brucella genome comparisons 
Of all the Brucella species/strains there are currently nine sequenced strains (available at 
http: //patric. vbi. vt. edu/) : B. melitensis 16M [78], B. abortus 9-941 [128], B. suis 1330 [258], B. 
ovis 63/290 [323], B. canis RM6/66, B. abortus 2308, B. suis Thomsen (biovar 2), B. melitensis 
63/9, B. abortus S19. The characteristics of the Brucella genomes are very similar, with the 
exceptions of B. suis biovars 2,3 and 4 whose genomes are slightly smaller they all have 
approximately 3.3 Mbp genomes comprising two chromosomes, one of 2.10 Mbp (Chr I) and a 
smaller chromosome approximately 1.2 Mbp (Chr II) in length [155]. Both chromosomes have a 
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G-C content of around 57% [128,258,78] and comparisons between the genomes of Brucella 
species have shown that they are very similar with an almost identical selection of genes and 
gene organisation [128]. There is a clear functional difference between the two chromosomes, 
Chr I encodes the vast majority of core metabolic process, such as transcription, translation and 
protein synthesis. Whereas, Chr II encodes a large amount of genes involved in membrane 
transport, energy metabolism and regulation [128,258,78]. The first direct genome comparison 
between B. melitensis 16M and B. suis 1330 has shown that the sequence identity for the 
majority of open reading frames (ORFs) is Z 99% [258]. However, despite the high degrees of 
similarity between B. melitensis 16M and B. suis 1330 there have been differences observed. B. 
suis 1330 contains 42 unique genes located in 22 genetic islands, whereas B. melitensis 16M 
contains 32 unique genes on 11 genetic islands, these differences seem to mainly effect genes 
with either unknown function such as hypothetical proteins or probable surface-exposed genes 
like outer membrane proteins (Omps) and membrane transporter genes [258,322]. The 
sequence of B. abortus 9-941 was released later than B. melitensis 16M and B. suis 1330, and 
comparisons between these three species have highlighted the high sequences homologies 
between these three strains even further [128]. Many of the genomic differences between B. 
melitensis 16M, B. abortus 9-941 and B. suis 1330 relate to small ORFs, where functional 
assays such as microarrays or proteomics studies are needed to help assess their function 
[128]. 
Perhaps the more interesting comparisons in Brucella genomics are between Brucella species 
and other members of the a2-proteobacteria such as Agrobacterium tumefaciens, 
Sinorhizobium meliloti and Mesorhizobium loti. The genomes of A. tumefaciens (5.67 Mbp, 
[357]), S. meliloti (6.7 Mbp, [109]) and M. loti (7.60 Mbp, [159]) are considerably larger than that 
of Brucella. However, despite this, comparisons between these organisms and B. Buis have 
shown that 1,902 (of 3388) B. suis ORFs were conserved in A. tumefaciens, S. meliloti and M. 
loti genomes [258]. Further analysis by Paulsen at al. has shown that B. Buis Chr I shares large 
regions of gene order with M. loti [258]. Indicating that these bacteria are very closely related. 
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1.1.3 Human brucellosis 
Human brucellosis is a non-lethal debilitating disease known to be caused by six of the nine 
species of Brucella (B. melitensis, B. abortus, B. suis, B. canis, B. pinnipedialis and B. cetr). Of 
these six, it is B. melitensis that causes the most severe infection and B. abortus, B. suis, B. 
canis, B. pinnipedialis and B. ceti causing milder forms of the disease in descending order of 
severity. As brucellosis is endemic in animals in many parts of the world these animals act as a 
reservoir for human infection [251]. The route of transmission from animal to human takes place 
via three recognised channels: 1. the consumption of infected animal produce (e. g. 
unpasteurised milk and cheese products or undercooked animal meat); 2. direct contact with 
infected animal birth products; 3. the inhalation of aerosolised Brucella. Brucellosis is a common 
occupational hazard for shepherds, abattoir workers, veterinarians, industrial dairy workers and 
laboratory personnel [249]. 
Once inside the human body Brucella infect professional and non-professional macrophages 
and they are then disseminated throughout the body via regional lymph nodes and 
subsequently into the circulation. After they enter the circulation the Brucella can be distributed 
to multiple organ systems high in reticuloendothelial tissue such as the spleen, liver, and 
haematopoietic system [249,283]. Infection usually takes one to eight weeks to incubate, 
dependant on inoculum size, Brucella species/strain and individual host resistance. After 
dissemination throughout the body brucellosis usually takes the form of either an acute disease 
or a chronic disease. 
The acute form of the disease usually presents itself within two to four weeks of infection. 
Brucellosis presents itself with a variety of flu-like symptoms including fever, sweats, chills, 
malaise and nausea coupled with anorexia, headaches, myalgias and back pain [285]. The 
clinical manifestations of brucellosis include a wide variety of non-specific symptoms including 
anaemia, enlargement and inflammation of the liver, spleen, uvea and vertebra, a decrease in 
blood platelets and meningitis [368,285]. 
Chronic brucellosis is described as symptoms that persist for more than a year after diagnosis 
[101]. Symptoms for chronic brucellosis include chronic fatigue, depression, weight loss and 
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arthritis. Brucella can also invade the central nervous system and cause neurobrucellosis, 
occurring in about 5% of cases in non-endemic areas rising to approximately 18% in endemic 
areas [253]. Neurobrucellosis presents itself as acute or chronic meningitis, with other clinical 
symptoms including encephalitis, intracerebral abscess, demyelination and radiculoneuritis 
[253]. 
If left untreated brucellosis symptoms can worsen and patients might eventually die. Treatment 
for brucellosis is complex, often consisting of a cocktail of two or more antibiotics over a six 
week period. The current recommended treatment for brucellosis is a combination of either 
doxycycline and rifampicin for six weeks, or doxycycline for six weeks and streptomycin for two 
or three weeks [253]. In uncomplicated cases of brucellosis, these treatments are usually 
effective in 90% of cases and relapses can often be treated with the same regimens [303,252]. 
Where rare complications occur, the most common being spondylitis, there is no consensus on 
the optimal antibiotic regimen [252]. Where neurobrucellosis occurs, regimens often take the 
form of triple or quadruple antibiotic cocktails for prolonged periods of time. Endocarditis is also 
a major complication of brucellosis and considered a medical emergency, surgery to remove the 
infected heart valve is usually required and antibiotic treatment is also used for patients to make 
a full recovery. However, endocarditis is still responsible for the bulk of mortality caused by 
brucellosis [252]. 
1.1.4 Brucella as a biological warfare agent 
Brucella species have traditionally been cited as potential agent of bioterrorism by the US 
Centers for Disease Control and Prevention (CDC) [1]. The reasoning behind this is that 
Brucella species are infective by the aerosol route and can cause a chronic debilitating disease 
that can be difficult to diagnose, which would cause wide spread panic and chaos after a 
deliberate release. The United States of America (USA) started developing B. suis as a 
biological weapon in 1942, testing it in animal field trials in 1944 and 1945, before stopping the 
offensive Brucella program in 1969 [267]. The USA is not the only country to experiment with 
Brucella as a biological weapon. In the former Soviet Union Brucella was developed as a 
biological warfare agent as part of the Soviet biological weapon program (250]. Reports have 
stated that both dry and liquid forms of Brucella were developed as biological weapons and that 
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they were tested on the island of Vozroshdeniye during the height of the Soviet biological 
weapon program (250]. Although Brucella species have not been directly used as a biological 
weapon they still pose a threat to armed forces personnel deployed to endemic areas of the 
world. A case of diagnosed brucellosis in a soldier six weeks after returning from active duty in 
Iraq was later revealed to be caused by the consumption of unpasteurised goat's cheese [235]. 
1.1.5 Diagnosis of brucellosis 
Diagnosis of brucellosis is difficult and the best way to confirm an infection is to isolate the 
organism from the host's blood or other tissue. Cultures from bone marrow are considered the 
absolute diagnosis due to the high numbers of Brucella in the reticuloendothelial system, 
although this is an invasive and painful technique [249]. There are also a number of serological 
tests available for the diagnosis of brucellosis. 
The Rose Bengal Plate Test (RBPT) is an antigen agglutination test that consists of Brucella 
cells stained with Rose Bengal and mixed with a buffer at pH 3.65. The test involves mixing the 
antigen with 30 pl of serum on a glass slide or enamel strip. After a brief incubation the slide is 
then examined for the presence of agglutination. Samples are usually confirmed positive if there 
is any agglutination present, although results can be graded depending on the speed of the 
agglutination [237,105]. However, to use the RBPT for B. canis diagnosis, specific B. canis 
antigens must be used due to the difference in lipopolysaccharide structure [283] and its cross 
reactivity with other bacterial species such as Escherichia coli 0116 and 0157, Francisella 
tularensis and Yersinia enterocolitica [249]. Indirect enzyme-linked immunosorbent assays 
(ELISAs) can be used as a diagnostic tool and routinely use purified 0 chain antigens. ELISAs 
overcome some of the problems associated with the RBPT and show a higher sensitivity and 
specificity [11]. 
Another serological test for brucellosis is the Complement Fixation Test (CFT). The CFT utilises 
anti-sheep red blood cell (SRBC) antibodies, whole SRBC, complement and antigen. Serum 
samples are mixed with Brucella antigen (usually whole Brucella cells) leading to the formation 
of antigen-antibody complexes. With the addition of anti-SRBC and whole SRBC, complexes 
form between the two. When the complement is added, and if there are no Brucella antibodies 
present the complement is utilised by the anti-SRBC and SRBC complexes causing SRBC lysis. 
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If there are Brucella antibodies present then the complement binds the anti-Brucella - Brucella 
antigen complexes and minimal SRBC lysis occurs. In sheep and goats the CFT is considered 
the most specific and sensitive method of serological diagnosis of B. melitensis infection [2031. 
In more recent years, the development of polymerase chain reaction (PCR) techniques have 
helped in both the typing and diagnosis of brucellosis. Positive PCR results can sometimes be 
obtained from tissue samples taken as little as 10 days after infection. The major genes used in 
the development of PCR diagnostic techniques are the 16S ribosomal RNA genes [239]. 
However, approaches originally used to evaluate the taxonomy and evolution of Brucella 
species could have applications as diagnostic tools. For example, multi-locus sequence typing 
(MLST), based on PCR analysis of DNA sequences of internal fragments of specific 
housekeeping genes, enables the characterisation of Brucella by their unique sequences 
[325,289]. Similarly, multiple locus variable number tandem repeats (VNTR) analysis (MLVA) 
takes advantage of polymorphisms in tandemly repeated DNA sequences for analytical 
purposes. MLVA technology for evaluation of Brucella species is a new technology and, in 
2006, two publications described MVLA markers that may be used for identification of Brucella 
species and, in some cases, specific Brucella strains [350,181]. These MVLA panels have been 
used to type strains of Brucella isolated from humans in Peru [300]. MVLA technology has been 
compared to other PCR-based typing methods, providing evidence that it is a comparable or, in 
some cases, a more useful diagnostic tool [110]. 
1.1.6 The intracellular trafficking of Brucella 
Brucella are characterised as facultative intracellular bacteria since they spend most of their life 
within host cells. They can infect either non-professional phagocytic cells like epithelial cells and 
fibroblasts, or professional phagocytic cells including murine peritoneal macrophages and 
human monocytes, neutrophils and bovine mammary gland macrophages [224]. The trafficking 
of Brucella through each type of cell differs between non-professional and professional 
phagocytic cells. 
1.1.6.1 Brucella trafficking through non-professional phagocytic cells 
The entry of Brucella into epithelial cells occurs via the use of unknown cell receptor molecules, 
and through phagocytosis using actin filaments and activation of GTPases (figure 1.1 A). During 
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early infection Brucella are routed to the early phagocytic compartments of the cells (figure 
1.1 B) and at this stage, the host cell has developed its late endosome which will develop into 
the lysosome and then the phagolysosome (figure 1.1 C). The majority of Brucella that are 
ingested into non-professional phagocytic cells are routed to the endoplasmic reticulum (ER) via 
the autophagocytic pathway. Here they join and fuse with the ER, using type 1 transmembrane 
glycoproteins called lysosome-associated membrane protein 1 (LAMP-1 depicted by., figure 1.1 
D& E). Brucella do not travel through the late endosome or golgi apparatus throughout 
intracellular trafficking. Once inside the ER, Brucella replicate without interfering with cellular 
function [224]. During this trafficking Brucella avoid phagosome contact and are therefore not in 
danger of being digested in the phagolysosome. 
1.1.6.2 Brucella trafficking through professional phagocytic cells 
Brucella enters professional phagocytic cells via binding to cell receptors such as FcR, C3bR, 
mannose receptor and the fibronectin receptor [347] (figure 1.2). Once bound, Brucella enters 
via lipid rafts (membrane areas rich in cholesterol, glycosylphosphatidylinostiol (GPI) and 
glycosphingolipids). Specifically, Brucella use cholesterol and GPI-anchored proteins as their 
lipid rafts [347,224]. Opsonised Brucella gain entry via the cell's Fc receptors [224] (figure 1.2 A) 
and, once Brucella have gained entry into the cell, development of the early Brucella-containing 
vacuole (BCV) occurs (figure 1.2 B). During the development of the BCV, the host cell starts to 
develop the early endosome, which will become the late endosome, then subsequently the 
lysosome and the phagolysosome (figure 1.2 C). The intermediate BCV forms by the acquisition 
of lysosomal-associated membrane proteins (LAMP) (figure 1.2 D) and fusion with the cells ER 
occurs within the first few hours of infection (figure 1.2 E). The Brucella enter the final stages of 
cell infection by formation of the replicative BCV which occurs without the need for LAMP-1, but 
with the recruitment of other ER markers including calnexin and calreticulin (depicted by . ), 
before replicating in the cisternae compartment of the ER [51] (figure 1.2 F& H). Brucella do not 
travel through the 
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late endosome (figure 1.2 C) or golgi apparatus during intracellular trafficking. Once inside the ER 
Bruce/la inhibit apoptosis and start to replicate [224]. Again, during intracellular trafficking the 
Brucella do not come into contact with the cells phagosome and so are not in danger of breakdown 
in the phagolysosome. 
1.1.7 Brucella virulence 
Brucella species are different from most pathogens as they have no classical virulence factors. 
They produce no known exotoxins, cytolysins, capsules, fimbria or flagella. Thus the virulence of 
Brucella stems from its ability to infect and replicate within a host and its ability to resist the host 
immune response. Brucella species are well adapted to their intracellular lifestyle and, although 
they have no classical virulence factors, there are a number of virulence factors that have been 
identified that could help explain Brucella pathogenicity (figure 1.3). 
1.1.7.1 Lipopolysaccharide (LPS) 
Lipopolysaccharide is an important constituent of the Gram-negative bacterial outer membrane. 
There are two types of Bruce/la LPS: smooth LPS which comprises lipid A, a core polysaccharide 
and an O-antigen side chain, and rough LPS where the O-antigen side chain is not exported to the 
cell surface. Although LPS could be considered a classical virulence factor, Brucella LPS is different 
from that of most other Gram-negative bacterial LPS. It is many times less toxic than the LPS of E. 
coli [119] and is highly resistant to macrophage degradation [103], offering some protection against 
the host immune response. Studies on B. melitensis LPS have characterised the reduced toxicity of 
Brucella LPS further [324). The difference between the LPS of rough and smooth species of 
Brucella is thought to alter the way in which different species of Brucella enter cells [324]. Smooth 
Brucella species are thought to interact with lipid rafts on the cell surfaces, whereas rough Brucella 
species (B. canis and B. ovis) seem not to interact with lipid rafts and more frequently fuse with 
lysosomes [178]. 
1.1.7.2 Type IV secretion system VirB 
Type IV secretion systems are a group of multi-protein complexes that enable bacteria to secrete 
molecules and proteins across the cell envelope [30]. For example, Bordetella pertussis secretes 
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Figure 1.3: Important factors needed for intracellular survival and replication in 
Brucella species. 
Red text = possible virulence factors; Blue text = important in intracellular 
survival factors. Adapted from [152] 
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the pertussis toxin through the Ptl system [65] and Legionella pneumophila export proteins through 
the Dot/Icm system [22]. The Brucella VirB system is an analogue of VirB in Agrobacterium 
tumefaciens [240] and is encoded by the virB operon which includes 12 proteins. The composition 
of the VirB system and the proteins that it secretes are still largely unknown, although progress is 
being made in discovering what the VirB system secretes [73]. 
Recent research has identified two proteins called VceA and VceC that are translocated into 
macrophages via the VirB secretion system, although the function of these proteins is yet to be 
determined [73]. Experimental evidence has shown that the genes encoding VirB are not needed by 
Brucella for the penetration and inhibition of phagolysosomal fusion in non-professional phagocytes. 
However, the same genes are needed for the Brucella to reach and reside in their replicative niche 
[77]. Brucella with deficiencies in the virB genes are unable to fuse with the ER and are instead 
directed to the lysosome and subsequently destroyed [224]. There is also evidence to show that the 
VirB system is not needed for dendritic cell maturation or the establishment of a type 1 adaptive 
immune response [28]. 
1.1.7.3 Two component regulatory system (BvrS/BvrR) 
The two-component regulatory system (TCRS) in Brucella is a homologue of the ChvI/ChvG system 
of Rhizobium meliloti and A. tumefaciens [124,193] which is needed for endosymbiosis and 
pathogenicity in Bryophyllum diagremontiana and Medicago sativa plants, respectively [55,56]. The 
TCRS consists of a regulatory protein, BvrR, and a sensory protein, BvrS. This regulatory system 
has been located in the genomes of B. melitensis, B. suis and B. abortus and the homology 
between each species differs only by several amino acids [302]. It is thought that the TCRS is 
responsible for sensing whether the bacteria are residing in an intracellular or extracellular 
environment, and for turning off unnecessary genes and turning on essential genes [302]. 
Sequencing of the Brucella genomes has found approximately 21 predicted TCRS [78,258,128], the 
best characterised being the BvrS/BvrR system. Mutations in the BvrS/BvrR cause problems in the 
production of outer membrane proteins 22 and 25 (Omp22 and Omp25) which, in turn, leads to 
reduced virulence in mice [302,124]. The Omp25 protein, which is regulated by the BvrS/BvrR 
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system may be involved in virulence through a mechanism that inhibits TNF-a release in human 
macrophages [89,151]. B. melitensis and B. ovis Omp25 mutants are attenuated in mice [88] and 
although B. abortus Omp25 mutants display different phenotypes to their wild-type strains, they are 
still virulent in mice, whereas BvrS/BvrR mutants are attenuated in mice [87,207], indicating that 
BvrS/BvrR influences other genes in Brucella that could be involved in virulence [207]. 
1.1.7.4 Brucella virulence factor A (BvfA) 
The Brucella virulence factor A (BvfA) is an 11 kDa periplasmic protein that is unique to Brucella 
with no homologues currently in GenBank (180]. B. suis BvfA mutants are highly attenuated both in 
vitro and in vivo, and the expression of BvfA is induced when B. Buis is within macrophages during 
phagosome acidification, suggesting that BvfA could be involved in the establishment of the 
intracellular niche [180]. 
1.1.7.5 Sugar metabolism 
The ability to metabolise different sugars for energy is important in bacterial survival. Brucella 
preferentially utilise an uncommon sugar called erythritol which provides them with a major 
advantage over competing bacteria [96]. There are only a few genes that have been shown to be 
important in the intracellular survival of Brucella that relate to sugar metabolism [168]. Erythritol 
metabolism is one example with the identification of two genes, eryD and eryC that are thought to 
be important for Brucella intracellular growth since mutants in eryD and eryC exhibit slower 
intracellular growth than their wild-type counterparts [39]. It is known that genes involved in the 
glycolysis pathway (glucose degradation) are absent in Brucella [78]. 
1.1.7.6 Nitrogen metabolism 
As nitrogen constitutes a large part of many different components of bacteria including proteins, 
nucleic acids and enzymes, the ability to metabolise nitrogen is extremely important in bacterial 
survival. There have been three genes identified in Brucella that encode for nitrogen metabolism. 
They are g/nA, g/nD and gInL and are genes involved in NH4; utilisation [168]. A homologue of GInA 
in Salmonella typhimurium has been shown to be important in its virulence [166]. 
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1.1.7.7 Amino acid and nucleic acid synthesis 
Due to the low nutrient nature of the intracellular environment, it may not be possible to gain all 
nutrients required for bacterial survival and growth from the environment. Therefore bacteria may 
have to synthesise their own amino acids and nucleic acids. Genes have been identified in B. suis 
that demonstrate its ability to make amino acids and nucleic acids (purD, purE, purF (purine 
synthesis) and carAB, pyrB and pyrD (pyrimidine synthesis)) [168]. Previous studies have shown 
that purE mutants of B. melitensis are attenuated in both mice and human monocyte-derived 
macrophages (66,85], highlighting that, whilst residing inside host cells, Brucella species may need 
to synthesise nucleotides. Similarly, a B. suis mutant of the aroC gene (involved in the synthesis of 
aromatic amino acids) was attenuated both in vitro and in vivo [104]. 
1.1.7.8 Oxidoreduction 
Brucella species contain the cydDCAB operon which encodes for cytochromes that are important in 
respiration. Within the operon is the cydD gene which is important in the intracellular survival of B. 
suis [168], a finding that has been strengthened by the discovery that a B. abortus cydB mutant was 
attenuated in the mouse model of infection [93]. 
1.1.7.9 Stress proteins 
Three genes have been identified that could be required for adaptation to the intracellular 
environment. These are hfq encoding host factor 1, htrA encoding a protease and Ion also encoding 
a protease [168]. B. abortus strains containing mutations in the hfg gene are more sensitive than 
wild type bacteria to hydrogen peroxide and low pH and they also fail to replicate in host 
macrophages [273]. Similarly, B. abortus Ion mutants show increased sensitivity to hydrogen 
peroxide and to certain antibiotics, and are attenuated in vitro and in vivo [272]. Mutants of the htrA 
gene show attenuation in vitro but are fully virulent in vivo, indicating that the gene may not be 
needed for full virulence in natural infections [263]. 
1.1.8 Animal models of brucellosis 
As brucellosis is a disease associated with a range of large animal species it is difficult to identify a 
suitable small animal model that accurately reflects brucellosis in nature. 
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1.1.8.1 Mouse model of brucellosis 
The most widely used and well characterised animal model of brucellosis is the mouse model. 
There are two strains of mice that are commonly used for studying brucellosis. These are the 
Brucella-resistant C57BU6 strain and the more susceptible Balb/C strain [20]. Mice are used 
because they are bred, housed, and handled for animal studies. Furthermore, the mouse immune 
response, although complex, is also well characterised, aiding the understanding of the immune 
response to Brucella species. 
The growth of Brucella species in mice varies depending on which mouse strain is used. Early 
studies into Brucella growth have evaluated its growth in four different strains; Balb/C, CBA/H, 
C57B1/10 and 131 013r. When mice were dosed intravenously with 5x105 Colony Forming Units (CFU) 
B. abortus, the splenic bacterial burden peaked at two weeks post infection, in all strains. In the 
Balb/C, C57BV10 and B1OBr strains the bacterial loads decrease steadily until around seven weeks 
post infection. However, in CBA/H mice bacterial loads decreased at three weeks post infection 
before persisting in the spleen at a constant level for seven weeks post infection, indicating that in 
this strain Brucella infection presents itself as a chronic infection [135]. In all these strains clearance 
of Brucella from the liver was relatively efficient [135]. Longer experiments have shown than in 
Balb/C mice growth of B. abortus reaches a plateau phase approximately eight weeks post infection 
before gradually declining up until 24 weeks post infection. In C57BI/10 mice the plateau phase is 
shorter with bacterial loads lower after eight week of infection. After 16 weeks Brucella recovery can 
be difficult in C57BI/10 mice [222]. 
Mice infected with Brucella do not produce any outward clinical signs of disease, so protection is 
measured by comparing the number of recoverable Brucella CFU from naive non-immunised mice 
with mice inoculated with a novel vaccine candidate or other treatment. Typically, mice immunised 
with a current animal vaccine are also included in the studies as positive controls. The majority of 
protection studies completed using the mouse model of brucellosis involve infection via the 
intraperitoneal (i. p. ) route with approximately 1x104 CFU of B. melitensis and, although this is an 
effective experimental technique, it does not truly represent a natural route of infection. Recently 
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there have been two studies published which specifically evaluate exposure of mice to Brucella via 
the aerosol route [246,156]. Kahl-McDonagh et al. demonstrated that inhalational infection with B. 
abortus causes a chronic infection in the lungs and peripheral organs at lower doses than 
inhalational infection with B. melltensis [156]. Olsen et al. used a jet nebuliser to dose mice with B. 
melitensis or B. abortus, reporting consistent Brucella growth in the liver, lungs and spleen between 
the two species, although they were unable to demonstrate protection from a 1x10' CFU dose of B. 
abortus vaccine strain RB51 against aerosol challenge [246]. 
Immunocompromised mice have also been used to study Brucella virulence and the Brucella 
specific immune response. Mice deficient in interferon regulatory factor-1 (IRF-14 ; deficient in IL-12, 
functionally impaired natural killer (NK) cells and cytotoxic CD8+ T cells) and mice lacking 
recombination-activating gene 1 (Rag14"; deficient in mature T and B cells) have both been studied 
[167,148]. IRF-1"" mice still have some control over a Brucella infection at low bacterial 
concentrations as challenge with 5x105 CFU of B. abortus are needed to cause death [167]. More 
recently IRF-1"1" mice were reported to succumb to infection after 9 days when given 1x107 CFU of 
B. melitensis [269]. Studies using Rag1''' mice have indicated that a T- and B-cell independent 
immune response can control a Brucella infection at a high level in the murine spleen, but not the 
liver. However, the presence of T and B cells is required for full clearance of the infection [148]. 
1.1.8.2 Other animal models of brucellosis 
Although the mouse model of infection is the best characterised experimental model for brucellosis, 
there are other animal models reported in the literature. These include infections in goats [217,92], 
beagles [248] and monkeys [260]. Research using these different models is pathologically more 
realistic and therefore important in furthering our knowledge of brucellosis. However, the mouse 
model is immunologically better characterised, cheaper, and easier to work with and so is more 
oftern the model of choice for Brucella research. 
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1.2 The immune response 
The immune response is a complex interaction of many different chemical signals, molecular 
pathways and cellular networks, the function of which is to defend the body against infection from 
pathogenic organisms. Although there is significant cross-over between different branches of the 
immune response it can be broadly split into two main categories: the innate immune response and 
the adaptive immune response. 
1.2.1 The innate immune response 
The innate immune response is the body's first line of defence against pathogens, consisting of 
various non-specific defence mechanisms, including physical barriers, phagocytosis, natural killer 
cell activation and initiation of the alternate complement cascade. 
1.2.1.1 Physical and chemical barriers 
The first major line of defence against pathogens is the skin and epithelium. The constant 
regeneration of the epithelium helps remove bacteria that have adhered to it. Flushing mechanisms 
such as tears and saliva aid in the prevention of bacterial colonisation of the mouth and eyes. The 
gastrointestinal and respiratory tracts are lined with mucus that assist in trapping bacteria which 
prevents infection of the lungs and digestive systems [200]. The enzyme lysozyme breaks down the 
bacterial cell wall, which reduces bacterial growth. Lysozyme can be found in bodily secretions such 
as sweat, tears and saliva. The general low pH of sweat and gastrointestinal fluids also aids in the 
prevention of infection [23]. 
1.2.1.2 Complement cascade 
The complement cascade ultimately leads to cell lysis via the creation of a pore in the cell 
membrane known as the membrane attack complex (MAC). There are three pathways of 
complement activation: the classical pathway, the lectin pathway and the alternative pathway. Only 
the alternative pathway is part of the innate immune system as it does not require any antigen 
specific cell signals for activation. This pathway is activated by the pathogen cell surface creating an 
environment favourable for complement binding and activation. Once activated, the complement 
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cascade leads to the generation of a C5 convertase whose function is to catalyse the first steps in 
the production of the MAC. The alternative complement cascade starts with the continuous low level 
breakdown of complement molecule C3 into C3b, a very reactive molecule with the ability to bind 
many different cell surface markers. When C3b binds to a bacterial cell surface then a molecule 
called Factor B is activated and cleaved into Bb which binds on to C3b on the microbe. C3bBb 
complex (C3 convertase) is an enzyme that increases the cleavage of C3 to C3b, creating a 
positive feedback for increasing the activation of complement [200]. C3bBb then further binds more 
C3b creating C3bBb3b complex or C5 convertase. C5 convertase cleaves C5 into C5a and C5b 
and, from this point on, the generation of the MAC is a non-enzymatic process. C5a is a strong 
immune modulator molecule which causes neutrophil activation, adhesion, migration and 
chemotaxis, and monocyte activation causing the release of cytokines such as IL-1 and IL-6, and it 
can cause mast cell degranulation. C5b is crucial for the formation of the MAC as it binds C6 and 
C7 forming C5b67, which then binds C8 and anchors itself in the bacterial membrane. C5b678 
causes the insertion and polymerisation of many C9 molecules causing the formation of the MAC. 
The MAC causes bacterial cell lysis and eventually cell death [276]. 
1.2.1.3 Innate pathogen recognition and activation 
The cells of the innate immune response include dendritic cells, macrophages, natural killer (NK) 
cells and neutrophils, all of which have important roles in the initiation of the immune response. 
Neutrophils are a major class of phagocytic cells that are abundant in the blood stream. Upon early 
infection neutrophils migrate to the site of infection where they play essential roles in the 
phagocytosis of the invading pathogen. Macrophages and dendritic cells have the ability to 
recognise general markers on pathogens called microbe-associated molecular patterns (MAMPs). 
These are recognised by a group of receptors called the Toll-like receptors (TLRs), which recognise 
a range of different MAMPs, both extracellular and intracellular. For example, TLR4 recognises 
lipopolysaccharide, and TLR9 recognises short methylated lengths of DNA called CpGs. Other 
TLRs include TLR5 (recognises flagellin), TLRs 6 and 2 (a TLR dimer that recognise 
diacyllipopeptides), TLRs 1 and 2 (another TLR dimer that recognise triayllipopeptides) [276]. 
Activation of TLRs leads to the increased phagocytosis by macrophages and release of pro- 
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inflammatory cytokines such as tumour necrosis factor-a (TNF-a), interleukin-12 (IL-12), and IFN-y. 
Activation via TLRs also causes the maturation of dendritic cells, leading to their migration to 
regional lymph nodes and the initiation of the adaptive immune response. Pro-inflammatory 
cytokines assist in the recruitment of further phagocytic cells such as neutrophils and NK cells [200]. 
NK cells develop in the bone marrow once fully developed, they circulate in the blood stream and 
are activated by macrophage derived cytokines. Upon activation NK cells kill infected cells via the 
release of cytotoxic granules and perforin. NK cells are also a major producer of IFN-y generated 
during an innate immune response. Production of cytokines such as IL-12 in conjunction with 
tumour necrosis factor - alpha (TNF-a) by macrophages can also stimulate release of IFN-y by NK 
cells. Many of the cytokines produced by the innate immune response also play important roles in 
shaping the adaptive immune response. 
Both macrophages and dendritic cells also play major roles as antigen presenting cells (APCs). 
After a pathogen has been phagocytosed antigens are displayed on the surface of the cell in 
conjunction with major histocompatibility complexes (MHC) II. These are recognised by cells of the 
adaptive immune response which helps in the development of the immune response. 
1.2.2 The adaptive immune response 
The adaptive immune response is another branch of the immune response that takes longer to 
establish itself during an infection than the innate response. However, once established, it is 
specific to particular pathogens and it is responsible for the clearance of an invading pathogen. The 
adaptive immune response is also responsible for the generation of immunological memory which 
makes vaccination possible. There is significant cross-over in elements of the adaptive immune 
response, but it can be broadly split into two categories: the humoral immune response and the 
cellular immune response. 
1.2.2.1 T cell maturation and differentiation 
T cells are all derived from the same progeny of lymphoid cells produced in the bone marrow, only 
reaching full maturity in the thymus. During their early development T cells express both CD4 and 
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CD8 molecules, and it is only when T cells are simulated to recognise either MHC I or II that they 
become designated as CD4+ T cells or CD8' T cells. T cells that are able to recognise MHC I 
molecules develop into CD8' T cells and those that recognise MHC II molecules become CD4+ T 
cells. At this point both populations of T cells are referred to as naive CD4+ T cells or naive CD8+ T 
cells. 
Once naive CD4+ T cells are activated by MHC II complexes the differentiation into Th1 or Th2 cells 
begins. The CD4+ T cells first differentiate into an intermediate cell type known a ThO cell, and the 
production of IL-2 by ThO cells stimulates it to proliferate further. ThO cells have the ability to 
differentiate into either Th1 or Th2 cells, largely determined by the type of invading pathogen and by 
cytokine signalling. Intracellular pathogens generally cause CD4+ T cells to differentiate into Th1 
cells, whereas extracellular pathogens generally give rise to Th2 cell populations. Cytokine 
signalling also affects the differentiation of ThO cells into Th1 or Th2 cells; cytokines such as IL-12 
(produced from macrophages), IL-23 (dendritic cells) and IL-18 (macrophages) lead to the rise of 
Th1 cells, whereas IL-4 (mast cells/I cells) and IL-13 (T cells) lead to the rise of Th2 cells. Th1 and 
Th2 cells are the co-ordinators of the immune response modulating the function of other cells via 
direct contact or secretion of different cytokines that direct the most appropriate response to a 
pathogen. The differentiation of naive CD4+ T cells into either Th1 or Th2 cells determines which 
type of immune response will be produced, either a cellular (Th1) or humoral (Th2) immune 
response. 
The activation of naive CD8' T cells is a simpler process as they are pre-designated to become 
cytotoxic T lymphocytes (CTLs). The differentiation of naive CD8+ T cells into CTLs takes place via 
activation from mature dendritic cells although in some cases the differentiation requires additional 
signalling from CD4+ T cells. The result of activation from both sources is the production of IL-2 by 
the naive CD8+ T cells which drives their proliferation and differentiation into CTLs. Once T cells 
have matured and differentiated into Thl cells, Th2 cells or CTLs, their functions in the immune 
response have different effects upon different cell populations. 
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1.2.2.2 The cellular immune response 
The main effector cells of the cellular immune response are the Th1 cells and CTL populations. The 
array of cytokines produced by Th1 cells defines their function within the immune response. Th1 
cells produce cytokines such as IFN-y (increasing activation of NK cells, macrophages and dendritic 
cells), TNF-a (increases nitric oxide production from macrophages), and granulocyte macrophage - 
colony-stimulating factor (GM-CSF, increases the production of macrophages and dendritic cells). 
The function of CTLs is to kill infected cells expressing foreign peptide presented in conjunction with 
MHC I via the release of cytotoxic granules and perforin similar to that of NK cells. Upon recognition 
of the antigen there is a clonal expansion of CTLs, which gives rise to two populations of CD8+ T 
cells, specifically CTLs or memory T cells. Activated CTLs secrete further cytokines such as IFN-y 
and IL-2. IFN-y stimulates macrophage activation and increases antigen presentation via MHC 
class I and II, which starts the cycle over again, acting as a positive feedback loop driving the 
cellular immune response [42]. 
1.2.2.3 The humoral immune response 
The humoral immune response is generated by a subset of cells known as B cells, which are 
generated in the bone marrow from common lymphoid progenitor cells. B cell antigen specificity 
arises from the B cell receptor (BCR) a membrane bound immunoglobulin coupled with two 
transmembrane signalling molecules Iga and Igo. The BCR is capable of recognising free antigen, 
however, when antigen binds to the BCR it is the two signalling molecules (Iga and Igo) that cause 
the signalling cascade that activates the B cells. B cell activation, leads to clonal expansion of the 
activated B cell population [276]. B cells then differentiate into plasma cells that produce pathogen- 
specific antibodies of the same specificity as the BCR on their cell surface. Antibodies themselves 
function in a number of different ways including neutralisation of toxins by binding active sites, 
binding directly to pathogens (opsonisation) thereby increasing phagocytosis of the pathogens, and 
activation of complement via the classical pathway [200]. Cytokines such as IL-4 and IL-5 produced 
by CD4+ Th2 cells also act upon B cells aiding in their maturation and differentiation. 
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1.2.2.4 Cross-talk and negative regulation of the immune system 
There is significant cross-talk between both the humoral and cellular immune responses. For 
example, secretion of IFN-y by CTLs causes plasma cells to switch antibody isotype from IgG1 to 
IgG2, which are better at opsonising bacteria and so causing increased phagocytosis by 
macrophages. Similarly, there are negative regulators of the immune response. For example, the 
secretion of IL-10 by Th2 cells acts to stop the production of cytokines by Th1 cells and 
macrophages and increase MHC class II expression thus depressing the cellular immune response 
[276]. In some cases IL-10 can be produced by some Th1 cells during a self-limiting cellular 
immune response. 
1.2.2.5 Immunological memory 
One of the key functions of the adaptive immune response is the generation of immunological 
memory. Immunological memory is the capacity of the immune system to rapidly recognise and 
react to a second exposure of a previously encountered pathogen with an aggressive immune 
response quicker than the first encounter. The mechanisms behind immunological memory are 
complex, but it is known that immunological memory is maintained by a small population of 
specialised memory cells. The generation of antigen specific memory cells occurs following the first 
exposure of an antigen to the immune system, during the clonal expansion of B and T cell 
populations. Upon activation from presented antigens the clonal expansion of T or B cells leads to a 
small population of either cell type becoming memory T or B cells. 
The memory T cell population can be further split into memory CD4* T cells or CD8` T cells. Most of 
these cells are dormant until a second exposure to a pathogen. However, there is a small 
population of memory cells that are dividing at any one time. It is thought that this division is 
induced by cytokines. For example, IL-7 is responsible for maintenance of CD4+ memory T cells 
and IL-15 contributes to maintenance of CD8r memory T cells [282]. Memory CD8+ T cells also 
express the anti-apoptotic marker called Bcl-2 which promotes cell survival and is thought to be one 
reason for the long-term survival of this cell type. CD4` and CD8' T cells can become one of two 
types of memory cell, either effector memory cells or central memory cells. Effector memory cells 
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quickly migrate to inflamed peripheral tissues where they rapidly mature into effector T cells and 
secrete large quantities of cytokine more quickly than naive T cells, and also display receptors for 
inflammatory cytokines for quick re-stimulation. In comparison, central memory cells have little or no 
effector function and reside in the peripheral lymphoid tissues (such as lymph nodes and the 
spleen) where, upon activation, they readily proliferate and differentiate into effector cells [282]. 
The immunological memory of B cells starts during clonal expansion and differentiation of activated 
antigen-specific B cells into either plasma cells or memory B cells. Upon activation memory B cells 
division is much quicker than naive B cells, and production of antibody is also quicker. Not only is 
the antibody produced by memory B cells released quicker, it is also of a different isotype than that 
produced by naive B cells. On first exposure to a pathogen the initial antibody to be produced is 
IgM (which has low affinity binding). It is only later during infection that IgG (which has high affinity 
binding) is produced. Upon activation memory B cells produce IgG, a better antibody for bacterial 
opsonisation and anti-toxin responses. 
Immunological memory is what makes vaccination possible. The process of vaccination exposes 
the body to the first encounter with material from a pathogen. Upon a second natural exposure to 
the same pathogen it is the immune system's memory cells that create the quicker immune 
response required to clear the infection before it establishes itself. 
1.2.3 The immune response to Brucella 
Defining an immune response to a pathogen can aid in the development of effective vaccines. The 
complete immune response to Brucella is not yet fully understood. Most of the research into the 
immune response generated to Brucella has been evaluated in the mouse model of infection. The 
Brucel/a-specific immune response can be broadly split into two categories: the innate immune 
response and the adaptive immune response. 
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1.2.3.1 The innate immune response to Brucella 
1.2.3.1.1 The roles of antigen presenting cells (APCs) during brucellosis 
APCs make up an important aspect of the immune response. APCs consist of macrophages and 
dendritic cells, and are one of the earliest lines of defence of the innate immune response. Early 
studies have shown that macrophages from infected animals such as guinea pigs [216,265] and 
cattle [102] have an increased rate of killing when compared to macrophages from uninfected mice, 
showing that following Brucella infection macrophages do become activated. Stimulation of human 
monocytes with heat killed B. abortus leads to the secretion of the proinflammatory cytokines TNF-a 
(increases macrophage activation and local inflammatory response), IL-10 (increases macrophage 
activation and induces T cell activation) and IL-6 (T and B cell growth and differentiation) [139], all 
important cytokines for inducing and shaping the immune response. Interestingly, during in vitro B. 
suis infection studies the production of TNF-a is inhibited by Outer membrane protein 25 (Omp25) 
[151], which is highly conserved between Brucella species [58] leading to the theory that all Brucella 
can inhibit TNF-a production. Inhibiting the production of a major cytokine like TNF-a means the 
immune response is lacking in a key cytokine. The inhibition of TNF-a could lead to decreased 
macrophage activation and a decrease in the inflammatory response which, in turn, leads to less 
cell recruitment and so a decrease in phagocytosis, a key component of the immune response 
against brucellosis. Dendritic cells have also been shown to produce cytokines upon infection with 
Brucella species. Infected human DCs not only increase the expression of certain cell surface 
receptors and MHC class I and II, but also produce a range of pro-inflammatory cytokines such as 
TNF-a, IL-6, IL-10 and IL-12. [375]. 
In the mouse the innate immune response differs from the human response in that there is no 
inhibition of TNF-a production. In vitro studies using murine macrophages infected with Brucella 
have shown that a similar array of cytokines is produced such as IL-1, IL-6 and TNF-a [83], with 
TNF-a being the first cytokine produced and production peaking at six to seven hours post infection. 
In the mouse TNF-a is needed for full Brucella clearance as mice deficient in the TNF-a receptor 
genes have exacerbated Brucella infections [371,372]. 
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1.2.3.1.2 The importance of IFN-y during murine brucellosis 
IFN-y is crucial for survival during a murine Bruce/la infection since, in the absence of IFN-y, Balb/C 
and C57BU6 mice die of brucellosis [229]. However, in Balb/C IFN-y deficient mice the bacterial 
burdens at 1 week post-infection are equivalent to that in wild-type mice. Balb/C IFN-y deficient 
mice die at 10.5 weeks post-infection, whereas wild-type mice start clearing Brucella infections 
around this time [229]. IFN-y patterns differ in C57BU6 mice as they produce IFN-y throughout the 
infection and, in its absence, have increased bacterial loads until they succumb to infection after 6 
weeks post infection [229]. Balb/C mice stop producing IFN-y during the first week of infection and 
this cessation of IFN-y production continues until the end of the infection. Yet Balb/C mice are able 
to control and clear the Brucella infection. Murphy et al. have shown that during this IFN-y deficient 
period, removing TNF-a and CD8+ T cells results in an increase in Brucella CFU recovered [228], 
suggesting that it is TNF-a and CD8+ T cells that are providing the control during IFN-y deficient 
periods [228]. Baldwin et al. have reported that macrophages from both resistant (natural 
resistance macrophage protein 1 (Nrampl) positive) and susceptible (Nramp negative) mice can 
control a Brucella infection ex vivo, showing that control of Brucella infection is not related to 
inherent differences in the macrophage ability of each strain [20]. Furthermore, it has been 
demonstrated ex-vivo that the decrease in IFN-y production could be attributed to a decrease in 
expression of the IL-12 receptor, IL-12Rß2 [284]. If susceptible Balb/C mice are treated with 
recombinant IL-12, the production of IFN-y increases, leading to a 1000-fold reduction of Brucella 
CFU during primary infection and increased survival during secondary infection [284]. 
1.2.3.1.3 The role of natural killer cells during brucellosis 
On first contact with Brucella, APCs phagocytose the Brucella, causing cell activation and release of 
cytokines such as IL-12 and IL-2. IL-12 activates NK cells, causing them to initiate killing of infected 
cells and production of their own cytokines such as IFN-y, which then causes macrophage 
stimulation, increasing proliferation and MHC class I and II expression [276]. It has been shown that 
NK cells are not of paramount importance in the early stages of a Brucella infection, as removal of 
NK cells in vivo does not alter the ability of mice to clear a Brucella infection [99]. Although this does 
not mean that NK cells don't play an important role in the immune response against Brucella, it 
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does demonstrate that in mice there is still a sufficient immune response for Brucella clearance 
without NK cells [99]. 
1.2.3.2 The adaptive immune response to Brucella 
The different arms of the adaptive immune response appear to have different roles in the clearance 
of a Brucella infection. 
1.2.3.2.1 The humoral immune response to Brucella 
Due to the intracellular nature of Brucella, antibodies are not as effective at clearing infection as 
they may be for an extracellular pathogen because antibodies access the intracellular environment. 
Important antibodies that aid in the clearance of a Brucella infection are IgG2a isotype antibodies in 
mice and the IgG3 isotype antibodies in humans [118]. IgG2a and IgG3 are effective for 
opsonisation of bacteria, thus increasing phagocytosis by macrophages [118]. The production of 
IFN-y causes class switching of IgG production from IgG1 isotypes to IgG2a in mice and IgG3 
isotypes in humans [276]. Antibodies generated against the 0-antigen of Brucella LPS are also 
thought to be important in stopping the spread of Brucella throughout the body [365]. Additionally, 
older studies show that passive transfer of sera or monoclonal antibody recognising the LPS or 
OPS can protect against B. abortus infections, confirming that antibody may be important in 
protecting against Brucella infections in mice [222,355]. 
1.2.3.2.2 The roles of T cells in the immune response to Brucella 
The role of T cells in Brucella infection has mainly been assessed in the mouse model of infection. 
A range of studies have shown roles for the CD8« T cell and the CD4+ T cell in the control of 
Brucella infection [242,15]. Specifically, primary roles for CD8' T cells have been demonstrated 
when infecting 02-microglobulin depleted C57BU10 mice (which have no cell surface MHC class I 
and therefore no CD8+ T cell response) with Brucella. Mice harbour an increased Brucella load 
during the infection, indicating that CD8' T cells are needed to reduce Brucella numbers [242]. 
Adoptive transfer of CD4` or CD8+ T cells from infected Balb/C mice to naive mice provides them 
with similar levels of protective efficacy against B. abortus 2308 [15]. This suggests a role for both 
CD4+ and CD8+ in Brucella infections. 
30 
In human infection specific subsets of T cells have been shown to be important. For example, 
Bertotto et al. have demonstrated that yö T cells increase dramatically among circulating blood 
lymphocytes during the acute phase of infection, although the mechanisms by which they help in 
the clearance of infection are as yet unknown [26]. There is also a subset of yb T cells known as 
Vy9VÖ2 T cells which increase in numbers in the peripheral blood of patients with brucellosis [241]. 
These Vy9VÖ2 T cells are a population of cells only found in primate species and so their 
importance in Brucella clearance has to be studied in brucellosis patients. It has been demonstrated 
that Vy9V62 T cells can decrease the growth of Brucella using either contact-dependant cytotoxicity 
such as lytic granules or by increased activation via signalling by soluble factors release by infected 
monocytes [241,247]. 
1.2.3.2.3 The roles of cytokines in the immune response to Brucella 
Of the range of cytokines induced by Brucella species there are some which appear to have a more 
important role during infection than others. Specifically, IFN-y is critical for Brucella clearance in 
mice as resistant mice strains with disruptions in the IFN-y gene die between six to ten weeks post- 
infection [229]. Additionally, both IL-12 and TNF-a are thought to play important roles in resistance 
to Brucella infections [371,372], and studies have shown that reducing IL-12 or TNF-a using specific 
antibodies four hours before challenge with virulent B. abortus results in an exacerbated infection 
[372]. Data has also indicated that IFN-y, TNF-a and IL-6 are present in at higher levels in serum 
from patients with acute brucellosis than in healthy volunteers [79]. In comparison, there is no 
difference between levels of IL-1 P, TGF-ß1, IL-2, IL-4 and IL-8 [8]. 
1.3 Vaccination against brucellosis 
The adaptive immune response can take days to establish which, in some cases, can mean that an 
infectious agent has already had time to produce an established infection within the body, causing 
the generated immune response to be less effective. Vaccination uses the immune system's ability 
to produce specific memory cells against pathogens to speed up the immune response to infection. 
On a second exposure to an antigen, both memory T cells and memory B cells recognise the 
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antigen and start multiplying immediately. This decreases the response time of the immune system 
limiting the time in which an infectious agent can establish itself. 
1.3.1 The history of human vaccination against brucellosis 
Although the current live attenuated vaccine strains of Brucella used in animals are not suitable for 
human use there are examples of human vaccination with live attenuated strains of Brucella, in the 
former Soviet Union (USSR) and China. In the former USSR there was a high prevalence of 
brucellosis in sheep and goats. This reservoir of brucellosis was the cause of 85 - 95 % of the 
cases of brucellosis reported in humans, because of this since 1953 - 54 the problem has been 
kept under control by the routine vaccination of the so called "at risk" populations [340]. Many of the 
live attenuated Brucella vaccines have the ability to induce a protective immune response against 
brucellosis, B. melitensis Rev. 1 and B. abortus strain 19 are two examples. However, both of these 
strains are still virulent in humans and so a new strain was developed in the former Soviet Union 
which was derived from B. abortus strain 19, called B. abortus 19-BA [340]. Strain 19-BA was 
administered as a dose of 1x109 cells via skin scarification and protection was effective for upto one 
year (although maximal protection was only for five-six months) [63,281]. The vaccine was usually 
well-tolerated in healthy adults but the number of general reactions to the vaccine increased in 
people who had previously had brucellosis and repeated vaccination had a tendency to cause 
hypersensitivity [281]. Epidemiological studies did show that the vaccine effectively reduced the 
incidence of acute human brucellosis by five to eleven fold [340]. Despite the well tolerated nature 
of strain 19-BA independent studies have shown that it can still cause acute brucellosis in some 
people [304]. In China another strain of B. abortus was used for human vaccination called 104M. 
This strain was administered as a dose of 7-10x1010 cells also via skin scarification. Strain 104M is 
reported to be more virulent than 19-BA and can give rise to serious illness if given by the 
subcutaneous route [63]. Nether the BA-19 or 104M vaccines would meet the requirements for 
efficacy and safety needed to be licensed in the western world [62]. 
There are also two examples of non-living Brucella vaccines that have been used in humans in 
France and the former USSR. In France a phenol-insoluble residue of lipid extract was prepared 
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from B. abortus S19 cells [63,194]. This vaccine was used to dose occupationally exposed groups 
of workers, who were administered two doses of I mg at two week intervals via the subcutaneous 
route [125]. The vaccine was very well-tolerated and there were no signs of hypersensitivity from 
multiple doses and reports stated the vaccination lasted upto two years (63]. Even though the 
vaccine was used for over two decades, evidence of clinical efficacy of the vaccine is not available 
and the vaccine is no longer used (63]. The other non-living Brucella vaccine used in the former 
USSR was derived from their live attenuated Brucella vaccine 19-BA. It was called Brucella 
chemical vaccine (BCV) and is made from a cell wall preparation of 19-BA extracted using 0.1 M 
acetic acid [63]. The optimal dose of BCV was 1 mg via the intramuscular route, which only induced 
mild local reactions [341]. The protection afforded by BCV was found to be comparable to the live 
19-BA vaccine and it caused less adverse reactions and no multiple dosing hypersensitivity 
indicating that this vaccine could warrant further study [311,63]. 
1.3.2 Live attenuated vaccines against Brucella 
Currently the most efficacious animal vaccines available for brucellosis are the live attenuated 
vaccines. These are live Brucella species that have known or unknown mutations resulting in 
attenuation of virulence. Live attenuated strains of Brucella species have been available for many 
years and are considered the most likely type of vaccine to elicit the type of immune response 
needed to clear or prevent infection. However, many of these live attenuated strains have issues 
regarding their use. For example, many may still cause infection or have the potential to revert back 
to full virulence. However, the main problem with live attenuated vaccines is confusion of diagnosis 
since there is no way of determining a vaccinated animal from a naturally infected animal. 
1.3.2.1 Brucella melitensis Rev. 1 
B. melitensis Rev. 1 was created by Elberg and Faunce and is derived from a streptomycin- 
dependant mutant that, upon subculture, lost its dependence but retained its resistance to 
streptomycin [90]. It was originally developed for the immunisation of sheep and goats but is now 
also used for cattle, delivered subcutaneously with a dose of approximately 109 CFU [236]. Rev. 1 
induces serum-specific antibodies that persist in the host and help in clearance of infection. The 
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stability of Rev. 1 has been proven by passage in several animal species [236]. However, there are 
some drawbacks to Rev. 1. Although it is attenuated, depending upon the time of vaccination and 
dose given, it can still cause infectious animal abortions. It also induces positive serology which 
interferes with diagnostic testing so that it is not possible to differentiate between vaccinated 
animals and field-infected animals [291]. 
1.3.2.2 Brucella abortus strain 19 
Created by Buck in 1930, B. abortus strain 19 was derived from a virulent isolate from a Jersey 
cow. After being left in the laboratory at room temperature for approximately one year, the isolate 
was found to be attenuated [35]. Strain 19's attenuation is thought to be due to its inability to grow 
on erythritol, and therefore it is slow to colonise the reproductive tracts of its ruminant hosts [291]. 
The efficiency of stain 19 is dependant on a number of variables, including the age of animal, dose 
given and the vaccination route used. The optimal dose for strain 19 has not been determined, 
although the minimal dose is thought to be between 5x108 and 109 CFU [236]. Although it is rare, 
strain 19 can still cause infectious abortions if given during pregnancy and isolated bacteria from 
these occurrences have been able to grow in the presence of erythritol, demonstrating that the 
mutation is reversible [291,96]. Strain 19 also produces positive serology so vaccinated animals are 
indistinguishable from field infected animals [291]. 
1.3.2.3 Brucella suis strain 2 
B. suis strain 2 was produced by Xie Xin in 1986, derived from an old laboratory strain of B. suis 
biovar 1 that had become naturally attenuated after serial transfer on culture media for several 
years [359]. Strain 2 has been used in China since 1971 for the vaccination of sheep, pigs, goats 
and cattle. The vaccine is given orally and is not known to cause abortions in animals and 
persistence in tissues has not been reported either [236]. 
1.3.2.4 Brucella abortus RB51 
B. abortus RB51 was created by Schurig et al in 1991. It is derived from a rifampin-resistant mutant 
of B. abortus 2308 that was repeatedly passaged on trypticase soy agar with varying concentrations 
of rifampin or penicillin [290]. Being a rough mutant of B. abortus, the RB51 O-chain component of 
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the LPS is located intracellularly. This roughness was found to be very stable after multiple in vivo 
and in vitro passages of the strain [290]. RB51 is attenuated in many animals including mice, 
guinea pigs, goats and cattle [291]. RB51 is a licensed vaccine and it has been found that it has an 
insertion sequence 711 (IS711) in the gene which encodes for glycosyltransferase (called wboA 
gene), an enzyme essential in the biosynthesis of O-chain of LPS [336]. 
1.3.2.5 Novel live attenuated Brucella vaccines 
Modern molecular manipulation techniques have enabled easier engineering of live attenuated 
strains of Brucella species for evaluation. There is a vast array of literature describing novel 
attenuated Brucella species [76]. For example, Kahl-McDonagh and Ficht have defined one B. 
melitensis deletion mutant named Dasp24 which persists for longer in vivo and provides superior 
protection against B. melitensis challenge in mice [158]. This mutant has also been tested for 
protective efficacy in a goat model, providing protection against infection abortions [157]. A B. 
abortus attenuated mutant recently created by Paulley et al. has mutations in the bhuA (Brucella 
heure utilisation) gene and exhibits reduced pathogenicity in both in vitro and in vivo experiments 
suggesting that heure utilisation is important for Brucella virulence [257]. The main problem with 
developing live attenuated vaccines for human use is the possibility of reversion back to full 
virulence and persistence of some strains. Two approaches have been used to try and overcome 
this problem. The first involves the creation of mutants in existing attenuated strains, creating highly 
attenuated live vaccines which are less likely to revert back to a virulent form [16]. The second is 
the microencapsulation of highly attenuated mutants for slow release and enhanced 
immunogenicity [17]. 
1.3.3 Non-living Brucella vaccines 
1.3.3.1 Brucella abortus 45/20 
B. abortus 45 was originally isolated from a cow in 1922. A rough mutant was obtained after 20 
passages through guinea pigs and was so named B. abortus 45/20. B. abortus 45/20 was able to 
protect guinea pigs and cattle from Brucella infections [213,214]. However, when used as a live 
vaccine it had the ability to revert back to its smooth virulent form, thus losing its attenuation and 
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interfering with diagnostic testing. As the live form had a tendency to revert to wild-type [225], 45/20 
was used as a bacterin (a suspension of killed bacteria) and incorporated with adjuvant, usually 
based on water/oil emulsions [291]. Protection from the killed 45/20 was variable and studies often 
gave mixed results when compared to strain 19. Killed 45/20 did not cause abortions or provide 
positive serology results. However, because of batch-to-batch variation, unpredictable efficacy, and 
severe local reaction at the injection site, vaccination with 45/20 was discontinued [291]. 
1.3.3.2 Recombinant sub-unit protein vaccines 
Recombinant sub-unit vaccines are attractive options for vaccination due to their ease of production 
and safety record. They are also proven to be licensable vaccines as shown by the development of 
the sub-unit hepatitis B vaccine [306]. There has been substantial research published describing 
the development of recombinant sub-unit vaccines to protect against brucellosis (table 1.1). As all 
the experimental techniques, Brucella species and strains used for the development of novel sub- 
unit vaccines are different it is difficult to compare all the research from the literature directly. Some 
of the more recent work to develop sub- unit vaccines against Brucella has been completed by 
Pasquevich et al. who have identified two novel protective recombinant outer membrane proteins, 
Ompl6 and Ompl9, from B. abortus [255]. Ompl6 and Ompl9 were tested in two different forms, 
lipidated and unlipidated, both in combination with incomplete Freunds adjuvant (IFA), Alum, or 
Cholera toxoid (CT). Vaccination with two 30 pg doses of the lipidated forms of Omp16 and Omp19 
in combination with IFA conferred significant protection against B. abortus. Interestingly, 
immunisation with the unlipidated forms of Omp16 and Omp19 induced greater protection against 
B. abortus infection and similar levels of protection to B. abortus strain 19. Immunisation with 
unlipidated Omp16 and Omp19 adjuvanted with Alum or CT also conferred protection against B. 
abortus challenge [255]. 
Increasing the efficacy of already identified vaccine candidates is also important. For example, the 
vaccine candidate L7/L12 is a well characterised novel protective antigen against Brucella and it 
has already been shown to be protective in the mouse model of brucellosis when administered as a 
DNA vaccine or recombinant protein [199,176,243]. Two more recent studies have shown that 
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liposomised and escherisome-mediated delivery of L7/L12 can help to increase the efficacy of this 
protective antigen [205,206]. 
Another sub-unit vaccine candidate to be evaluated builds upon two already identified sub-units, 
Brucella lumazine synthase (BLS) [334] and Omp3l [46]. Created by Cassataro et al., this protein is 
a combination of BLS with the 27 amino acid exposed loop of Omp3l attached to its N-terminus. 
When mice are immunised with BLS, Omp31 or a combination of the two proteins and subsequently 
challenged with B. ovis, protection is observed. However, when mice are immunised with the hybrid 
protein the level of protection seen against B. ovis increases to better than that of B. melitensis 
Rev. 1. Immunisation with this hybrid protein also confers protection to challenge with B. melitensis 
but to a lesser degree than against B. ovis [47]. The main problem associated with recombinant 
sub-unit vaccines is that they are generally less immunogenic than live attenuated or killed whole 
cell preparations [262]. To overcome this problem protein vaccines are often administered with an 
adjuvant. 
1.3.4 Adjuvants 
Adjuvants are used for various purposes such as increasing the immunogenicity of a recombinant 
protein, to reduce the number of vaccinations needed for protective immunity, to act as a delivery 
system to increase uptake of antigen by the mucosa, or to cause slow release of the antigen 
leading to a longer lasting immune response. Although important features of any vaccine 
formulation there are only a handful of licensed adjuvants available for human use. They are 
aluminium compounds, a micro-fluidised oil/water emulsion called MF59 and some virosomes [162]. 
Due to the limited amount of adjuvants available for human use the search is on for the next big 
breakthrough in adjuvant technology. 
1.3.4.1 Aluminium salt adjuvants 
After being discovered in the 1920s aluminium salts remain the only adjuvant licensed for human 
use in the United States by the Food and Drug Administration (FDA). First described in the open 
literature by Glenny et al. [117], aluminium salts have been widely adopted as the most common 
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adjuvants used in humans. This is due to the fact that aluminium salts are well tolerated and there 
is a large array of data to support their safe use over the years [189]. The most common of the 
aluminium salt adjuvants are aluminium phosphate and aluminium hydroxide (also known as 
Alhydrogel). The mechanisms of action for aluminium salt-based adjuvants are three fold: (i) they 
create a depot effect at the site of immunisation leading to slow release of the antigen [189], (ii) they 
stimulate immune cells via activation of complement, and (iii) they increase the activation of 
macrophages [162]. Licensed vaccines that currently use aluminium salt technologies as an 
adjuvant include the adsorbed Diphtheria and Tetanus toxoids and the recently licensed 
recombinant Hepatitis B vaccine [4]. The limiting factor of aluminium salt adjuvants is their induction 
of an antibody response and bias toward the generation of a Th2 type immune response. 
1.3.4.2 Freund's adjuvants 
One of the most potent adjuvants developed to date is Complete Freund's Adjuvant (CFA) [106]. 
Developed in the mid 1930s by Freund, it is composed of an water-oil emulsion containing killed 
mycobacteria. Although it is a potent stimulator of the immune system, CFA is very reactogenic and 
so deemed unsuitable for human use [342]. Incomplete Freund's adjuvant (IFA) is a less potent 
version of CFA which does not contain the mycobacteria. IFA is more suitable for human use and, 
although in extreme cases it can still cause granulomas in humans, it has been used in some 
influenza vaccines in the United Kingdom [342]. 
1.3.4.3 Immunostimulatory complexes 
The immunostimulatory complexes (ISCOMs) (figure 1.4), were first discovered by Morein et a/. in 
1984 [223]. Originally designed as a presentation method for proteins from enveloped viruses, the 
ISCOMs function has developed and they have become a well characterised adjuvant technology. 
ISCOMs are approximately 40 nm cage-like structures that form naturally when saponins derived 
from the Quillaja saponaria tree in South America, cholesterol and phospholipids are mixed under 
specific conditions [259]. The use of ISCOMs in humans and animals can be limited due to the 
toxicity of the saponins used. To remove the impurities a partially purified fraction of the saponins 
such as Quil A was produced. However, Quil A was also found to be unsuitable for human use as it 
has associated toxicity [24], and so it is now used in the veterinary field. The development of further 
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purified fraction of the saponins has led the way in the development of ISCOMs for human use, the 
most common of which is ISCOPREP®, a highly purified fraction of saponin (259]. The immune 
response generated by ISCOMs is generally broad, stimulating both antibody and cellular immune 
responses. Mice immunised with ISCOMs show increased recruitment of neutrophils, mast cells, 
macrophages and dendritic cells, all of which also show signs of increased activation via the 
secretion of immune modulators such as IL-1, IL-6, IL-12 and IFN-y [298,7]. There are a number of 
currently licensed ISCOM-based vaccines on the market in the veterinary medicine field, including 
Canvac CCi (made by Pfizer, a vaccine for Bordetella bronchiseptica in dogs) and Equilis® 
Prequenza (an equine vaccine against influenza) [3]. 
1.3.4.4 Oligodeoxynucleotides (CpG) 
Oligodeoxynucleotides containing CpG motifs (CpG) are short lengths of unmethylated CpG 
dinucleotides that are recognised by the innate immune system [171]. Unmethylated CpG 
dinucleotides are relatively common in the genomes of most bacteria but are suppressed and 
methylated in vertebrate genomes [172]. The innate immune system contains a range of pattern- 
recognition receptors (PRRs) that bind a range of molecules that are expressed across a variety of 
pathogens [173]. The best known PRRs are the TLR protein family. The stimulation of TLR9 (which 
recognises CpG) leads to the secretion of cytokine such as IL-6 and IL-10 from B cells and IFN-y 
and TNF-a from dendritic cells. Although there are no licensed CpG in use currently there have 
been a number of ongoing clinical trials to confirm the safety of CpG technology [2,61,174]. 
1.3.5 DNA vaccination 
DNA vaccination is a relatively new technology that was first described in the 1990s. In 1992, Tang 
et al. first described the basic principle of eliciting an immune response from DNA directly 
administered to the skin of mice [317]. The construction of DNA vaccines involves the insertion of a 
protective antigen gene in to a plasmid vector with a eukaryotic expression system. The purified 
plasmid is then directly inoculated into the animal or human and the hosts own cells synthesises the 
antigen, using RNA transcription and translational mechanisms in ribosomes. The antigen is then 
presented to the immune system, producing an immune response that aids in the clearance of the 
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infection [274]. DNA vaccines are able to elicit good cellular immune responses which are generally 
considered the appropriate immune response for intracellular pathogens such as Brucella [123]. 
The first experiments completed in small animals [317,108,275] and in non-human primates 
[196,192] spawned large amounts of optimism about this new technology. It was the transfer of this 
technology from small animals to humans that caused problems since early DNA vaccine trials in 
humans gave poor levels of immunity [201] and cast a shadow over the early enthusiasm of DNA 
vaccination for human use. However, in recent years there has been a resurgence in DNA vaccine 
technology. With the ever increasing improvements in molecular techniques and DNA vaccine 
construction, DNA vaccines are becoming increasingly effective at eliciting strong immune 
responses. Recently, four DNA vaccines have been licensed in the veterinary medicine fields 
against a range of diseases including West Nile virus [71] in horses and infectious haematopoietic 
necrosis virus [114] in salmon. There is also now a strong body of work that has shown DNA 
vaccine to have some efficacy in humans when specific vaccination regimes are used [195]. 
1.3.5.1 DNA vaccines for brucellosis 
Several studies indicate that DNA vaccines are able to provide protective efficacy against 
brucellosis (table 1.2). For example, Yang et al. tested a bank of potentially immunogenic antigens 
taken from the B. melitensis 16M genome as DNA vaccines in the Balb/c mouse model of protection 
against B. melitensis [364]. From their panel of antigens, the two best performing were a chaperone 
protein called trigger factor/immunophilin protein (TF) and bp26 (a periplasmic diagnostic antigen). 
When animals were dosed with both bp26 and TF in combination a 20-fold reduction in B. 
melitensis numbers was observed when compared to control mice [364]. Similarly, Commander et 
a/. have identified two protective antigens which produced 2-log reductions in Brucella spleen loads 
compared to control immunised mice [59]. These proteins are invasion protein B (InvB) and Omp25. 
lnvB shows good protection as a DNA vaccine against B. melitensis challenge but there is a frame- 
shift mutation in the B. suis homologue meaning that this vaccine might not work against B. suis. 
Omp25 is also a good vaccine candidate and is well conserved between all species of Brucella. 
L7/L12, a ribosomal antigen, has been used to provide a 1-log reduction in Brucella spleen loads 
when used as a DNA vaccine [176]. Luo et al. have improved upon the protective efficacy of L7/L12 
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by immunising mice with an L7/L12-Omp16 DNA vaccine. Mice then challenged with B. abortus had 
a 2-fold reduction in B. abortus CFU recovered [199]. One of the most effective DNA vaccines 
developed was a tripartite DNA vaccine encoding BSCP31 (an immunodominant protein in 
Brucella), superoxide dismutase and L7/L12. When mice were immunised with three doses of 50 pg 
DNA vaccine it induced a cytokine profile showing a Th1 bias, with increased INF-y and TNF-a 
production, and an increase in CD8` T cells. When immunised mice were challenged intravenously 
with 5x106 CFU of B. abortus 2308 mice displayed a 3.58 PU reduction in spleen loads 
1.3.5.2 DNA vaccine prime-boost strategies 
The principle of DNA prime-boost strategies is to first prime the immune system to an antigen using 
a DNA vaccine vector and then to boost the immune response generated by immunisation with the 
antigen in a different form, for example, as a protein [358]. This is known as a DNA prime protein 
boost strategy. This heterologous prime-boost strategy can lead to a stronger immune response 
than when only homologous antigen delivery is used. Prime-boost strategies have helped to 
enhance the effectiveness of DNA vaccines in human clinical trials and, in early 2008, two phase I 
clinical trials proved that prime-boost strategies using antigens from Human Immunodeficiency 
Virus (HIV) were successful at inducing strong immune responses in humans [129,345]. There has 
been only one known example of a prime-boost strategy being evaluated for Brucella species. 
Cassataro et al. used a DNA vaccine encoding Omp3l to prime the immune system and 
recombinant Omp3l protein to boost [49]. Results from this study indicated that the prime boost 
strategy induced higher levels of IFN-y, an important cytokine for protection against Brucella, but 
also higher levels of IL-10, a negative regulator of the immune system that can dampen down the 
Th1 immune response. There was also no difference between cytotoxic T cell responses in any of 
the immunisation groups. Protection studies against B. ovis and B. melitensis both revealed that 
mice immunised under the prime-boost vaccination regimen did not have a significantly lower 
bacterial burden in their spleens when compared to mice immunised with the individual 
components. 
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1.4 ATP - binding cassettes 
ATP-binding cassettes (ABC) proteins are one of the largest protein super families and they are 
found in all prokaryotes and eukaryotes. Although ABC proteins are extremely versatile they all 
contain one defining feature, the ability to hydrolyse ATP to ADP, providing the energy needed for 
active transport. The import and export of molecules across cell membranes is essential for 
bacterial survival, and ABC transporters are responsible for much of this movement. In fact, 5% of 
the E. coli genome encodes for ABC proteins [191 ]. 
1.4.1 Structure of ABC systems 
ABC proteins are well conserved proteins. The primary sequences and configuration of the sub-unit 
proteins in ABC systems are especially well maintained throughout the family of ABC systems 
[112]. Typically, ABC transporters consist of a highly conserved ATPase domain (the ATP-binding 
cassette, also known as the nucleotide binding domain), the role of which is to bind and hydrolyse 
ATP to ADP, which provides the energy needed for transport [326]. The ABC protein contains two 
conserved motifs called Walker A (G-X-X-G-X-G-K-S/T, where X represents any amino acid 
residue) and Walker B (o-o-o-r-D, where o designates a hydrophobic residue) [328]. Together the 
Walker A and Walker B motifs form the structure for ATP-binding [327]. These two motifs can also 
be found in any ATP-binding proteins, including those not associated with transport. ABC 
transporters also contain a signature sequence (LSGGQ/KQR) that is very well conserved between 
all ABC transport proteins. This sequence is also known as the linker peptide or C motif [112]. 
Although the configuration of ABC systems varies (figure 1.5 and 1.6), the majority of ABC systems 
comprise two hydrophilic ABC domains associated with two hydrophobic membrane-spanning 
domains (inner membrane (IM) proteins). Import systems are only found in prokaryotic organisms 
and contain both ABC domains and IM domains, along with extra-cytoplasmic binding proteins (BP) 
designed to bind the specific allocrite of that ABC system. In Gram-negative bacteria the BP are 
located in the periplasm whereas, in Gram-positive bacteria, they are anchored to the outer 
membrane of the cell via N-terminal lipid groups [261]. In comparison, ABC systems involved in 
export functions usually contain only IM and ABC domains fused together either via the N-terminus 
(IM-ABC) or the C-terminus (ABC-IM), which homodimerise to create a functional system [68]. 
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1.4.2 The roles of ABC systems 
ABC systems import a diverse range of substrates into the bacterial cell including peptides [82], 
polyamines [142], metal ions [57], amino acids [138], iron [170] and sulphates [163]. Substances 
exported by ABC transporters include antibiotics in both producing and resistant bacteria [219,330], 
fatty acids in Gram-negative bacteria [68] and toxins [137]. In addition to transporters, many ABC 
proteins have roles in house-keeping functions, such as regulation of gene expression [332] and 
DNA repair [68,121 ]. 
1.4.3 ABC systems and their roles in bacterial virulence 
For a long time ABC transporter proteins were thought of as important proteins for import and 
export processes only. There is now increasing instances of ABC transporters being cited as 
virulence factors [112]. Bacterial ABC systems that have been identified as virulence factors include 
putative ABC importers in Yersinia species responsible for nitrogen and amino acid import [160]. 
The mntA gene has also been identified in Bacillus anthracis [115]. Creation of a mntA knockout 
mutant of B. anthracis resulted in impaired growth in rich culture broth and increased sensitivity to 
oxidative stress. Using signature-tagged mutagenesis (STM) techniques, the oppD and oppFABC 
genes were identified in Staphylococcus aureus as virulence factors [218]. Recently there has been 
a lot of interest in polyamines and their roles in bacterial virulence [296]. There are two ABC 
transporter systems that are known to import polyamines, they are potABCD and potFGHI. Proteins 
from these systems have been identified as potential virulence factors in some bacteria. Genes 
identified in Streptococcus pneumoniae that encode proteins with homologies to E. coli PotD and 
PotA have been identified potential virulence factors [264]. There are also a number of other 
occasions where polyamine transport systems have been identified in human bacterial pathogens 
[202,362,296]. 
Although different families of ABC transporter proteins have been identified as virulence factors in 
pathogenic bacteria, one of the most common types of ABC transporters associated with virulence 
are those responsible for the import of metals. For example, the ABC transporter genes ybtPQ in Y. 
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pestis genes are required for iron import and mutation of ybtP make the bacteria avirulent in mice 
[100]. Streptococcus pyogenes mtsABC genes are important for import of both iron and 
manganese, and mutations in the mtsABC genes gives rise to an attenuated phenotype [149]. The 
Zinc importer znuA in Haemophilus dureyi is another example of an ABC transporter gene 
associated with virulence. Mutants in the znuA gene show decreased virulence in the rabbit model 
[188]. There is also some evidence that ABC transporters can be involved with cell attachment, 
which is also classed as a virulence characteristic. It has been shown that mutants in the glutamine 
transporter gene glnQ in group B Streptococcus show a decrease in fibronectin adherence along 
with reduced invasion in vivo [315]. 
1.4.4 Immunogenicity of ABC transporter proteins and their roles as 
potential vaccine candidates 
Proteins that are most commonly associated with immunogenicity are those visible to the host's 
immune system. For ABC transporters, this would be the membrane-anchored binding proteins in 
Gram-positive bacteria. However, in Gram-negative bacteria, the ABC systems are contained within 
the periplasmic space. However, it has been shown that proteins that are held within the 
periplasmic space or even embedded in the inner membrane in Gram-negative bacteria can be 
immunogenic [112]. The concept that ABC transporter proteins can be immunogenic when not 
visible to the immune system seems unlikely. However, if the bacteria have damaged cell walls or 
are phagocytosed and presented to the immune system by APCs it is likely these proteins would be 
displayed. Examples of immunogenic ABC transporter proteins include an amino acid ABC 
transporter protein of Brucella ovis identified by Teixeira-Gomes et al. using two dimensional 
electrophoresis and immunoblotting [319]. ABC transporter proteins have also been identified in 
Enterococcus faecium as potential targets for antibody therapy [40]. An immunodominant ABC 
transporter protein has also been identified in the problematic bacterium methicillin-resistant 
Staphylococcus aureus [41 ]. 
ABC transporter proteins have been successfully tested as vaccine candidates against a variety of 
different pathogens. An example is the LoIC protein in Burkho/deria pseudomallei [1301 which is 
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part of the putative LoICDE ABC system in B. pseudomallei, who's likely function it is to sort 
lipoproteins between the inner and outer membranes. When administered along with ISCOMs and 
CpG adjuvant, LoIC offers good protection against lethal B. pseudomallei challenge [130]. Similarly, 
PiuA and PiaA are ABC transporter proteins associated with iron uptake in Streptococcus 
pneumoniae. PiuA and PiaA have been shown to have protective properties against S. pneumoniae 
in the mouse model of protection [33]. In addition, ABC transporters proteins have also shown 
potential as novel vaccines for Y. pestis infection, the causative agent of plague. OppA is an ABC 
transporter binding protein putatively involved in the uptake of oligopeptides that has been shown to 
induce a protective immune response against experimental challenge with Y. pestis [316]. 
1.4.5 ABC transporters in Brucella 
A number of studies involving Brucella ABC proteins have been published in the open literature 
(table 1.3). Most of the research focuses on ABC protein-deficient mutants and their phenotypes 
and virulence. Some Brucella ABC transporter proteins can be considered virulence factors which, 
when mutated, result in the creation of an attenuated mutant. The znuA gene is putatively involved 
in zinc import in B. abortus, and is important in intracellular survival and virulence in mice [164]. 
Deletions of the znuA gene in B. abortus creates an attenuated mutant that is capable of protecting 
mice against wild-type B. abortus challenge [363]. Similarly, Kim et at created 4400 mutants of B. 
abortus to identify genes involved in internalisation and intracellular growth, reporting the 
identification of 25 genes, two of which were ABC transporter genes znuA and cydC [165]. 
Additionally, other genes of the cydDCAB operon (putatively involved in cytochrome bd biogenesis) 
are considered important in B. abortus, as a cydB mutants is defective in intracellular survival and 
lacks virulence in the mouse model of infection [93]. The cydD gene has been identified as 
essential for intracellular replication by B. suis [168]. Together, this suggests that cytochrome bd 
biogenesis is required for replication in the intracellular environment. Furthermore, iron import also 
may be important for bacterial survival since genes identified in B. abortus show that the ABC 
transporter protein FbpA is required for intracellular growth [94]. 
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1.5 Project aims 
There is currently no licensed human vaccine against brucellosis. Although there are live attenuated 
vaccines available for animal use, many of these can cause infection in humans, making them 
unsuitable for licensing for human use. The development of a sub-unit vaccine would be the safer 
alternative to a live attenuated vaccine. Although significant research into sub-unit vaccines has 
been initiated, to date no sub-unit vaccine has been effective enough for further development in 
humans and animals. Recently, ABC transporter proteins have been identified in bacteria as 
potential virulence factors [112] and there is evidence in the literature that ABC transporter proteins 
could make effective novel vaccine candidates [130,316,295,33]. Therefore, ABC transporter 
proteins could be tested as novel vaccine candidates against Brucella species. The aim of this 
project is to select, produce and evaluate ABC transporter proteins as potential sub-unit vaccines 
against Brucella melitensis. 
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Chapter 2- Materials and Methods 
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2.1 Bioinformatic techniques 
2.1.1 Identification of ABC systems in Brucella melitensis, Brucella abortus, 
Brucella suis, Brucella canis & Brucella ovis 
The prediction of ABC systems in sequenced bacterial genomes is based on the homology of 
experimentally identified or predicted ABC proteins from other bacterial systems. The Artemis 
viewer (available from www. sanger. ac. uk) was used to visualise the annotated Brucella genomes 
[78,258,128]. Using the annotated genomes, ABC proteins were searched for using an array of 
related words, specifically "ATP-binding cassettes", "binding protein", or "outer membrane protein". 
For completeness all proteins that were labelled as hypothetical or conserved hypothetical proteins 
were also checked. Hits were compiled and then genes upstream and downstream were also 
checked to ensure that all genes from one system were identified. After the genome searches were 
completed protein sequences were aligned using the basic local alignment search tool (BlastP) 
against other ABC proteins using the ABC systems: Information on Sequence Structure and 
Evolution (ABCISSE) database [68]. The ABCISSE database comprises 24000 proteins from 9500 
annotated systems over 795 different organisms. Where searches on ABCISSE were unclear, 
proteins were aligned using BlastP searches against the Genbank database to clarify function. 
Proteins searched against ABCISSE that scored a threshold e-value of 198 were assigned to an 
ABC family and sub-family where applicable. This method was completed for all sequenced strains 
of Brucella, then ABC system lists were compiled and compared. 
2.1.2 Identification of membrane-spanning domains 
Genes of interest had to be checked for membrane-spanning domains since, if present, they could 
cause problems with protein purification techniques in downstream processing. Sequences of the 
genes were obtained using the annotated genomes downloaded from Genbank. An internet-based 
program called, TMHMM v 2.0 (http: //www. cbs. dtu. dk/services/TMHMM-2.0was used to identify 
membrane-spanning domains [175]. Once membrane-spanning domains had been identified 
primers were designed to exclude these sections of the protein. If there were too many membrane- 
spanning domains to avoid, primers were designed to amplify the entire gene. 
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2.2 Microbiology Techniques 
2.2.1 Materials 
Chemical reagents and materials were mainly sourced from Sigma-Aldrich Ltd (Poole, UK). All 
restriction enzymes were acquired from Roche Diagnostics Ltd (Lewes, UK). Distilled water (dH2O) 
and phosphate-buffered saline (PBS) were obtained from Gibco (Paisley, UK). Bacto agar, yeast 
extract and tryptone were purchased from Oxoid Ltd (Basingstoke, UK). Brucella melitensis 16M 
DNA was kindly provided by Dr. N. Commander (Veterinary Laboratories Agency VLA, Weybridge, 
Surrey). 
2.2.2 Media Preparation 
Bacteria were cultured in Luria broth (L-broth), Luria agar (L-agar) or 2x Yeast Tryptone (2xYT) 
broth. L-broth consists of 1% (w/v) bacto tryptone, 0.5% (w/v) bacto yeast extract and 0.5% (w/v) 
sodium chloride in dHZO. 2x YT media constituents are 1.6% (w/v) Bacto tryptone, 1% (w/v) Bacto 
yeast extract, 0.5% (w/v) sodium chloride and 0.5% (v/v) glucose in dH2O. L-agar was made by the 
addition of 2% (w/v) bacto agar to L-broth. All media was sterilised before use by autoclaving and 
subsequently stored at room temperature. Antibiotics were used when necessary. Stock ampicillin 
was made at a concentration of 50 mg/ml, and was used to supplement L-broth or L-agar to a final 
concentration of 100 pg/ml. Chloramphenicol was made at a stock concentration of 34 mg/ml and 
added to media to a final concentration of 34 pg/ml. All stock antibiotics were filter sterilised through 
a 0.22 pm filter before use in any media. 
2.2.3 Growth of Escherichia cola 
Escherichia coli strains were routinely cultured for cloning, expression and purification purposes. E. 
coli were grown in L-broth at 37°C, shaking at 180 rpm. Alternatively, E. colt was grown on L-agar 
plates incubated at 37°C. 
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2.2.4 Maintenance of E. coil strains 
E. coli strains were maintained in 15% glycerol. Strains were grown overnight and 850 pI of culture 
was mixed with 150 pl of sterile glycerol. Stocks were then transferred to -70°C for long term 
storage. 
2.2.5 Culture of Brucella melitensis 16M and inoculum preparation 
B. melitensis 16M and Rev. 1 were cultured on serum dextrose agar (SDA) or serum dextrose (SD) 
broth. Cultures or plates were incubated at 37°C, 10% CO2. Challenge inoculum preparations were 
prepared from Brucella cultured on SDA for three days, harvested into PBS. Inoculum CFU was 
calculated using nephelometry readings (where a transmission value of 42-46% equates to a 1x1010 
CFU) and concentrations were adjusted accordingly. Administration of Brucella to mice was 
completed within 1 hour of inoculum preparation and exact CFU doses were enumerated following 
serial dilution of inoculum on SDA plates. 
2.3 Molecular Biology Techniques 
2.3.1 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction (PCR) was used to amplify the genes of interest for use in the cloning 
of recombinant proteins. Oligonucleotide primers were designed to amplify the genes (Table 2.1). 
Genes were amplified using varying PCR conditions and cycling temperatures (Tables 2.2 and 2.3). 
Basic PCR components were 10 pl 10x PCR buffer, 0.5 pl dNTP mix, 0.4 pl Taq polymerase, 15.6 
pl nuclease-free water, 0.5 pl forward primer and 0.5 pl reverse primer. Basic PCR temperatures 
were 96°C (10 minutes), (96°C (30 seconds), 50°C (30 seconds), 72°C (1 minute) for 30 cycles), 
72°C (10 minutes). All temperature cycling was performed in either a Thermo Cycler 9600 or 2400 
(Applied Biosystems, Warrington, UK). All oligonucleotide primers were synthesised by MWG 
Biotech (Milton Keynes, UK). Nuclease-free water (Promega UK, Southampton UK) was used as a 
negative control in all PCR reactions. Once PCR reactions were complete, all reactions were cooled 
to 4°C. 
56 
.4 co 
a) 
E 
U 
u) 
L 
w 
C 
N 
4) 
C 
G) 
C) 
rr N 
21 
Q. 
E 
N 
0 
u) U) 
7 
N 
u) U 
C 
u) 
u) 
N 
a) 
0 
(D 
C 
0 
0) 
0 
N 
0 
to 
F- 
U) 
N 
N 
0 
CL 
rn 
c c 
0 
v 
Jo- 
0 
E 
0 
c N 
0) 
ö 
G' 
V 
V 
7 
Q 4) 
N 
m 
O 
Q A) 
Nr 
vO 
Ica 
w 
A) 
Ur 
my 
>r_ 
N 
UE 
v 
2 
7 
QN 
O 
rk-. E 
N 
äý 
3 
QN 
0c 
vy 
2- 
-2 
QN 
Uc 
my 
>cc 2` 
QN 
Uý 
vO 
cc 
22 
(1) 
Jc 
NO 
>cC 
00 
4) 
o 
U 
ý Q 
Ü ý UU' 
Ü Q 0 U Q 
ö 0 ä V V V 
U (D (D F- 
Ü ý Q Ü H 
166- 
ý 
Cý 
Q U 
(ýj 
U 
V Cý 
(ý 
:. V 
Ü Q 
~ FV- 
U U 0 V 
V 
V V Q Cý C9 ý 
U Q F- 0 U F - 
'> 
c Ü Ü V ~ Imo- Ü e 
14 w < - 
0 
< 
0 
V U m 
u; ý 
` 
V V 
o 
Q 
U 
< 
H Q 
Ü 
V V 
ý Ü U y 
U Q 
H ¢ I- 
Ü 
Cý C9 
a) 
w 
t U U Ü V C') 
I- U 0Q 
0 
y 
h- 
(9 V 
(D U 
0 
a 
C9 Q 
V Ü ý U o V Ü ö 
Uý 01 
U 
0 ÜH 
0 
U 
U' 
o Vr 
Q. 
- 
ý 
Cý 
O 
U ÜZ y 
Ü O H 0 
ý 
Ü 
QU 
Qw 
Z 
0 QO j 
(ý 
Hd 
t 
F- X 
w CD 
X 
U 
Q 
j Q 
t 
-X ý ý 
LL LI- a LL 
u7 
ä N N Ü Ü 0 0 ci 
ä 
0 0 «5 
m m m m m m m m m m 
C 
O 
8 
t 
N 
N 
Ö 
C 
(1) 
c) 
O 
U 
a) 7 
m 
G 
0 
8 
a. O 
N 
N 
u) 
0 
a) 
'O 
8 
u) 
57 
rn c c 
0 Ü 
MN^, 
W 
a) 
C) 
C) 
c_ 
0. 
E 
N 
c 0 
0 
a 
a 
E 
CL 
0 
N 
N 
d 
: °. E 0000 0ýLf) U. ) U)4. ) 
0 
&n un Q to 
NNZN 
G 
0NN I- N 
=d ý7 
.NNcN 
a. d 
cr l! 
E '0 T 2-L IU 
ö to 
ZýQ. ooKX) 
U) 
0o 
vN 
EW 
ro 
06 n. ce m r- co rE 
c 
m 
0 0. A E 
0E '-'-r-r- U> 
mCL 
E 
ä o 
z . -.. -ý 
c (0(OZ(0 
o000 
"ö 
0N JU 
58 
Table 2.3: Optimal PCR temperature cycles for PCR reactions 
Optimal PCR temperature conditions 
Amplification Cycle 
Den. °C 
(Time 
minutes) 
Den. °C 
(Time 
minutes) 
Ann. °C 
(Time 
minutes) 
Ext. OC4 
(Time 
minutes) 
Ext. C 
(Time 
minutes) 
Cyc. °C" 
ZnuA 96 (5) 96 (0.5) 59 (0.5) 72 (1) 72 (10) 30 
Cgt 96 (5) 96 (0.5) 59 (0.5) 72 (1) 72 (10) 30 
LoIE 96 (3) 96 (0.5) 60 (0.75) 72 (2) 72 (5) 30 
CydD 96 (5) 96 (0.5) 59 (0.5) 72 (1) 72 (10) 30 
OppA 96 (5) 96 (0.5) 59 (0.5) 72 (1) 72 (10) 30 
1= Denaturing step 
2= Amplification denaturing step 
3= Amplification annealing step 
4= Amplification extension step 
5= Final extension step 
6= Number of amplification cycles 
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2.3.1.1 Pfu polymerase PCR 
Pfu polymerase was also used during some PCR methods to produce DNA fragments for cloning. 
This is a proof-reading polymerase designed to reduce sequence errors during amplification. 
However, Pfu leaves blunt ends on PCR products. In order to clone into the pCR®T7/NT-TOPO® 
vector, the PCR product required the addition of 'sticky ends' before ligation. 
2.3.1.2 Addition of sticky ends to blunt end PCR products 
PCR product was purified using a Qiagen QlAquick PCR purification kit using manufacturers 
instructions. Purified PCR (5 NI) product was mixed with 1.5 pi Taq polymerase and 1.5 pI dNTP. 
This mix was then heated to 72°C for 10 minutes, and then chilled to 4°C. 
2.3.2 Agarose gel electrophoresis 
DNA was visualised using agarose gel electrophoresis. Gels were prepared using 0.7 or 1% (w/v) 
UltraPure agarose (Amersham Biosciences, Chalfont-St Giles, UK) dissolved in 1x TAE buffer 
(40mM Tris-acetate, 1mM EDTA). Ethidium bromide was added to a final concentration of 0.5 
pg/ml. DNA was prepared by mixing samples in a ratio of 1: 6 with 6x DNA loading buffer (40% (w/v) 
sucrose and 0.4% Bromothemol blue (w/v) in dHZO). Up to 20 pl of DNA was loaded in to a single 
well of a gel, along with suitable molecular weight ladders (Roche Diagnostics Ltd Lewes, UK). Gels 
were run in Sub-Cell GT gel tanks (Bio-Rad laboratories Ltd., Hemel Hempstead, UK) at a voltage 
of 70-100 V for 60-90 minutes. The gels were visualised and photographed under ultraviolet light 
using a GelDoc 1000 Molecular Analyst system (Bio-Rad Laboratories Ltd., Hemel Hempstead, 
UK). 
2.3.3 Cloning Techniques 
2.3.3.1 Plasmid - pCR®T7/NT-TOPO® 
The pCR®T7/NT-TOPOO (Invitrogen Ltd, Paisley, UK) plasmid (Figure 2.1) was used for the initial 
cloning of genes in this study. This vector was chosen because it has several features that are 
useful for cloning, protein expression and purification. This plasmid has a single deoxythymidine 
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Figure 2.1: pCR®T7/NT-TOPO® plasmid map 
Schematic diagram showing important features of this plasmid, such as 
the T7 promoter, His6 Tag and the ampicillin resistance gene (adapted 
from Invitrogen manual pCR®T7 TOPO® TA Expression Kits Version 121st 
October 2002). 
BamH I 
Modified T7 RBS 6xHis 
Promoter 
Hind III EcoRl 
T7 
Terminator 
TOPO® Cloning 
Site 
pCRT7®/NT-TOPO® f1 Origin 
2870 bp 
Ampicillin resistance cassette 
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overhang which can be used for the effective ligation of PCR products amplified using Taq 
polymerase as Taq polymerase leaves a single deoxyadenosine overhang on PCR products. It also 
has an ampicillin resistance gene, which allows for the effective selection of transformed E. coli 
colonies on selective media. The modified T7 promoter in the plasmid is an inducible promoter 
which allows expression of the protein to be switched on by the addition of isopropyl-Beta-d- 
thiogalactopyranoside (IPTG). Also encoded within the plasmid is an N-terminal 6x histidine tag (His 
6). This enables the expressed proteins to be purified via affinity-tagged chromatography and also 
allows the detection of the protein using Western blotting via a biotinylated anti-histidine antibody. 
2.3.3.2 Plasmid - pTrcHis A/B 
The pTrcHis A/B plasmid was used as the cloning and expression vector for the genes synthesised 
by Geneart AG (Regensburg, Germany), as Geneart AG required a vector without the 
deoxythymidine overhangs present in the TOPO® vectors. This vector is commercially available 
from Invitrogen Ltd (Paisley, UK). This has similar features to the pCR®T7/NT-TOPO® plasmid 
(Figure 2.2), including ampicillin resistance, an N-terminal Hise tag, and an IPTG-inducible 
promoter. 
2.3.3.3 Ligation of genes into pCR®T7/NT-TOPO® 
Cloning of genes into this pCR®T7/NT-TOPO® was carried out using the manufacturer's 
instructions. Ligation mixtures contained 0.5-4 pi PCR products, 1 pl salt solution, 1 pl TOPO® 
vector, and dHZO to give a final volume of 5 pl. This mixture was incubated for 5 minutes at room 
temperature then stored at -20°C. Alternatively, cloning reactions mixtures were left at 16°C 
overnight and then stored at -20°C. 
2.3.3.4 DNA sequencing 
After PCR and cloning of DNA into pCR®T7/NT-TOPT0, the plasmid constructs were sequenced. 
All sequencing reactions were completed by Lark Technologies Inc (Takeley, Essex, UK). 
Sequencing results were visualised and analysed in SegManTM II (DNAStar Inc, Madison WI, USA) 
for errors that may have occurred during amplification. Insert-specific sequencing primers were 
designed using Clone Manager professional suite version 8 (Scientific & Educational Software, 
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Figure 2.2: pTrcHis A/B plasmid map 
Schematic diagram showing important features of this plasmid, 
including the pTrc promoter, His6 Tag and the ampicillin 
resistance gene (adapted from Invitrogen manual pTrcHis A, B 
and C vectors for expression of recombinant proteins containing 
N-Terminal 6xhis tags in E. coli version G 17th October 2005). 
pTrc RBS ATG start 6xHis Multiple cloning site 
promoter 
EcoRl 
Hind III 
BamH I 
Xho I 
Pst I 
F Ampicillin 
cassette 
pTrc promoter 
pTrcHis A, B 
4400 bp 
pBR322 origin 
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Cary, NC, USA). The universal primers T7 forward primer (5' - TAATACGACTCACTATAGGG - 3') 
and the reverse primer pRSET reverse primer (5' - TAGTTATTGCTCAGCGGTGG - 3') were also 
used for sequencing. 
2.3.3.5 Transformation of plasmid constructs Into competent maintenance 
or expression cells 
Plasmid DNA constructs were transformed into different E. coli strains for maintenance or 
expression. Table 2.4 outlines the E. coli strains used in this study. All transformations were carried 
out according to the E. cola strain manufacturer's instructions (Invitrogen). 
2.3.3.6 Plasmid DNA purification 
Plasmid DNA was purified from 3 ml of overnight E. coli cultures using a Qiagen QlAprep Spin 
Miniprep Kit (Qiagen, Crawley UK) according to manufacturer's instructions. Purified plasmid DNA 
was stored for long term usage at -20°C and for short term usage at 4°C. Quantification of the 
plasmid DNA was performed using a GeneQuant II spectrophotometer (Amersham Biosciences, 
Chalfont-St Giles, UK) according to manufacturer's instructions. Purified plasmid DNA was 
visualised using agarose gel electrophoresis (section 2.3.2). 
2.3.3.7 DNA restriction digestion 
Digestion of DNA was performed using restriction enzymes (Roche Diagnostics Ltd Lewes, UK) 
according to the manufacturer's instructions. DNA restriction digest mixtures contained 5 pl DNA, 
10 U of each restriction enzyme, 2 pl of appropriate incubation buffer and dH2O to a final volume of 
20 pl. DNA digestion reactions were incubated at either 37°C for 2-4 hours or at 16°C for 16-20 
hours, as appropriate. 
2.3.4 Production of PotD and PotF DNA vaccines 
2.3.4.1 DNA vaccine construction and vector pcDNA3.1 
DNA vaccines encoding the PotD and PotF genes were constructed by Geneart (Regensburg, 
Germany). PotD and PotF genes were inserted into the DNA vaccine vector pcDNA3.1 (figure 2.3). 
The pcDNA3.1 vector was chosen for use as the DNA vaccine vector as it has had extensive use in 
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Table 2.4: E. coli strains used in this study 
N/A = Not applicable 
E. coli strain Resistance Comments Available from 
E. co/iTOP10F N/A Maintenance strain 
Invitrogen Ltd, Paisley 
UK 
E. coli BL21 N/A Expression strain 
Invitrogen Ltd, Paisley 
UK 
E. coli BL21* N/A Expression strain 
Invitrogen Ltd, Paisley 
UK 
E. coil BL21 pLysS Chloramphenicol Expression strain 
Invitrogen Ltd, Paisley 
UK 
E. coli BL21* (DE3) Chloramphenicol Expression strain 
Invitrogen Ltd, Paisley 
pLysS UK 
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Figure 2.3: pcDNA3.1 plasmid Map 
Schematic diagram showing important features of this plasmid, including 
the human cytomegalovirus promoter needed for expression in 
mammalian cells, ampicillin resistance gene for growth and selection in 
bacterial cells, the neomycin resistance cassette for expression of the 
protein in mammalian cell lines and the pUC origin for high copy number 
replication in E. coli (adapted from Invitrogen manual pcDNA3.1 (t) 
Version 1 1997-2001). 
T7 Multiple cloning site 
promoter 
EcoRl 
Not I 
Xho l 
Xba l 
Hind 111 
Apa I 
Bam HI 
Human cytomegalovirus 
(CMV) promoter 
pcDNA3.1 
5428 bp 
Ampicillin resistance 
cassette 
Neomycin resistance 
cassette 
pUC on 
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the Brucella field [59,199,364,10]. 
2.3.4.2 Transformation and storage of DNA vaccines into E. coil 
DNA vaccine constructs were transformed into E. coli TOP10 host cells for long term storage and 
large scale DNA vaccine production. Glycerol stocks of E. coli TOP10 cells containing DNA 
vaccines were made and stored at - 80°C. 
2.3.4.3 Large scale production of DNA vaccines 
Large scale production of DNA vaccines was achieved using Qiagen endotoxin free giga prep kits 
(Qiagen, Crawley UK), used according manufacturers instructions. Preparations of DNA vaccines 
were ensured endotoxin free by the use of virgin plasticware and the pre-soaking of any glassware 
in 0.5 M NaOH for at least 4 hours before use in the assay. The concentration of the DNA vaccines 
was calculated using an A260 reading and the purity of all DNA vaccines produced was assessed 
using A2601A280 ratio. DNA preparations with AZ60/A280 ratios of 1.8-2.0 were considered of suitable 
purity for further use. 
2.3.4.4 Expression of recombinant DNA vaccines in mammalian cells 
COS-7 (African Green Monkey kidney cells) cells obtained from the European Collection of Cell 
Cultures (ECACC, Porton Down, UK) were cultured in Dulbecco's modified essential medium 
(DMEM, Gibco BRL, Paisley, UK) supplemented with 10% foetal bovine serum (FBS), 2 mM 
glutamine and 1 mM penicillin-streptomycin. The cells were grown in 150 cm3 tissue culture flasks 
in a monolayer culture, and passaged when they reached a confluent layer. The cells were grown at 
37°C, 5% C02 and relative humidity. The passaging of cells was completed by the removal of the 
cell monolayer using trypsin EDTA solution (0.15% (w/v) trypsin, 0.01% (w/v) EDTA in PBS) and 
seeding into fresh flasks at a cell density of 1x107 cells. COS-7 cells were transfected with DNA 
vaccine constructs in complex with GeneJuice® transfection reagent (Novagen, Madison, USA), 
according to manufacturer's instructions. After 48 hours incubation at 37°C, 5% CO2 and relative 
humidity, cells were harvested and resuspended in 100 pl 2x Laemilli buffer (Sigma - Aldrich Co 
Ltd, Poole, UK). The samples were then boiled for 5 minutes before evaluation of protein 
expression by Western blotting (section 2.4.1.2). Western blots were probed with mouse anti-sera 
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raised against the protein of interest, PotD or PotF, generated from the animal trial performed 
during this work (section 2.5.3). 
2.4 Protein techniques 
2.4.1 General protein techniques 
2.4.1.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS- 
PAGE) 
Preparation of samples for sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS- 
PAGE) differed depending on the type of sample. E. coli cells were centrifuged at 13000 rpm for 2 
minutes before being mixed with SDS reducing buffer (4 ml dHZO, I ml 0.5M Tris-HCI pH 6.8,0.8 
ml glycerol, 1.6 ml 10% (w/v) SIDS, 0.4 ml 2- ß-metcaptoethanol, 0.05% (w/v) Bromophenol blue) in 
a ratio of 3: 2, then lysed in a boiling water bath for 5 minutes. Purified protein was mixed in a ratio 
of 3: 2 with SDS reducing buffer, and then added to a boiling water bath for 5 minutes. SDS-PAGE 
was performed using the PhastSystemTM (Amersham Biosciences Chalfont-St Giles, UK) according 
to the manufacturer's instructions. Briefly, 1 pl of each sample was loaded onto an application comb 
and applied to a PhastSystemT"" gel. Proteins were run on 10-15% gradient polyacrylamide gels, 
and suitable molecular weight makers were added to the gels to determine the size of relative 
bands. Low molecular weight makers were purchased from Amersham Biosciences (Chalfont-St 
Giles, UK) and the markers were prepared in the same way as purified protein for SDS-PAGE. 
When SDS-PAGE gels were to be Western blotted, biotinylated markers or full-range rainbow 
markers (Amersham Biosciences Chalfont-St Giles, UK) were used. PhastGel Blue R (Amersham 
Biosciences, Chalfont-St Giles, UK) was used to stain the SDS-PAGE gels according to 
manufacturer's instructions. Gels were stained for 20-60 minutes before immersing in destain (25% 
(v/v) methanol, 5% (v/v) acetic acid and 70% dH2O) until the blue colour had gone, and destain was 
changed where necessary. Gels were then fixed using 5% glycerol, 5% acetic acid and 90% dH2O. 
Gels were dried in a drying oven overnight at 37°C. 
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2.4.1.2 Western blotting 
Electrophoresis of proteins was performed using SDS-PAGE gels as previously described. 
ImmobilonTM-P nitrocellulose membrane (Millipore, Bedford, MA, US) was activated by soaking in 
methanol for 1 minute, then washed in dH2O for 1 minute and soaked in transfer buffer (25 mM Tris, 
150 mM glycine, 10% (v/v) methanol, pH 8.3) for 1 minute. Six pieces of filter paper were also 
soaked in transfer buffer. Once electrophoresis was complete the gel, nitrocellulose and filter paper 
was assembled on the PhastSystemTM. The transfer of proteins from the gel to the nitrocellulose 
membrane was performed using the PhastSysteMTM according to manufacturer's guidelines. To 
develop Western blots the nitrocellulose membrane was blocked (to reduce non-specific binding of 
primary and secondary antibodies to the nitrocellulose membrane) using 5% (w/v) skimmed milk 
powder dissolved in PBS (Blotto) for 16-20 hours at 4°C. Primary antibody (mouse anti-histidine 
IgG, AmershamTm Biosciences, Chalfont-St Giles, UK) was added at a dilution of 1: 1000 and 
membranes were then incubated at room temperature for 1 hour. Membranes were rinsed using 
Blotto and then washed three times using PBS containing 0.05% (v/v) tween-20 (PBST). Secondary 
antibody (goat anti-mouse IgG conjugated to horseradish peroxidase (HRP), (Bio-Rad laboratories 
Ltd., Hemel Hempstead, UK)), along with avidin-HRP (to allow marker detection, Bio-Rad 
laboratories Ltd, Hemel Hempstead, UK) was added at a dilution of 1: 1000. The membrane was 
incubated at room temperature for 1 hour. The membrane was rinsed and washed again using 
PBST and developed by the addition of 3,3'-Diaminobenzidine (DAB peroxidase substrate, Sigma- 
Aldrich Co. Ltd., Poole, UK) according to manufacturer's instructions. Reactions were stopped by 
rinsing the membrane for 30 seconds in dHZO. Membranes were then left to dry at room 
temperature overnight. Alternatively, Western blots were developed using Enhanced 
Chemiluminescence (ECL) detection reagents (AmershamTm Biosciences, Chalfont-St Giles, UK). 
In this case, nitrocellulose membranes were placed on a plastic cover and 1 ml of detection reagent 
(ECL detection reagent 1 and 2 in a 1: 1 mix) was added to the membrane. Membranes were then 
incubated for 1 minute at room temperature. The membrane was then sandwiched between two 
plastic covers and the detection reagent was squeezed off. Membranes were then exposed to 
Amersham ECL hyperfilm (AmershamTM Biosciences, Chalfont-St Giles, UK) for 30 seconds -2 
minutes in a darkroom under red light conditions. ECL hyperfilm was then developed by submersion 
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in ECL developer solution (Sigma-Aldrich, Poole, UK) for 1 minute, then washed in H2O for 1 minute 
before being exposed to ECL fixer solution (Sigma-Aldrich, Poole, UK) for 1 minute, and a final 
wash in H2O for 2 minutes. Developed and fixed hyperfilms were then left to air dry for at least 4 
hours. 
2.4.2 Expression and Purification techniques 
2.4.2.1 Protein expression 
To evaluate protein expression glycerol stocks of expression strains of E. coil (section 2.2.4) were 
streaked onto L-agar plates supplemented with the appropriate antibiotics and incubated at 37°C for 
16-20 hours. One colony from this plate was used to inoculate a 100 ml L-broth culture containing 
appropriate antibiotics. This was then incubated for 16-20 hours at 37°C. E. coli cultures were 
started by inoculating 400 ml L-broth culture containing appropriate antibiotics and 4 ml of 10% (v/v) 
sterile glucose with 10 ml of overnight culture. Cultures were grown to 0.4-0.6 OD800, (mid-log 
phase) and 1 ml of culture was removed as a pre-induction sample. Cultures were then induced by 
the addition of IPTG to a final concentration of 1 mM, then cultures were left for 3-4 hours before a 
1 ml post-induction sample was taken. Cultures were centrifuged at 10000 rpm, the supernatant 
was removed and the pellets were stored at -20°C for future use. Pre- and post-induction samples 
were evaluated by SDS-PAGE (section 2.4.1.1) and Western blotting (section 2.4.1.2). Gels and 
blots were examined for protein bands of the correct size (as predicted using EditSeq DNAStar Inc, 
Madison WI, USA). If appropriate sized band were present, then protein solubility was addressed 
(section 2.4.2.2). Table 2.5 shows the optimal expression conditions for all of the protein vaccine 
candidates. 
2.4.2.2 Solubility of proteins 
The assess the solubility of the expressed proteins, protein pellets generated in section 2.4.2.1 
were resuspended in 4 ml of PBS containing 300 pg/ml DNAase I and one complete EDTA-free 
protease inhibitor tablet (Roche Diagnostics Ltd Lewes, UK). Suspensions were sonicated 4 times 
(SoniPrep 150, Sanyo MSE, Leicester UK) at a amplitude of 10 microns for 30 seconds with 30 
second rests between. The suspension was then centrifuged at 15,000 rpm for 15 minutes at 4°C. 
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The supernatant and pellet were separated and the pellet was resuspended in 4 ml PBS. Both the 
supernatant and pellet were processed for SDS-PAGE (section 2.4.2.1) and Western blotting 
(section 2.4.2.2). SDS-PAGE gels and Western blots were then examined for appropriate sized 
bands, and proteins that appeared in the supernatant samples were deemed soluble and proteins 
that appeared in the pellet samples were deemed insoluble. 
2.4.2.3 Large scale expression 
Large scale protein expression was carried out as outlined in section 2.4.2.1 using optimal growth 
conditions for expression of each protein. Culture volumes of 2L and 4 L, supplemented with 
appropriate antibiotics where necessary, were used for large scale expression. Cultures were 
centrifuged for 20 minutes at 10000 rpm, and supernatants were discarded and pellets were stored 
at -20°C until needed. 
2.4.2.4 Urea extraction of insoluble proteins 
Where expressed proteins were found to be insoluble, urea extraction was performed. Pellets were 
resuspended in 30 ml of PBS containing 300 pg/ml DNAase I and one complete EDTA-free 
protease inhibitor (Roche Diagnostics Ltd Lewes, UK). Suspensions were sonicated and 
centrifuged (section 2.4.2.2), and the supernatant was discarded and the pellets were resuspended 
in 15 ml extraction buffer (8 M urea, 40 mM tris, 750 mM sodium chloride, 2 mM reduced 
glutathione, 0.2 mM oxidised glutathione pH 7.5). This re-suspension was left to incubate at room 
temperature for 1-2 hours or, if longer extraction time was needed, re-suspensions were stored at 
4°C for 16-20 hours. Samples were then filtered through a 0.45 pm filter followed by a 0.22 pm filter 
before purification. 
2.4.2.5 Preparation of soluble proteins 
Pellets of soluble protein were resuspended, sonicated and centrifuged as in section 2.4.2.2. Pellets 
were resuspended in 15 ml PBS containing 300 pg/ml DNAase I and one complete EDTA-free 
protease inhibitor (Roche Diagnostics Ltd Lewes, UK). Suspensions were filtered through a 0.45 pm 
filter followed by a 0.22 pm filter before being purified. 
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2.4.2.6 Purification equipment 
All purification steps were completed using an AKTA Fast Protein Liquid Chromatography system 
(FPLC) (Amersham Biosciences, Chalfont-St Giles, UK) under the control of Unicorn software 
version 4.0 (Amersham Biosciences, Chalfont-St Giles, UK). All buffers used on the FPLC were 
made using ultra pure distilled water (ddH2O) and filter sterilised through a 0.22 pm filter prior to 
use. Purification of proteins was achieved using Immobilised Metal Affinity Chromatography (IMAC). 
Pre-packed 1 ml HisTrapTM columns were obtained from Amersham Biosciences (Chalfont-St Giles, 
UK) and used according to manufacturer's instructions. 
2.4.2.7 Purification of Insoluble proteins 
Expressed insoluble proteins were urea extracted as described in section 2.4.2.4. Filtered 
denatured proteins were applied to the column using extraction buffer (section 2.4.2.4). Once 
loaded onto the column the concentration of extraction buffer was lowered by mixing the extraction 
buffer with start buffer (40 mM Tris, 750 mM Sodium chloride pH 7.5) gradually over a 30 column 
volume (CV) (30 ml) period. This causes the His6 tag protein bound to the column to refold into a 
natural conformation. After refolding, the column was washed using 100% start buffer. All unbound 
protein and wash step fractions were collected. Elution of Hiss-tagged bound protein was achieved 
using elution buffer (40 mM tris, 750 mM sodium chloride, 500 mM imidazole pH 7.5). Elution was 
performed using stepped increases in concentrations of imidazole starting at 10% (50 mM), 20% 
(100 mM), 50% (250 mM) and 100% (500 mM), by diluting elution buffer with start buffer. During the 
elution stage 1 ml fractions were collected, then evaluated by SDS-PAGE (section 2.4.1.1) to 
determine the protein fraction location and purity. Insoluble proteins which would not bind or refold 
on the column were purified in their denatured state using the soluble purification method (section 
2.4.2.8) with the addition of 8M urea to all buffers used. Proteins were then refolded by buffer 
exchange (section 2.4.2.9). 
2.4.2.8 Purification of soluble proteins 
Expressed soluble proteins were prepared for purification as described in section 2.4.2.5. Filtered 
proteins were loaded onto the column in start buffer (as in section 2.4.2.7), the column was washed 
using 100% start buffer, and unbound protein and wash-step elutions were collected. Proteins were 
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eluted from the column (as in section 2.4.2.7) and fractions were then evaluated by SDS-PAGE 
(2.4.1.1) to determine protein fraction location and purity. 
2.4.2.9 Buffer exchange 
Buffer exchange was achieved using dialysis. Different methods were used for denatured proteins 
and for folded or refolded proteins. All correctly folded or refolded proteins were buffer exchanged 
from elution buffer into PBS. Proteins were loaded into a Slide-A-Lyzer 10000 MWCO dialysis 
cassette (Pierce Biotechnology Inc. Rockford, Illinois, USA) using a needle and syringe and placed 
in 4L PBS at 4° C for 12-20 hours. Proteins that were purified in a denatured state needed to be 
refolded using dialysis. Samples were eluted from the column in 8M urea and refolding was 
achieved by slowly buffer exchanging into lower concentrations of urea buffers, then into PBS. The 
Proteins were loaded into a Slide-A-Lyzer 10000 MWCO dialysis cassette (Pierce Biotechnology 
Inc. Rockford, Illinois, USA) and the cassettes were suspended in 4L of 4M urea containing 40 mM 
Tris, 750 mM sodium chloride, 1 mM reduced glutathione, 0.1 mM oxidised glutathione at pH 7.5 
and placed at 4°c for 2-4 hours. The dialysis cassettes were then transferred to 2M urea buffer 
containing 40 mM tris, 750 mM sodium chloride, 0.5 mM reduced glutathione, 0.05 mM oxidised 
glutathione at pH 7.5 and placed at 4°C for 2-4 hours. Proteins at this stage could be left overnight if 
needed. In the final step, cassettes were transferred to PBS and left at 4°C for 12-16 hours. 
2.4.2.10 Determination of protein concentration 
The Bicinchoninic Acid (BCA) protein assay (Pierce Biotechnology Inc. Rockford, Illinois, USA) was 
used according to manufacturer's instructions to measure protein concentration. A known 
concentrated stock of bovine serum albumin (BSA) was diluted in PBS to produce a standard curve 
for the assay. 
2.4.2.11 Storage of proteins 
After purification, buffer exchange and concentration determination, 1 ml aliquots of all proteins 
were prepared and stored at -80°C. Repeated freezing and thawing of proteins was avoided to 
prevent damage to the proteins. 
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2.5 Animal Studies 
2.5.1 Animals studies and suppliers 
Vaccine efficacy trials were carried out at the VLA, Weybridge or Dstl, Porton Down using 6-11 
week old female Balb/C mice obtained from Harlan (Oxon, UK) or Charles River Laboratories Inc 
(Kent, UK). All animal work carried out in this study was completed in accordance with the Scientific 
Procedure Act 1986 under project and personal licences authorised by the Home Office. 
2.5.2 Protein and adjuvant preparation 
Inoculation formulations were prepared by diluting 10 pg of recombinant protein, 12.5 pg AbISO-- 
100 immunostimulatory complex (ISCOMs, Isconova, Uppsala, Sweden) and 6.25 pg CpG 
Oligodeoxynucleotides 10103 (CpG, Coley pharmaceuticals group, Massachusetts USA), CpG 
10103 sequence: 5'-TCGTCGTTTTTCGGTCGTTTT-3') in 100 pl of sterile PBS. Alternatively, 
inoculum was prepared by mixing 10 pg of protein with 20 % (v/v) Alhydrogel (Sigma, Poole, UK) in 
100 pl PBS, or 10 pg of protein was mixed with 50 % (v/v) incomplete Freund's adjuvant (IFA, 
Sigma, Poole, UK), which was then homogenised until a white emulsion was formed. Where DNA 
vaccination was administered 100 pg DNA vaccine was dissolved in 100 pI of dH2O. 
2.5.3 Mouse inoculation schedule and serum collection 
Mice were inoculated with 100 pl of the vaccine formulations (section 2.5.2), administering 50 pl 
intramuscularly into each hind leg muscle. Mice were inoculated with formulation three times at 
three week intervals where protein was used. Blood samples were taken at day 58 in all 
experiments via collection from tail veins. After collection blood samples were stored at 4°C for at 
least 1 hour but no more than 20 hours to allow blood to clot. Blood was centrifuged at 13000 rpm 
for 15 minutes, and the serum was collected and stored at -20°C until needed. When DNA 
vaccinations were being administered mice were given four doses of 100 pg DNA at three week 
intervals. 
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2.5.4 Animal challenge and splenic colonisation assays 
Infection of mice with B. melitensis was measured by splenic colonisation. Mice inoculated with 
candidate vaccine formulas were left for 30 days after the final inoculation until challenge. Mice 
were then challenged with approximately 1x10° colony forming units (CFU) of B. melitensis 16M via 
the intraperitoneal (ip) route. Mice were then left 15-18 days before mouse spleens were harvested 
and homogenised into 0.1 ml PBS and serially diluted. Each serial dilution was plated out in 
triplicate and plates were incubated for 7 days at 37°C. Brucella colonies were enumerated to 
provide the CFU per spleen. Mice administered PBS or adjuvant only were used as negative 
controls. Mice immunised i. p. with a single dose of 2x105 CFU of Rev. 1, the current standard 
Brucella melitensis animal vaccine, were included as positive controls. 
2.6 Immunological techniques 
2.6.1 Enzyme Linked Immunosorbant Assay (ELISA) 
2.6.1.1 Plate coating 
ELISAs were carried out using 96-well immulon 2HB plates (Corning, NY, USA). Plates were coated 
using two different coating solutions. Columns 1-3 were coated with anti-mouse fab-specific 
antibody (Sigma, Poole, UK) diluted to a final concentration of 5 pg/ml in PBS, with 100 pl per well. 
Columns 4-12 were coated with the antigen of interest diluted to a concentration of 5 pg/ml, with 
100 pl per well. Coated plates were stored at 4°C for at least 18 hours before use but kept no longer 
than 5 days at 4°C. 
2.6.1.2 ELISA sample and standard preparation 
All dilutions were made using 2% (w/v) skimmed milk powder + 0.05% (v/v) tween 20 (Sigma, Poole 
UK) diluted in PBS (blotto). Antibodies used as standards were purified commercially available 
antibodies, isotype-specific where necessary (Sigma, Poole, UK). A starting concentration of 0.2 pg 
was used for the standard curve. Serum samples taken on day 58 of the experiment were diluted 
1: 10,000 in blotto before use in the ELISA assay. 
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2.6.1.3 ELISA method 
All washing steps were carried out using PBST using a Skatron 96-well automated plate washer 
(Molecular devices, CA, USA). All incubation steps were carried out at 37°C ±2 °C for 1 hour unless 
otherwise stated. Coated plates were washed and 100 pl blotto was added to each well before 
incubation. Next, plates were washed and standard or serum samples were added; 100 NI of 
standard (section 2.6.1.2) was added to wells Al-A3,100 pl samples were added to wells A4-A11. 
Diluted pre-inoculation sera (section 2.6.1.2) was added to wells of column 12 as a negative control 
for the assay. Blocking buffer was added to all other wells on the plate. Standards and samples 
were serially diluted down the plate, standards to row G and samples to row H, and plates were 
then incubated. After incubation plates were washed and 100 pl of secondary antibody ((goat anti- 
mouse conjugated to HRP, isotype-specific where necessary), AbDserotec Oxford, UK) was added 
to each well, and plates were then incubated. After incubation the plates were washed and 100 NI of 
substrate buffer (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) tablets (ABTS) (Sigma, Poole 
UK) dissolved in a phosphate-citrate buffer (11.76 g/l citric acid, 12.49 g/l sodium hydrogen 
phosphate pH 4.37) and 20 pl hydrogen peroxide (Sigma, Poole UK) per 50ml of buffer, prepared 
not more that 30 minutes before use, was added to each well. Plates were incubated at 37°C for 10- 
30 minutes to develop. 
2.6.1.4 Plate reading and analysis 
Developed ELISA plates were read using an automated plate reader (Thermo Life sciences 
Multiskan Ascent plate reader, Basingstoke, UK). Plates were read at a wavelength of 414 nm and 
data was saved as a Microsoft® Office Excel file for further analysis. Data was analysed using 
ELISA for Windows version 2.0 software freely available from Centre for disease Control (CDC) 
website (http: //www. cdc. gov/ncidod/dbmd/bimb/ELISA. htm). ELISA for Windows uses a four- 
parameter logistic fit curve to calculate unknown sample concentration of antibody in pg/ml. 
2.6.2 ELISPOTS assays 
Enzyme linked immunosorbent spot (ELISPOT) reagents were purchased from purchased from 
Mabtech (Nacka Strand, Sweden), MilliporeTM' (Watford, Hertfordshire, UK) or Sigma-Aldrich (Poole, 
UK). Assays were carried out in a class II biosafety cabinet unless stated otherwise. 
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2.6.2.1 ELISPOT plate coating 
Sterile multiscreenHTS - IP filter plates (Millipore, Watford, Hertfordshire, UK) were coated with anti- 
cytokine antibody diluted in carbonate/bicarbonate buffer (Sigma, Poole, UK) to a concentration of 
15 pg/ml, and 100 pi was added to each well. Plates were then stored at 4°C for at least 18 hours 
but no more than 4 days before use. 
2.6.2.2 Antigen and positive control preparation 
Antigens were diluted in DMEM culture media (DMEM containing 10% fetal bovine serum (FBS, 
Sigma, Poole, UK) and 1% penicillin/streptomycin/L-glutamine solution (Gibco, Paisley, UK)) to a 
final on plate concentration of 10 pg/ml. A negative control consisting of cells incubated with no 
stimulatory antigen, and a positive control containing of 2 pg/ml concanavalin A (conA - Sigma, 
Poole UK) were also prepared. 
2.6.2.3 Harvesting of ex-vivo splenocytes 
Spleens were removed from inoculated or naive mice and homogenised through a 40 pM nylon 
sieve into 5 ml of DMEM. Red blood cells were lysed by the addition of 10 ml of red cell lysis buffer 
(Sigma, Poole, UK) before being incubated at room temperature for 1 minute, and splenocytes were 
then centrifuged at 1200 rpm for 10 minutes. Ex-vivo splenocytes were then resuspended in 15 ml 
of FACS Flow Buffer (FFB) and centrifuged at 1200 rpm for 15 minutes. Splenocytes were then 
resuspended in between 1-2 ml of DMEM, before enumeration using a haemocytometer or 
CellometerTM Auto T4 automated cell counter (Peqlab Biotechnologie GmbH, Farham, UK). 
Sufficient cells were removed for non-deplete ELISPOT assays before depletion steps could be 
completed. Cell concentrations were altered to 5x108 cells/ml before use in ELISPOT assays. 
2.6.2.4 CD4' and CD8' cell depletion 
All reagents for cell depletion assays were purchased from Miltenyi Biotec Ltd (Surry, UK) unless 
otherwise stated. Ex-vivo splenocytes were harvested as in section 2.6.2.3. Harvested splenocytes 
were split into two separate cell populations and their volumes altered to I ml. One cell population 
received 100 pl anti-mouse CD8a (Ly-2) microbeads, while the other cell population received 100 pl 
anti-mouse CD4 (L3T4) microbeads, and both cell populations were incubated for 30 minutes on 
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ice. During this period MACSTM LS columns were loaded into a QuadroMACST"' separation unit. 
Columns were equilibrated by washing with 3 ml of FFB, after which microbead-labelled cell 
populations were added to each column and the flow-through was collected. Columns were then 
washed three times with 3 ml of FFB and the flow through collected. Collected cells were 
centrifuged at 1200 rpm for 15 minutes before being resuspended in 1-2 ml of DMEM. Cell 
concentrations were then determined using a CellometerT"' Auto T4 automated cell counter (Peqlab 
Biotechnologie GmbH, Fareham, UK). Cells concentrations were altered to 5x10° cells/ml before 
use in ELISPOT assays. 
2.6.2.5 ELISPOT method 
Plates were washed once with DMEM culture media and then blocked with 200 NI of DMEM culture 
media. Plates were incubated at room temperature for 2 hours. During this period mouse spleens 
were prepared as described in sections 2.6.2.3 and 2.6.2.4. Once cells preparations were 
completed, 100 µl of ex-vivo splenocytes were plated onto 96 well multiscreen HTS IP elispot plates 
(Millipore TM, Watford, Hertfordshire, UK) along with 100 pI of stimulatory antigen. Plates were then 
incubated for between 16-20 hours in relative humidity at 37°C, 5% CO2. Next, the cell and antigen 
mix was aspirated from the wells and plates were washed 3x with PBST and then 2x with dH2O. 
Biotinylated detection antibody was diluted to 1-2 pg/mI in 10% BSA in PBS and 100 pl was added 
to each well. The plates were then incubated at room temperature for 2 hours. Plates were washed 
3x with PBST and the enzyme conjugate (Streptavidin-HRP) was added (100 p1/well) at a dilution of 
1: 100. Plates were incubated at room temperature for 1 hour. BCIP/NBT developing substrate was 
prepared by dissolving 1 BCIP/NBT tablet (Sigma-Aldrich, Poole, UK) in 10 ml of pre-warmed dHZO 
and once dissolved the solution was filtered through a 0.45 pm syringe filter. Plates were washed 
4x with PBST and 2x with PBS and 100 pl BCIP/NBT substrate was added to each well. The plates 
were then left at room temperature to develop for 5-20 minutes. The reaction was stopped by 
removing the substrate solution and adding 100 pl dH2O per well. Plates were left to air dry for 16 - 
20 hours before reading using an Elispot Reader System ELR04 (Advanced Imaging Devices, 
Strasberg, Germany). 
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2.6.2.6 ELISPOT data analysis 
Subtractions of cells with no stimulatory antigen were deducted from cells with stimulatory antigen 
and analysis of the data was performed using Graphpad Prism 4 (Graphpad software Inc, CA, 
USA). 
2.6.3 ISCOMs & CpG assays 
2.6.3.1 Cellular uptake of CpG 
2.6.3.1.1 Preparation of cell populations 
J774A. 1 (mouse macrophages) cells obtained from the European Collection of Cell Cultures 
(ECACC, HPA Porton Down, UK) were cultured using DMEM culture media in 150 cm3 cell culture 
flasks (Comings Ltd, UK) at 37°C, 5% CO2 and relative humidity. The cell culture flasks were 
seeded with 1x10' cells and incubated until a confluent layer of cells had formed (approximately 2 
days). The cells were then scraped from the flask and 1x107 cells were seeded into a new flask to 
continue the cell line growth. 
2.6.3.1.2 Confocal microscopy 
J774A. 1 cells were scraped from a flask and counted using a CellometerTM Auto T4 automated cell 
counter, the cell density was adjusted to 3.5x105 cells/ml using DMEM. One ml of cells was plated 
out onto 22 mm2 glass-bottomed Wilco dishes (Intracel, Royston Hertfordshire. UK), and cells were 
then incubated for 16-20 hours at 37°C, 5% CO2 and relative humidity. The supernatant from the 
cells was removed and 1 ml (5 jig/ml) of 5' carboxyfluorescein (FAM) labelled phosphothioate 
backbone CpG 10103 (FAM-CpG), synthesised by ATDBio (Southampton University, UK), i 10 pg 
ISCOMs was added to the cells. The cells were then incubated for up to 20 hours. Cells were 
removed from the incubator at 1,2,4,6,8, and 16 hours, at which point 8 random confocal images 
were taken of the cells using an Olympus IX70 confocal laser-scanning microscope. An argon laser 
was used to excite the FAM-CpG at 488 nm and fluorescence was detected at 530 nm. Image 
processing was completed using Fluoview version 5.0 software (Olympus Corporation). 
80 
2.6.3.2 Stability of ISCOMs and CpG 
2.6.3.2.1 Preparation of low pH buffers 
Low pH citric acid buffers were used to incubate the ISCOMs & CpG. A 0.2 M solution of sodium 
phosphate (28.4 g/L) and a 0.1 M solution of citric acid (19.2 g/L), were mixed to get the pH 4 buffer 
used. The pH 4 solution was created by mixing 19.3 ml of 0.2 M sodium phosphate and 30.7 ml of 
0.1 M citric acid. 
2.6.3.2.2 Preparation of ISCOMs & CpG in low pH buffers 
Concentrated ISCOMs ± CpG were diluted to stock concentrations of 250 pg/ml and 125 pg/ml 
(respectively) in either pH 4 or neutral (PBS) buffers. For stimulation use in ELISPOT assays, these 
stocks were further diluted to 40 pg/ml and 20 pg/ml in DMEM, then 100 pl was used per well, 
equating to a4 pg ISCOMs and 2 pg CpG stimulatory concentration (section 2.6.2). 
2.6.4 Statistical analysis 
Statistically analysis for all data was carried out using Graphpad Prism 4 (Graphpad software Inc, 
CA, USA). 
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Chapter 3- ATP- binding cassette systems 
of Brucella 
82 
3.1 Introduction 
ABC systems play a major role in the import and export of substances across the cell membrane, 
along with roles in house-keeping functions, such as regulation of gene expression [332] and DNA 
repair [68,121 1. ABC proteins comprise one of the largest protein superfamilies in prokarya, eukarya 
and archea [132]. ABC systems can play important roles in bacterial lifestyle, virulence and survival 
[112]. DNA-DNA hybridisations between the species had previously revealed 90% similarity 
between the species, leading to the suggestion that all Brucella species should be classified as B. 
melitensis [337,338]. However, it is widely acknowledged that the differences in host specificity and 
pathogenicity are related to Brucella genetics, although there is currently little experimental 
evidence to support this, a few studies have found differences between the Brucella species 
genomes that may support this hypothesis [54,128,269]. 
The recent sequencing of B. melitensis 16M [78], B. abortus 9-941 (128] , B. suis 
1330 [258], B. 
ovis 63/290 (NCBI: NC_009504/5 Unpublished) and B. canis RM6/66 (NCBI: NC_010103/4 
Unpublished) has enabled the genomic comparison of the different Brucella species. The aim of this 
work was to create and compare inventories of the predicted functional ABC systems in Brucella 
from which to identify putative vaccine candidates to down select for evaluation. 
3.2 Creating Brucella ABC system inventories 
The prediction of ABC systems in sequenced bacterial genomes is based on the similarity of 
experimentally identified or predicted ABC proteins from heterologous bacterial systems. Brucella 
genomes were visualised using the Artemis viewer (available from www. sanger. ac. uk). ABC 
proteins were located within the genomes by searching for related words, specifically "ATP-binding 
cassette", "binding protein" or "outer membrane protein". For completeness all genes labeled 
hypothetical and conserved hypothetical protein were also checked. Once all searches were 
completed the protein sequences of each gene were aligned using the basic local alignment search 
tool (BlastP) [12] against other ABC proteins using the ABC systems: Information on Sequence 
Structure and Evolution (ABCISSE) database (68,70]. When all hits were compiled, genes located 
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upstream and downstream from ABC proteins were checked to ensure that all proteins from each 
system were located. This method was completed for all sequenced strains of wild-type Brucella (B. 
melitensis 16M, B. abortus 9-941, B. suis 1330, B. ovis 63/290 and B. canis RM6/66), and complete 
ABC system inventories were compiled and compared. 
The ABC system inventories also include any system that contains mutated genes. However, these 
systems were not counted toward the total ABC system numbers because functionality of a system 
with mutated genes present cannot be addressed using bioinformatic techniques. Within the 
genomes of all of the Brucella species evaluated, single ABC system components were located that 
did not seem to belong to complete ABC systems. These were included in ABC system inventories 
and termed lone components, although these were not included in total ABC system counts as they 
did not comprise a complete system. Analysis of these data was achieved by grouping the ABC 
systems into ABC system importers, exporters, cellular processes and functionally unknown 
systems. The total ABC system numbers were compared, along with comparisons of the ABC 
systems family and function. The full inventories and alignments of the Brucella ABC systems, 
along with ABC family acronym descriptions can be seen in appendix A. 
3.3 Brucella ABC systems - general observations 
The Brucella strains investigated in this study all have approximately 3.3 Mb genomes comprising 
two chromosomes of approximately 2.1 Mb and 1.2 Mb. Despite being smaller in size it is 
chromosome two that encodes the most ABC system genes in all the studied Brucella strains. The 
total number of predicted functional ABC systems encoded by each of the five Brucella strains is 
similar but does show some variability (table 3.1), with B. melitensis 16M encoding the most 
systems (79 systems), followed by B. canis RM6/66 (74 systems), B. suis 1330 (72 systems), B. 
abortus 9-941 (64 systems) and, finally, B. ovis 63/290 (59 systems). Interestingly, of these, the four 
strains with the largest number of ABC systems (B. melitensis 16M, B. abortus 9-941, B. suis 1330, 
and B. canis RM6/66) are all of species able to cause disease in humans (whereas there are no 
reported cases of B. ovis infections in humans). These four strains also have lower numbers of 
predicted mutated genes within their ABC systems when compared to B. ovis 63/290. 
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3.4 Numbers of ABC systems in intracellular vs. environmental bacteria 
Brucella genomes encode a high percentage of ABC system genes, with an average of 8.8% of 
their 3.3 Mb genomes dedicated to ABC systems. This high proportion of ABC systems in Brucella 
species is also reinforced when comparing the proportion of ABC systems in other intracellular 
pathogenic bacteria. For example, Burkholderia pseudomallei and Burkholderia mallei have 105 
(5.8%) and 77 (4.9%) predicated ABC systems, respectively, and their genomes are 7.2 Mb and 5.8 
Mb in size [238,136,131]. The percentage of ABC system genes encoded in the genomes of the 
intracellular pathogens Francisella tularensis (1.8 Mb) and Mycobacterium tuberculosis (4 Mb) are 
only 1.2% and 2.5%, respectively, showing that there is no great need for intracellular bacteria to 
encode large numbers of ABC system genes [18,179,31]. Studying an even larger range of 
intracellular bacteria highlights that, in terms of numbers of ABC systems, Brucella species are less 
like their intracellular counterparts (figure 3.1). The high proportion of ABC system encoded on the 
Brucella genome could be related to their ancestry with other environmental bacteria such as 
Nitrobacter and Agrobacterium. These bacterial species are also members of the a-proteobacteria 
and have also been shown to encode high proportions of ABC systems compared to their genome 
sizes [132] (figure 3.2). This high proportion of ABC systems encoded by these Brucella strains 
could increase their survival rates when in diverse conditions. 
3.5 ABC system functions 
The predicted functionality of the ABC systems within the Brucella genomes is dominated by ABC 
systems involved in the import of nutrients (table 3.2) and, although this is not uncommon among 
bacteria, it is probable that Brucella species utilise ABC transporters to provide most of the nutrients 
they require [132,78). In support of the findings of Paulsen et al. [258], the larger 2.1 Mb 
chromosome encodes a large proportion of the ABC systems involved in molecular export and 
cellular process whereas the ABC systems located on the smaller 1.2 Mb chromosome are largely 
biased toward nutrient acquisition, leading to the theory that this second chromosome is important 
in the acquisition and processing of nutrients in Brucella. 
In this study, the ABC systems of these Brucella strains have been classified into classes, families 
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and sub-families (figure 3.3) according to the functional classification system described by Dassa 
and Bouige [68]. The Brucella strains encode 8-12 class 1 systems, characterised by an ABC-IM 
domain fusion and comprising predicted export systems, and 5 class 2 systems, characterised by 
two fused ABCs and with predicted functions in antibiotic resistance and house-keeping. However, 
it has been observed that most of the ABC systems of Brucella species belong to class 3 with roles 
predicted in import processes. The further classification of Brucella ABC systems into families and 
sub-families shows that there are a high number of ABC systems of specific importer families, 
particularly the MOI (minerals and organic ions), MOS (monosaccharide), OPN (oligopeptides and 
nickel), OSP (oligosaccharides and polyols) and OTCN (osmoprotectants taurine cyanate and 
nitrate) families, all of which primarily function to acquire nutrients. Importing ABC transporters have 
also been shown to be important in nutrient acquisition by Agrobacterium tumefaciens and 
Sinorhizobium meliloti, two other a-proteobacteria, showing that ABC transporters are particularly 
important at nutrient acquisition for this genus (109,357]. 
Since these ABC systems have been identified by blast searches for similar systems, it is possible 
to assign each ABC system with a predicted substrate which it imports. This data can be used to 
assess the substrate-specific ABC transporter import ability for all of the Brucella strains. Table 3.3 
shows the range of predicted substrates imported via ABC transporters present in the Brucella 
genomes. Overall, the results indicate that there is little difference in the import ability of the four 
strains of Brucella that are pathogenic to humans. However, an interesting observation that can be 
made from this data is that B. ovis is lacking the ability to import 8 of the 26 listed nutrients via ABC 
transporters. In fact, all of the 29 pseudogenes that are present within the B. ovis ABC system 
inventories occur within nutrient import systems. The nutrients that B. ovis is unable to import using 
ABC transporters include polyamines (specifically spermidine and putrescine), nickel, thiamine, 
glycine betaine, erythritol, xylose and molybdenum. It is possible that the defective uptake of these 
substrates by B. ovis may contribute to its likely lack of virulence in humans. For example, 
spermidine and putrescine are important organic polycationic molecules for maintaining 
conformation of nucleic acids, efficient DNA replication, transcription and translation. Polyamines 
have more recently been associated with bacterial virulence and pathogenicity in humans 
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Substrate B. melitensis B. abortus B. suis B. ovis B. canis 
Branch chain amino **** *** *** ** *** 
acids 
Iron (III) **** **** **** **** **** 
Cobalt - * * 
* * 
Zinc * * 
Thiamine * * * - 
* 
Putrescine *** ** ** - 
** 
Sulphate ** ** ** ** ** 
Phosphate * * * * * 
Molybdenum * * * - * 
Spermidine ** ** * - 
* 
Ribose *** *** *** *** *** 
Galactoside - ** ** ** 
* 
Xylose * * * - * 
Erythritol * * * - 
* 
Dipeptides ** ** ** ** *** 
Oligopeptides **** **** *** *** **** 
Nickel * - * - 
* 
Maltose * * * * 
Oligosaccharide or *** * ** ** *** 
polyol 
SN-glycerol-3-phosphate * * * * - 
Taurine *** *** *** * *** 
Glycine betaine * - * - 
* 
Nitrate * * * * * 
Polar amino acids - - - * 
* 
Cystine * * * 
General L amino acids * - * 
Table 3.3: Brucella ABC transporters import ability by substrate 
This table does not include any ABC system with pseudo genes present. 
**** >5 functional systems 
*** 3 or 4 functional systems 
** 2 functional systems 
*I functional system 92 
- No functional systems 
[296] and therefore have been targeted as vaccine candidates in a number of human pathogens 
[295,130]. The loss of nickel transport might not have a large impact on B. ovis as knockout mutants 
in the nik gene cluster in B. suis have shown little difference in intracellular growth rate to wild-type 
Brucella, although some enzymes do show reduced activity leading to the conclusion that the 
import of nickel could be compensated for by other bacterial systems [153]. 
This study has also identified one ABC system present in the B. melitensis genome that has been 
categorised as a new ABC system (currently labelled NEW1). The system comprises 4 proteins, 1 
ABC protein, 1 IM protein and 2 BP. The BP and IM seem to be related to the BP and IM proteins of 
the MOS family. However, the ABC protein is too different to be related to the MOS family. It is 
unknown what this new ABC system is yet; experimental data would be needed to help define its 
function. 
3.6 ABC systems/genes absent in at least one Brucella species 
Although there is much similarity between the Bnicella ABC systems, there are also systems that 
are present in some species but absent in others (table 3.4). The systems that are missing from 
each species are not critical for bacterial survival but these missing systems could contribute to the 
pathogenicity and virulence of each of the Brucella species. There are a range of systems missing 
from each of the Brucella species. B. ovis (5 missing systems), B. canis (4 missing systems) and B. 
abortus (4 missing systems) are the species that are the most disrupted by missing systems. 
Strikingly, all of the species are missing at least one 0228 system. There is currently only one well 
characterised o228 system in E. coli, termed LoICDE, which is responsible for the release of 
lipoproteins from the inner cell membrane to the outer cell membrane [361]. All other o228 systems 
have as yet undiscovered functions. This makes it difficult to assess what impact, if any, the loss of 
these systems would have on Brucella lifestyle and virulence. The absence of the ISB (formally 
ABCX) system from the genomes of B. ovis and B. canis is a very interesting observation as the 
ISB systems are soluble complexes involved in labile [Fe-S] biogenesis, which are important in 
resistance to oxidative stresses. This indicates that B. ovis and B. canis reside in environments that 
are low in oxygen or high in oxygen reducatants, or that they lack enzymes that need labile [Fe-S] 
centres [232,244] This could be a factor of the reduced virulence of both B. ovis and B. canis. 
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The CDI system missing in B. ovis is comprised of two proteins FtsE (ABC protein) and FtsX (IM 
protein) [183]. This system has been extensively studied in E. coli and other bacteria including 
Bacillus subtilis [113] and Mycobacterium tuberculosis [220]. The CDI system is involved in cell 
division and it has been shown that mutants in the ftsE gene in E. coli have reduced growth 
capacity [286]. Of all of the Brucella species only B. canis is missing the MKL systems. It is 
unknown if not having the MKL system has any impact on the lifestyle of B. canis. However, 
research using Pseudomonas put Ida has shown that this system might have some link to toluene 
tolerance as Tn5 insertions within the ttgA2 gene, which codes for the MKL ABC protein, elicits a 
toluene-sensitive phenotype [339]. 
3.7 Conclusions 
In this study the ABC systems of B. melitensis 16M, B. suis 1330, B. abortus 9-941, B. canis 
RM6/66 and B. ovis 63/290 have been re-annotated using the ABCISSE database in order to 
provide new information and a uniform annotation and classification of ABC systems in these 
closely related species. The creation of ABC system inventories has been completed for a variety of 
organisms [31,69,191,268]. These inventories are all designed to assist in the understanding of the 
bacterial lifestyles and increase our knowledge of the bacterial survival and virulence. Previous 
analysis of the Bnicella genomes has shown that there is over 90% genome similarity between the 
six traditionally recognised Brucella species [337,338]. Similarly, the ABC systems inventories 
compiled in this work reflects the close similarities of the Brucella species. However, despite the 
high genetic homology of Brucella, this work has highlighted differences in the predicted numbers 
and functions of the ABC systems encoded by each Bn, cella species. It is widely accepted that the 
four species that may cause human brucellosis are B. melitensis, B. suis, B. abortus and B. canis. 
This study has shown that these four species of Brucella have a larger set of ABC systems encoded 
within their genomes than B. ovis, which is not known to cause human disease. Although it is 
difficult to ascertain the exact effect the loss these ABC systems has on B. ovis, it is possible to 
hypothesise that, along with other genetic differences observed [54], they contribute to its overall 
reduced virulence in humans. Overall, the identified differences observed in the ABC system 
inventories of the Brucella strains studied should contribute to a greater understanding of 
differences in the lifestyles of the Brucella species. 
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Chapter 4- Evaluation of vaccine 
candidates 
96 
4.1 Introduction 
Current Brucella vaccines are generally live attenuated vaccines and although this type of vaccine 
does elicit a cellular immune response, they do have many disadvantages. Brucella melitensis 
Rev. 1 is one of the most widely used animal vaccines but can still cause infections in vaccinated 
animals [29] and is also indistinguishable from a natural Brucella infection during diagnostic testing 
[291]. Additionally, Rev. 1 can cause disease in humans and is therefore unsuitable as a human 
vaccine. A protective sub-unit vaccine would be an effective way of decreasing the problems 
associated with Brucella around the world. Such sub-unit vaccines often have fewer side effects 
than live attenuated vaccines and would be easily distinguished from naturally infected animals due 
to the specific immune responses generated. 
4.1.1 Selection of vaccine candidates 
Eight ABC transporter proteins were selected for evaluation as sub-unit vaccine candidates using 
literature searches to identify homologous protective ABC transporter proteins from other bacteria 
[316,130,18,295] and homologous ABC transporter proteins involved in virulence in Brucella 
species [164,168,94,277]. The down-selected proteins were PotD, PotF, Cgt, CydD, LoIE, FbpA, 
OppA and ZnuA. 
4.1.1.1 PotD (BMEI10923) and PotF (BME10411) 
The Pot systems in E. coli are responsible for the import of polyamines (putrescine, spermidine and 
spermine). Polyamines are required for various cellular functions including nucleic acid and protein 
synthesis. They are part of the mineral and organic ions (MOI) import family of ABC transporters 
[107]. Polyamines are the cell's major sources of polycations which bind to intracellular polyanions 
such as nucleic acids and ATP to modulate their structure [142,68]. The crystal structure of both the 
E. coli PotF and PotD proteins have been resolved and, despite only having 35% amino acid 
homology, they are structurally very similar [331,310]. PotF is the binding protein of the putative 
potFGHI putrescine import system of B. meltensis 16M. This system is specific for putrescine and 
cannot bind other polyamines. In E. coli PotD is the binding protein of the putative potABCD 
spermidine import system. PotD preferentially binds spermidine although it can bind putrescine at a 
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lower affinity [142]. Brucella melitensis, B. abortus, B. suis and B. ovis all encode the putative 
potABCD system within their genomes. In comparison, all four species have the potFGHI system 
present but B. abortus and B. ovis have mutations in one or more of the system component proteins 
which may inactivate the system or reduce its functionality. There is now evidence in the literature 
that polyamines have roles in bacterial pathogenesis [296]. 
4.1.1.2 Cgt (BME10984) 
Cgt is an ATP-binding cassette protein fused to an inner membrane protein (ABC-IM). Cgt forms 
part of the ß (1-2) glucan (CHV) export subfamily which is a part of the drugs, peptides and lipids 
(DPL) ABC family [68]. Cgt is involved in ß (1-2) glucan export in Brucella [277]. One study has 
shown that B. abortus mutants lacking the Cgt genes are able to infect HeLa cells as efficiently as 
wild-type bacteria, but intracellular replication in HeLa cells was significantly reduced indicating that 
the Cgt genes could be important for intracellular survival [277]. 
4.1.1.3 CydD (BME110762) 
CydD is an ABC-IM fusion protein that is part of the DPL family, within the cytochrome bd 
biogenesis (Cyd) subfamily of ABC systems (68,266). The Cyd genes are involved in oxidoreduction 
and form part of the cydDCAB operon, in which CydD assists in the construction of the cytochrome 
bd oxidase encoded by the cydAB genes [168]. The Cyd operon has been shown to be important 
for Brucella virulence, as B. abortus CydB knockout mutants are shown to have increased 
sensitivity to low pH and reactive oxygen intermediates (93]. 
4.1.1.4 LoIE (BMEI1139) 
The Lol ABC systems are required for the release of lipoproteins from the inner membrane into the 
periplasm for sorting into the outer membrane [234]. These Lol systems comprise IoICDE and IolAB 
genes where IoICDE is responsible for the lipoprotein recognition and Io/AB are binding proteins 
that assist in the movement of the lipoprotein across the periplasm [234]. LWIE is part of a putative 
WED system in Brucella and it lies within the 0228 ABC family [68]. Generally, the o228 ABC family 
is not well understood and a specific function has not yet been assigned. There are some 0228 
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genes without a function assigned present within the B. melitensis 16M genome and it is possible 
that these are the missing lol system genes in Brucella. 
4.1.1.5 FbpA (BME110584) 
FbpA is an iron binding protein that is part of the MOI ABC family [68]. FbpA is responsible for the 
uptake of iron (III) [94]. Research has shown that the B. abortus FbpA is expressed in macrophages 
after 24 hrs growth [94], demonstrating that it could be important for Brucella survival in the 
intracellular environment. 
4.1.1.6 OppA (BME110735) 
OppA is the binding protein of the OppABCD ABC system. OppA is part of the oligopeptide and 
nickel (OPN) ABC importer family [68]. Studies of the E. coli and Salmonella typhimurium OppA 
have shown it to be one of the most abundant proteins in the periplasm of Gram-negative bacteria 
[134]. There are two putative sets of OppA genes in the Brucella genomes, each sharing a 70% 
sequence identity. This ensures that even though there may be a high concentration of OppA in the 
periplasm, there is still the ability to import a broad range of different oligopeptide molecules. OppA 
has been investigated as a vaccine candidate for Yesinia pestis [316]. Specifically, mice immunised 
with OppA adjuvanted with Alhydrogel showed a delayed time to death when challenged with Y. 
pestis. 
4.1.1.7 ZnuA (BMEII0178) 
Zinc is an important trace element for most organisms. There are a large number of enzymes or 
proteins that use zinc as a structural or catalytic cofactor [256]. ZnuA is the binding protein of the 
putative znuABC operon in Brucella, and it is part of the metal (MET) ABC import family [68]. Two 
studies have been completed on ZnuA in B. abortus. Kim et al. have shown that deletion of the 
znuA gene results in reduced intracellular survival both in vitro and in vivo [164). Yang et al. showed 
that a znuA deletion mutant of B. abortus could be used as an attenuated live vaccine in mice [363]. 
The B. abortus znuA deletion mutant showed equivalent protection to B. abortus strain 19 and B. 
abortus RB51 vaccine. 
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4.2 Production of vaccine candidates 
Eight ABC transporter proteins were selected as possible vaccine candidates (Table 4.1 and 
Section 4.1.1). The genes were located on the B. melitensis 16M annotated genome and visualised 
using the Artemis viewer. Membrane-spanning domains were identified using an internet-based 
programme called TMHMM version 2.0 (http: //www. cbs. dtu. dk/services/TMHMM-2.0[175] (Figure 
4.1, section 2.1.2). PCR primers were designed to exclude membrane-spanning domains as they 
can cause problems in expression and purification processes. PCR was used to amplify the genes 
from B. melitensis 16M genomic DNA (section 2.3.1). PCR products were then ligated into the 
expression vectors pCR®T7/NT-TOPO® or pTrcHisA/B (section 2.3.3.1 and 2.3.3.2) (Invitrogen 
Ltd, Paisley, UK) and transformed into maintenance and expression strains of E. coli. Plasmid 
constructs were sequenced to check for PCR errors by Lark Technologies Inc (Takeley, Essex, UK) 
(section 2.3.3.4). Expression and solubility studies were carried out to assess the level of protein 
production and solubility of the protein produced (section 2.4.2.1 and section 2.4.2.2). Once optimal 
expression conditions were obtained, large scale expression of the vaccine candidates was started 
(section 2.4.2.3). Vaccine candidate purification was achieved using AKTA FPLC under the control 
of Unicorn Version 4.0 software (sections 2.4.2.6,2.4.2.7 and 2.4.2.8). Examples of AKTA 
purification traces are shown in figures 4.2-4.9. An SDS-PAGE gel of all the purified vaccine 
candidate proteins are shown in figure 4.10. 
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4.3 Evaluation of vaccine candidates 
4.3.1 Expression of vaccine candidates 
It is important to assess the expression of the vaccine candidates during growth to show the 
vaccine candidate genes are functional. To do this, gamma irradiated B. melitensis 16M, B. suis 
Thomsen and B. abortus 2308 produced during stationary phase growth was used to produce 
Western blots. These Western blots were probed using antigen specific polyclonal mouse antisera 
generated from the immunology studies (section 4.3.2). The Western blots were then developed 
using ECL technology (Figures 4.11 and 4.12). 
The Western blots indicate that there may be variability between strains in expression of some of 
the vaccine candidates. Expression of PotF, OppA and LoIE are the only candidates that yield 
bands of the expected size in all three Brucella strains tested. Bands of approximately the correct 
sizes for PotD (39.8 kDa) and CydD (35.9 kDa) are detected in B. melitensis 16M and B. abortus 
10505, whereas expression in B. suis cannot be confirmed using this method. FbpA production is 
only detected in two of the three strains, B. melitensis 16M and B. suis Thomsen. However, 
expression is not detected in this strain of B. abortus during stationary phase growth. Cgt and ZnuA 
expression was not detected in any of the strains tested. The western blots show some additional 
bands in the negative controls lanes of CydD, Cgt, FbpA and PotF detection. However, the bands 
are of different sizes to the proteins of interest and so are likely to be caused by cross-reacting E. 
coli contaminants during the purification process. 
Although not all of the proteins have been shown to be expressed, it is clear that this method has its 
limitations. The irradiated Brucella used has been grown to stationary phase in culture media. Thus 
a single timepoint in the growth of these organisms is reflected. Growth in culture media may not 
accurately reflect protein expression in a natural infection. 
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4.3.2 Immunisation schedule 
Evaluation of the vaccine candidates was achieved by assessing both their protective efficacy and 
the immune response generated in the murine model of B. melitensis infection. Two different animal 
experiments were completed. The experiments both used 9-11 week old female Balb/c mice 
inoculated with 10 pg of vaccine candidate adjuvanted with 12.5 pg ISCOMs mixed with 6.25 pg 
CpG administered three times intramuscularly at three week intervals (section 2.5.2). On day 75 of 
experiment 1 mice were culled and spleens were removed for ELISPOT assays (section 2.6.2). On 
the same day in experiment 2 mice were challenged with approximately 1x104 CFU of B. melitensis 
16M (i. p. ) and splenic colonisation assays were performed 15 days later (section 2.5.4). Negative 
control groups of mice immunised with PBS or adjuvant only were also included. Mice immunised 
with a single dose approximately 2x105 CFU of Brucella melitensis Rev. 1 were included as a 
positive control. Experiment 2 was split into three parts and each part contained the controls as 
listed above. 
4.3.3 Antigen - specific humoral immune response 
Total antigen-specific IgG was measured in the sera of samples taken on day 58 of the experiment 
via ELISA (Figure 4.13). Antibody responses were generated by mice immunised with each of the 
proteins. Responses generated in experiment 1 and experiment 2 were comparable, showing that 
independent studies produced similar results. The proteins that elicited the highest IgG response 
were PotF, FbpA and ZnuA, with PotD, CydD and OppA the next highest. Cgt elicited the lowest 
IgG response from all of the eight proteins tested. 
The IgG responses to the proteins were further analysed for lgG1 and IgG2a responses (Figure 
4.14). IgG1 antibodies are generally a marker of a Th2 immune response and IgG2a antibodies are 
used as a marker for Th1 immunity. PotD, PotF, CydD and ZnuA induced balanced IgG1: IgG2a 
immune responses (p > 0.05, t-test). In comparison, LoIE, OppA and Cgt induced Th2-biased 
humoral immune responses (p < 0.05, t-test). The only protein to stimulate a Th1-biased cellular 
immune response was FbpA (p < 0.05, t-test). 
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Figure 4.13: Comparison of antigen-specific IgG responses generated by mice immunised with 
the individual vaccine candidates 
This graphs show the total specific IgG response from mice immunised with the different ABC transporter 
proteins. Data shown is the average Total IgG concentration from six mice. 
significant increase of total IgG production from immunised mice compared to naive mice (p < 0.0001, t-test) 
significant increase of total IgG production from immunised mice compared to naive mice (p < 0.001, t-test) 
significant increase of total IgG production from immunised mice compared to naive mice (p < 0.01, t-test) 
Naive and adjuvant only sera was included on each plate. However, concentrations obtained were below assay 
detection limits of 10 pg/ml 
Error bars indicate the standard deviation of the data 
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4.3.4 Evaluation of antigen-specific memory response 
Cytokine analysis on ex-vivo splenocytes taken from immunised mice was also completed using 
ELISPOT assays. The production of IFN-y, IL-2 and IL-4 cytokines was assessed. IFN-y is a crucial 
cytokine in Brucella resistance and it has been shown that mice that lack the IFN-y gene will die of 
brucellosis, whereas wild-type mice will naturally clear a Brucella infection [229). IL-2 is a good 
marker of the cellular immune response and has also been shown to inhibit intracellular growth of B. 
abortus in both in vitro and in vivo experiments [150]. In comparison, IL-4 was assayed as marker of 
the humoral immune response, which is thought to be less important for survival in Brucella 
infections. Results from initial assays showed that high numbers of IFN-y produced cells were 
observed when stimulated with 10 pg/ml of antigen (figure 4.15). However, 5 of the 8 proteins 
tested (PotD, PotF, CydD, OppA, and ZnuA) over-stimulated cells when 10 pg/ml of antigen was 
used, leading to saturated ELISPOT wells and unreadable high results. In comparison Cgt, LoIE, 
and FbpA proteins induced readable numbers of IFN-y producing cells when stimulated with 10 
pg/ml of protein. Increased number of IFN-y producing cells were observed in the naive mice, 
possibly because the antigen used to simulate the ex vivo cells was not endotoxin-free, leading to a 
non-specific endotoxin response. However, even with this high naive reading, ex-vivo splenocytes 
from immunised mice stimulated with 10 pg/mI antigen showed increased levels of IFN-y production 
when compared to stimulated ex-vivo splenocytes from naive mice. 
The detection of IL-2 and IL-4 producing cells was more consistent between groups than IFN-y 
(figures 4.16 & 4.17). Specifically, similar numbers of IL-2 producing cells (400-500 cytokine- 
producing cells per 5x105 cells) were induced by all proteins except LoIE which induced lower 
numbers of IL-2 producing cells. Naive mice had decreased numbers of IL-2 producing cells 
compared to immunised mice, with <100 cytokine-producing cells per 5x105 cells. The number of IL- 
4 producing cells was lower than the number of both IL-2 and IFN-y producing cells with 200-350 
cytokine-producing cells per 5x105 cells in all groups. 
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4.3.5 Evaluation of protective efficacy of vaccine candidates 
To determine whether the proteins might provide protection against brucellosis, inoculated mice 
(Section 4.3.2) were challenge with approximately 1x104 CFU of B. melitensis 16M and splenic 
colonisation assays were performed to determine the Brucella colonisation levels. For logistical 
purposes, the eight vaccine candidates were evaluated in three separate trials each with their own 
controls. The results (figures 4.18,4.19 and 4.20) showed that a protective effect was provided to 
mice immunised with PotD (3.61 PU, PU = protection units calculated by, mean Loglo CFU of PBS 
inoculated mice - mean Loglo CFU of vaccine candidate immunised mice p<0.001), PotF (2.46 
PU, p<0.05) or the control vaccine Rev. 1 (3.61,2.73 or 2.83 PU, when compared to control mice 
immunised with PBS). This demonstrated that, of the eight ABC transporter proteins tested, PotD 
and PotF provide the best promise as novel vaccine candidates against Brucella melitensis 16M. In 
one of the three trials the ISCOMs and CpG administered alone elicited an immune response 
capable of generating a controlling protection against Brucella infection (2.51 PU, p<0.05). If the 
protection data is viewed as % of animals without detectable levels of Bn. rcella in the spleen (less 
than 10 CFU per spleen), results show that 83% (5/6) of PotD-immunised mice and 60% (3/5) of 
PotF-immunised mice have no detectable levels of Brucella, whereas only 20% (1/5) of Rev. 1- 
immunised mice had no detectable levels of Brucella. Overall, the PotD and PotF proteins showed 
comparable, if not better, protection against B. melitensis than the live attenuated animal vaccine 
Rev. 1. 
Significant protection against brucellosis was not observed following immunisation with any of the 
other six proteins and, interestingly, two of these six proteins, LoIE (-0.43 PU) and ZnuA (-0.72 PU), 
appeared to cause an increase in bacterial spleen load when compared to PBS, although this was 
not significant. An interesting observation was found in Brucella recovered from mice immunised 
with LoIE, since they exhibited abnormal colony morphology (personal communication, Dr Nicky 
Commander). Colonies were larger than normally expected and were mucoidal in appearance. 
Colonies were selected from these plates for 16S rDNA sequencing to confirm their Brucella 
identity, results of which identified the abnormal colonies as B. melitensis. This effect could be due 
to the fact that LoIE is part of the ABC system responsible for the export of fatty acid to the outer 
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membrane of the cell [233]. Another interesting observation of this work was the protection 
observed by the ISCOMs and CpG alone. Although only significant in trial 1 (2.51 PU, P<0.05), 
there is also at least a ten-fold reduction in the numbers of B. melitensis recovered from spleens of 
mice inoculated with the adjuvant when compared to PBS inoculated mice seen in the other two 
trials. 
Although it is difficult to fully understand the protective effects of PotD and PotF alone because of 
the controlling effect of the adjuvant, this data indicates that the PotD and PotF proteins 
administered with ISCOMs and CpG show good protective properties comparable to that of Rev. 1. 
4.4 Conclusions 
This study has evaluated eight ABC transporter proteins as vaccine candidates against B. 
melitensis. The results from this work have shown that both PotD and PotF are newly identified 
putative novel protective proteins against brucellosis. It is clear that both PotD and PotF proteins, 
when administered with ISCOMs and CpG, stimulate a balanced Th1/Th2 immune response in 
vaccinated mice. This immune response is characterised by the production of similar IgG1/IgG2a 
antibody levels along with high numbers of IFN-y producing cells and similar numbers of IL-2 and 
IL-4 producing cells. This shows that although it is perceived that a cellular immune response is 
needed to clear a Brucella infection, in this case a balanced Th1: Th2 immune response has been 
generated that seems to have been strong enough to provide protection. Further work will be 
required to assess why PotD and PotF afford good protection when other proteins tested with 
similar immunological profiles do not protect. WE generated a Th2 type immune bias, which is not 
considered the desired immune response needed to clear a Bruce//a infection. WE also induced 
the lowest numbers IFN-y and IL-2 producing cells. These non-protective properties could be due to 
WE inducing a low cellular immune response. However, ZnuA protein induced an immune 
response with similar numbers of IFN-y and IL-2 producing cells as PotD and PotF, but higher 
numbers of IL-4 producing cells was observed. Despite eliciting an immune response similar in 
nature to both PotD and PotF, ZnuA did not show any significant levels of protection. This shows 
that although IFN-y production is important in the clearance of Brucella, this alone is not enough to 
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induce a protective immune response, an observation that has been made before in previous novel- 
vaccine approaches to brucellosis [59]. 
During the three protection studies presented here it has been observed that the adjuvant only 
control is able to induce a level of control over the Brucella infection (2.51,1.41 and 0.95 PU). It is 
not known why ISCOMs and CpG induce this protective effect. However, the adjuvant is designed 
to elicit a Th1-type immune response which is considered the desired response for clearance of 
Brucella. The longevity of the protection provided by the adjuvant is an interesting factor, since the 
final immunisations were given 30 days before challenge. Thus, for the adjuvant to exhibit a 
controlling effect after this long is surprising. Although, ISCOMs and CpG have been used as a 
combination vaccine previously against other pathogens this effect has not been observed before 
[130,98]. Further studies will have to be completed to fully understand this effect. 
It is clear from the work in this chapter that PotD and PotF are newly identified novel vaccine 
candidates against brucellosis. However, it has been difficult to fully assess their protective 
properties due to the varying levels of protection observed by the adjuvant. To fully assess the 
protective properties of PotD and PotF further studies will be required and an understanding of the 
adjuvant effect will be needed. 
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Chapter 5- Evaluation of ISCOMs and CpG 
as an immunostimulant 
128 
5.1 Introduction 
The use of adjuvants to enhance the immune response when using recombinant sub-unit vaccines 
is commonplace. The use of dual adjuvants, however, is less common. Research using oil-based 
adjuvant systems and CpG has shown that the addition of CpG can enhance the immune response 
generated to vaccines [230,190]. The co-administration of ISCOMs and CpG as an adjuvant is less 
common but has been used successfully [130,98]. Immunisation with ISCOMS or CpG leads to a 
non-specific measurable cellular immune response [298,171]. In some cases immunisation with 
CpG alone can elicit a strong enough immune response to clear a subsequent infection 
[122,343,154]. 
Adjuvants are designed to either enhance all aspects of the immune response or to target specific 
branches of the immune system. ISCOMs and CpG, when used together or separately, are 
designed to elicit cellular immune responses [298,173]. The CpGs activate TLR9, an internal TLR 
that recognises short unmethylated DNA. Signalling through TLR9 causes the release of cytokines 
such as IFN-y, IL-6, IL-12 and TNF-a [171]. 
ISCOMs are 30-40 nm cage-like structures derived from cholesterol, phospholipids and saponins 
[307]. Studies comparing ISCOMs to oil-based adjuvants have shown they induce similar humoral 
antibody responses but much higher CD8' T cell responses [64]. The administration of ISCOMs to 
mice induces a strong inflammatory response starting with the recruitment of large numbers of 
neutrophils and mast cells, followed closely by macrophages, dendritic cells and lymphocytes [298]. 
In animal vaccination trials a negative control group consisting of adjuvant only is usually included 
to show that the adjuvant alone is not causing the protective effect observed by the adjuvanted 
vaccine candidates. In the protection studies detailed in Chapter 4, ISCOMs and CpG were used to 
adjuvant the vaccine candidates. Collation of the data from the chapter shows that ISCOMs and 
CpG alone provides a level of control over a Brucella infection in mice (figure 5.1). Although not as 
effective as Rev. 1, mice immunised with ISCOMs and CpG and challenged with B. melitensis 
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16M harboured significantly reduced Brucella loads in their spleen when compared to PBS- 
immunised mice. This protective effect of ISCOMs and CpG is an interesting observation as the B. 
melitensis challenge was administered 30 days after the final immunisation indicating that the 
protective immune response could remain after this time. 
CpGs are an innate immune stimulator that can provide protection against various pathogens 
including viral, bacterial and parasitic pathogens, when administered to mice prior to exposure. For 
example, protection against malaria was provided to mice when administered with CpG one or two 
days prior to challenge [122]. Similarly, mice dosed with CpG two or six hours before exposure to 
Mycobacterium tuberculosis H37Rv subsequently had reduced H37Rv levels up to five weeks after 
the challenge [154]. Mice have also been shown to be protected from Burkholderia pseudomallei 
and Burkholderia mallei challenge when inoculated with CpG between two and ten days before 
challenge [343,356]. 
In one study, candidate Brucella vaccines were evaluated using CpG as adjuvants. Although the 
vaccine candidate P39 was protective when administered with CpG at four and eight weeks after 
challenge, mice immunised with CpG alone showed no protection at either timepoint [10]. These 
observations indicate that CpGs do not induce a long-lasting effect during Brucella infection. 
Many strategies have been adopted to try and enhance the immune responses generated by CpG 
[231]. Early studies evaluated the incorporation of CpG into existing depot-forming adjuvants such 
as aluminium salt adjuvants. In one study, mice immunised with recombinant hepatitis B surface 
antigen adjuvanted with CpG and aluminium salt adjuvants had antibody titres 35 times greater 
than mice immunised with recombinant hepatitis B surface antigen with aluminium salts alone, 
indicating that together CpG and aluminium salts were a more effective adjuvants [72]. Similar 
studies have shown that combining CpG and emulsigen adjuvants enhances the immune response 
generated to herpesvirus glycoproteins in rabbits and sheep, providing evidence that this 
enhancement method is not limited to mice (144,143]. Some of the more recent and novel 
approaches to enhancing CpG activity include coupling of CpG to a polysaccharide carrier such as 
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a modified 0-(1-3)-D-glucan schizophyllan (SPG, an extracellular polysaccharide produced by the 
fungus Schizophyllum commune) [221], binding of CpG to cationic carbon nanotubes [27], 
packaging of CpG to fusogenic liposomes (FL, derived from conventional liposomes with an 
inactivated Sendai virus-derived accessory protein attached) [366] and co-administration of CpG 
with polyphosphazenes (synthetic water-soluble, biogradable polymers) [230]. There are also 
examples of CpG being packaged into liposomes to enhance their immunotherapeutic efficacy 
[354]. However, at the time of writing there is no known published literature describing the 
enhancement of CpG activity using ISCOMs. The results from Chapter 4 suggest that the co- 
administration of ISCOMs with CpG could enhance or prolonging the immune response generated 
by CpG. To investigate this further, this chapter describes a number of in vitro and in vivo studies 
designed to evaluate the stimulatory and properties of ISCOMs and CpG when used together as 
adjuvants. In all experiments the CpG 10103 (5'-TCGTCGTTTTTCGGTCGTTTT-3') was used, as 
in Chapter 4. 
5.2 IFN-y generation in ex-vivo splenocytes treated with ISCOMs & CpG 
This experiment aimed to determine if the co-administration of ISCOMs with CpG may induce a 
greater immune response than administration of CpG alone. IFN-y responses were measured in 
naive ex-vivo mouse splenocytes stimulated with CpG ± ISCOMs. The ex-vivo splenocytes were 
harvested from naive mice and homogenised through a 40 pM cell sieve, and the red blood cells 
were lysed using red cell lysis buffer (Sigma, UK). The cell populations were adjusted to 5x10° 
cell/ml and stimulated with 4 pg ISCOMs ±2 pg CpG. IFN-y release was measured via ELISPOT 
assay after 20 hours stimulation at 37°C, 5% C02 (figure 5.2). 
The results from this experiment indicate that ex-vivo splenocytes stimulated with ISCOMs and CpG 
or CpG alone produce high numbers of IFN-y producing cells. However, cells stimulated with 
ISCOMs and CpG together produce significantly (P < 0.05) higher numbers of IFN-y producing cells 
(300 IFN-y producing cells per 5x105) than cells stimulated with CpG alone (280 IFN-y producing 
cells per 5x105). Similarly, cells stimulated with CpG and ISCOMs or CpG alone both induce 
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Figure 5.2: IFN-y generated when ex-vivo splenocytes were stimulated with 4 
pg ISCOMs ±2 pg CpG. 
The number of IFN-y producing cells was measure via ELISPOT assay 
generated by the stimulation of naive mouse ex-vivo splenocytes with 4 pg 
ISCOMs ±2 pg CpG after 20 hours. The data shown was generated from five 
mice and at least twelve wells were mouse per stimulation group. 
= Significant increase in IFN-y production when compared to no stimulation and ISCOMs group (P 
< 0.0001, t-test) 
Significant increase in IFN-y production when compared to CpG stimulation (P < 0.05, t-test) 
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significantly more IFN-y producing cells (P < 0.0001) than unstimulated cells (56 IFN-y producing 
cells per 5x105) or cells stimulated with ISCOMs alone (64 IFN-y producing cells per 5x105). 
This finding could be responsible for increased macrophage activity, CD8' T cell activation and NK 
cells activation, leading to an increased immune response that may result in an enhanced response 
to Brucella infection. 
5.3 Post inoculation IFN-y production from ex-vivo splenocytes over a6 
week period 
In order to understand the long-term anti-Brucella effects of ISCOMs and CpG treatment, IFN-y 
production was observed over a six week period in inoculated mice. To evaluate the immune 
response to ISCOMs and CpG 30 days after final administration, four groups of 12 Balb/C mice (6 - 
8 weeks old) were inoculated with either 12.5 pg ISCOMs & 6.25 pg CpG, 12.5 pg ISCOMs, 6.25 
pg CpG or 100 pl PBS. Three inoculations were given three weeks apart (as used in Chapter 4 
protection studies, sections 2.5.2 and 2.5.3). Then, at 24 hours, 2 weeks, 4 weeks, and 6 weeks 
after the final vaccination, three mice from each group were culled and the resting number of IFN-y 
producing cells was measured via ELISPOT assay (figures 5.3 and 5.4). 
At 24 hours after the final administration, the number of IFN-y producing cells in mice given 
ISCOMs and CpG or CpG alone was significantly higher (p < 0.01) than the number of IFN-y 
producing cells from negative control mice and mice administered ISCOMs only. Two weeks after 
the final administration the numbers of IFN-y producing cells in all groups was reduced to a similar 
number as in negative control animals, after which the number of IFN-y producing cells steadily 
increased over the six week period tested. If the average number of IFN-y producing cells for each 
group at 2,4 and 6 weeks is plotted and an analysis of co- variance (ANCOVA) statistical analysis 
is completed, these data show that the number of IFN-y producing cells in the animals administered 
ISCOMs and CpG group increases at a significatly greater rate (P < 0.001) than in any of the other 
treatment groups (figure 5.4). This steady increase in the number of IFN-y producing cells after 
administration of ISCOMs and CpG is interesting as it is a pattern that is not known to have been 
reported before. However, the same pattern also occurs in animals inoculated with PBS only which 
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Figure 5.4: ANCOVA linear regression analysis of increasing IFN-y production 
by ex-vivo splenocytes over six weeks. 
11 
10 
9 
8 
7 
-tea ö6 Q5 
Lf) 4 
-2 
U1 
ANCOVA linear regression analysis of the number of resting IFN-y producing cells from 
inoculated mouse ex-vivo splenocytes. Panel A shows a graphical representation of the 
ANCOVA analysis of the 2,4, and 6 week data from figure 5.3. Panel B shows ANCOVA p 
values comparing slopes between groups. 
Panel A error bars indicate the standard deviation of the data 
A 
0 
B 
246 
time (wks) 
" CpG 
" PBS 
ISCOMs & CpG ISCOMs CpG PBS 
ISCOMs & CpG - p<0.0001 p<0.001 p<0.0001 
ISCOMs *** p=0.4 p=0.156 
CpG ** ns - p<0.04 
PBS *** ns * - 
p< 0.0001 
**=p<0.001 
*=p<0.04 
ns = not significant 
ANCOVA linear regression analysis   ISCOMs & CpG 
" ISCOMs 
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is unexpected. Overall, the data generated in this experiment indicates that ISCOMs and CpG 
together lead to an increasing immune response over time. These data indicate that there could be 
a slow release of the CpG from the ISCOMs causing this increasing immune response. 
5.4 Cellular uptake of CpGs 
The internalisation of CpG is important in inducing an immune response as TLR9 (which is 
activated by CpG) is located inside the cell. It is possible that enhancing the rate of CpG uptake into 
host cells might play a role in inducing a more sustained immune response to the ISCOMs and CpG 
adjuvant. To determine the uptake of CpGs in the presence of ISCOMs, confocal microscopy was 
used to visualise CpGs within cells using a 5' carboxyfluorescein (FAM) labelled phosphothioate 
backbone CpG 10103 (FAM-CpG) synthesised by ATDBio (Southampton University, UK). Murine 
macrophage J774A. 1 cells were cultured in 150 cm3 flasks to approximately 80% confluence before 
being harvested into 10 ml of DMEM complete media. The J774A. 1 cell concentration was adjusted 
to 3.5x106 cells/ml and two 1 ml samples were placed into a 22 mm glass bottomed Wilco dish 
(Intracel, Royston Hertfordshire). These cells were incubated for 20 hours at 37°C, 5% CO2 and with 
relative humidity. The supernatant was removed and 5 pg FAM-CpG ± 10 pg ISCOMs was added 
(section 2.6.3.1). When using confocal microscopy it can be difficult to determine if molecules are 
internalised or attached to the surface of the cells. As proof-of-principle to demonstrate that FAM- 
CpGs were internalised, cells were stained with LysoTrackerTM red (Invitrogen, Paisley, UK), which 
stains the lysosomes of the J774A. 1 cells with a red fluorescent dye. If the FAM-CpGs are 
internalised into the lysosomes of the cells then the LysoTrackerTM red and the FAM-CpG co- 
localise to produce an orange colour when viewed under the confocal microscope (figure 5.5). 
Images of cells that had been dosed with ISCOMs only were also taken to confirm that ISCOMs do 
not have any natural fluorescence that would interfere with measurements of the FAM-CpGs. 
LysoTrackerT"" red was not used during time course experiments as its intensity overpowered the 
fluorescence of the FAM-CpG in earlier time points. Following inoculation of the J774A. 1 cells with 
ISCOMs and CpG, cells were imaged at 1,2,4,6,8 and 16 hours. At each timepoint eight random 
fields of view were imaged. Representative images of CpG uptake are shown in figure 5.6. Figure 
5.7 shows the percentage of cells containing FAM-CpG over the 16 hour period studied. 
137 
U) 
ci) 0 
a) 
U) cE 
CD 
Q ii 
0m 
U co 
138 
C 
(0 
CD 
CL 
U 
LL 
Ct 
0 
U, 
a) 
rn 
cu 
E 
U) 
Q 
v N- N- 
-) 
9- O 
U) 1) 
rn co 
E 
a O U 
N 
O 
U 
E 
CO 
U 
O 
C 
0 
0 
0 
E 
M 
0 
Coo 
139 
OO 
NQ 
ON 
NL 
Oo 
m 
N a) 
Um 
C 
rý 
Q 
N 
5 0) 
U) co 
E 
O 
L 00 
NO 
Dj 
C 
7 (ß 
O 
NO 
LN `- 
N 
O 
o 
UC 
LL 
}, N 
3N aD 
CM 
a) ca xE 
C a) N-p 
NL 
3N 
O (ý N 
U aý 
CY) cn U 
oQY 
E Co 
ONw 
Nmc 
N a 
Y 
"ý 
Ü 
CNW 
O 
ý 
Üý 
ýLOÜ 
- -0-0 
II E 
U- cc nL 
E 
000 ca äý II (D (D 
QW rný 
M 
(O ICO 
Q- t co 
O 
O II OÜ 
c(U 
Cl) 
CN a) 
OQ 
II ýN 
V0 rn 
NL 
3OC 
1L < F- '0 
E 
0 
v 
i 
cý m 
140 
0 
U 
9- 
0 
U 
N 
U, 
N 
CL 
a) 
t_ 
c 
r 
U 
U- 
0 
a) 
(6 
Q 
N 
N 
(0 
N 
U 
C 
tD 
C1 
LL 
L 
1 
LL 
L 
00 
11 
W 
t 
Co 
11 
L 
0 
L 
N 
II E 
ZL 
O 
ý II 
II ý 
<m 
141 
Figure 5.7: Uptake of FAM-CpG ± ISCOMs over a 16 hour period. 
The graph shows the percentage of J774A. 1 cells positive for internalisation of FAM-CpG. J774A. 1 
cells were administered 5 pg FAM-CpG ± 10 pg ISCOMs at 1,2,4,6,8 and 16 hours after the cells 
were visualised using confocal microscopy. Eight random fields of view were captured at each 
timepoint. The % of FAM-CpG positive cells was calculated as a percentage of the total cells on 
each image. Each bar on the graph represents the average % FAM-CpG positive cells over the eight 
fields of view captured. Although there is no significant difference at 16 hours cells administered 
both ISCOMs and CpG seem to have a greater uptake of CpG. 
Error bar indicate the standard deviation of the data 
- ISCOMs & CpG 
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LL 
hours 
= significantly greater FAM-CpG in cells administered with ISCOMs and 
FAM-CpG when compared to cells administered with FAM-CpG only (p < 
0.0002, t-test) 
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The results from this study indicate that FAM-CpG are internalised quicker in the presence of 
ISCOMs than they are when administered to cells alone. Within 2 hours of administration 
approximately 30 % of the cells inoculated with ISCOMs and CpG were positive for CpG uptake. In 
comparison, approximately 6% of cells inoculated with FAM-CpG only were positive for FAM-CpG. 
At time points 2,4,6 and 8 hours the cells inoculated with ISCOMs and CpG contain significantly (P 
< 0.0002) more internalised CpG than the cells dosed only with CpG showing that, in the presence 
of ISCOMs, FAM-CpG are more effectively internalised. After 6 hours approximately 95 % of the 
cells dosed with ISCOMs and FAM-CpG contained FAM-CpG. In comparison, it took 16 hours for 
approximately 96 % of cells that were dosed with FAM-CpG alone internalise FAM-CpG. After eight 
hours of incubation, cells administered with ISCOMs and CpG started to die, due to the toxicity of 
the saponin component of the ISCOMs. Overall, this data provides evidence to suggest that 
ISCOMs assist in the internalisation of FAM-CpG. 
5.5 Stability of ISCOMs & CpG at low pH 
When CpGs enter the cell they localise in the lysosomes of the macrophages. These vacuoles are, 
in a rudimentary sense, the digestive organelles of the cells. Lysosomes contain many different 
digestive enzymes such as lipases, proteases and nucleases and are more acidic than the cytosol, 
maintaining a pH of approximately 4.8 by pumping in H+ ions from the cytosol using H' ion pumps 
[276]. One theory related to the long lasting immune response induced by ISCOMs and CpG is that 
the ISCOMs stabilise CpGs. Specifically, when the ISCOMs and CpG mix are phagocytosed and 
trafficked through into the lysosomes, the ISCOMs could be providing the CpG with some protection 
from the low pH and the enzymes present in the lysosomes. To assess the stability of CpG in the 
presence of ISCOMs, a pH 4 buffer was prepared from a mixture of sodium phosphate and citric 
acid buffers (section 2.6.3.2) and ISCOMs ± CpG were incubated in the buffer for eight weeks at 
37°C to simulate the low pH of a lysosome. At one week intervals the ISCOMs ± CpG were diluted 
to working concentrations (40 pg/ml ISCOMs and 20 pg/ml CpG (section 2.6.3.2.2)) and 100 pI of 
the mixture (4 pg/ml ISCOMs and 2 pg/mI CpG) was used to simulate naive mouse ex-vivo 
splenocytes. The number of IFN-y producing cells was measured via ELISPOT assay to assess the 
activity of the ISCOMs and CpG (figure 5.8). 
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The results from this experiment show that ex-vivo splenocytes stimulated with ISCOMs and 
CpG or CpG alone both produce more IFN-y producing cells than cells stimulated with ISCOMs 
alone (p < 0.05, figure 5.8). Similarly, the cells stimulated with ISCOMs and CpG appear to 
produce more IFN-y producing cells than cells stimulated with CpG alone, although the 
difference is not significant (P > 0.05). 
The results also indicate that the activity of both ISCOMs and CpG and CpG alone decreases 
over time when incubated at 37°C and pH 4. However, the decrease in activity over time is the 
same for both CpG alone and ISCOMs and CpG indicating that, in this assay, the ISCOMs do 
not seem to stabilise the CpG. 
5.6 Conclusions 
The aim of this work was to further explore and understand why the ISCOMs and CpGs 
provided protection during a Brucella infection 30 days after final administration. 
Other studies have reported the increase in efficacy of CpG as an immunostimulant using many 
novel techniques [221,27,230,231,354]. If the efficacy of CpG as a vaccine adjuvant could be 
increased by administration with a pre-existing adjuvant technology like ISCOMs this would be 
very advantageous. 
The observations made in Chapter 4 have shown that ISCOMs and CpG can have a controlling 
effect over a Brucella infection 30 days after the final inoculation (figure 5.1). One theory that 
may explain this is that the ISCOMs are stabilising the CpG which, in turn, means that the 
innate immune system is being induced more effectively by the CpG. The first experiment in this 
study has shown that stimulation of naive mouse ex-vivo splenocytes with ISCOMs and CpG 
induced more IFN-y producing cells than stimulation with ISCOMs or CpG alone, which shows 
that together they could induce a better immune response than when either is administered 
alone. The experiments performed in this study have demonstrated that, when administered 
together, ISCOMs and CpG could be a better adjuvant combination that when used separately. 
Specifically, these experiments have shown that ISCOMs can assist internalisation of CpG into 
cells at a faster rate than CpG alone, perhaps inducing a faster and/or longer immune response. 
145 
Although a number of experiments have been performed it has been difficult to demonstrate 
interactions between ISCOMs and CpG during an in vitro assay as cells start to die 6 to 8 hours 
after administration of ISCOMs. Thus, an animal experiment was completed to determine the 
resting IFN-y response over a6 week period after inoculation with CpG ± ISCOMs. After three 
doses of ISCOMs and CpG the number of IFN-y producing cells drops after the first 24 hours 
but increases slowly over a six week period to levels observed 24 hours after the final 
inoculation. Interestingly, all of the other inoculated groups also showed this pattern, although at 
a significantly lower rate than the animals given ISCOM and CpG. The high quantity of IFN-y 
producing cells observed 24 hours after the final inoculation in the experimental groups is the 
initial stimulation of the innate immune system by the ISCOMs and/or CpG. However, in the 
PBS treated mice the response could be caused by the inoculation trauma which is not an 
uncommon response to a trauma event even in the human population [329]. What is clear from 
this data is that ISCOMs and CpG do cause a slow increase in the number of IFN-y producing 
cells over a6 week period. This 6 week period is equivalent to 42 days after final inoculation, so 
the data is applicable to the challenge experiments in chapter 4 where mice were challenged 30 
days after final inoculation. 
The stability assay carried out in this study indicated that ISCOMs were not able to stabilise the 
CpG in the pH 4 conditions used. However, although the pH 4 conditions used to incubate the 
CpG ± ISCOMs are harsh and mirror one aspect of the lysosome environment, there are also 
other lysosomal conditions that are harder to effectively reproduce in vitro. This assay is limited 
to mimicking the pH of the lysosome but along with the low pH of the lysosome environment, 
there are also a plethora of enzymes that could attack CpGs causing breakdown and 
inactivation. Although it would be possible to incubate the ISCOMs and CpG at pH 4 along with 
enzymes, it would be difficult to accurately mimic the lysosome environment. Although this 
assay is limited, it does highlight that CpG 10103 ± ISCOMs maintain their activity under very 
harsh conditions, retaining approximately 50 % of the activity after 5 weeks of incubation at pH 4 
when compared to 1 week of incubation. The slow decrease in activity could be because CpG 
10103 is a class B CpG which has a fully phosphorothioate backbone, which is inherently stable 
and resistant to breakdown [305]. 
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Although the mechanism by which ISCOMs enhance CpG uptake into cells is not fully 
understood one theory may be that when the CpGs and ISCOMs are mixed the CpG are 
protected/stabilised by the ISCOM cages and the CpG and ISCOMs are internalised together. 
As the ISCOMs are larger than the CpG they are more likely to be phagocytosed as foreign 
antigens which would cause them to be trafficked to the lysosomes where TLR9 is present. 
The data described in this chapter has shown that ISCOMs and CpG induce high numbers of 
IFN-y producing cells which could assist in the clearance of a bacterial infection. It has also 
been demonstrated that ISCOMs increase the rate of internalisation of CpG into cells. Mice 
administered ISCOMs and CpG also produce a slowly increasing resting IFN-y response up to 
six weeks post final inoculation. All these data suggest that ISCOMs and CpG could be better 
adjuvants when combined and administered together. There is also evidence to suggest that 
ISCOMs and CpG can produce a low level immune response 30 days after final inoculation 
which is strong enough to control a Brucella infection. 
147 
Chapter 6- Optimisation of PotD and PotF 
as vaccine candidates 
148 
6.1 Introduction 
The identification of the novel protective vaccine candidates PotD and PotF is a step forward in 
finding a suitable human and animal vaccine against brucellosis. During the course of this study 
it has been observed that, as well as being used to adjuvant PotD and PotF proteins, ISCOMs & 
CpG alone can be used to control a Brucella infection, making it difficult to fully assess the 
protective capabilities of PotD and PotF. It is possible that the CpGs are continuously being 
slowly released from the ISCOMs causing the immune response to be boosted. This slow 
release could mean that the CpGs are still present at 30 days after the final inoculation, the 
point at which inoculated mice are challenged. 
Work presented in Chapter 5 has shown that mice inoculated with ISCOMs & CpG show higher 
resting IFN-y production after 42 days than mice immunised with either ISCOMs or CpG alone. 
This provides some data to help explain the controlling effect that ISCOMs and CpG have on a 
Brucella infection. In this chapter, further studies have been designed to try to eliminate the 
controlling adjuvant effect in order to assess the potential of PotD and PotF as vaccine 
candidates against brucellosis. 
The aim of this chapter is to fully explore the protective efficacy of PotD and PotF proteins 
observed in Chapter 4 using a number of animal trials designed to test PotD and PotF protective 
efficacy over longer time periods and in combination with different adjuvants. The creation and 
evaluation of PotD and PotF DNA vaccine is also presented in this chapter. 
6.2 An evaluation of protective efficacy of PotD and PotF vaccine 
antigens after 60 days 
During the course of this project, mice have been challenged 30 days after their final inoculation 
with proteins adjuvanted with ISCOMs and CpG. Results from Chapter 5 indicate that there 
could be an immune response still present in mice inoculated with ISCOMs and CpG at this 
timepoint. Extending the time of challenge from 30 days to 60 days after the final inoculation 
may enable a reduction in the immune response generated by ISCOMs and CpG in order to 
evaluate the protective efficacy of PotD and PotF. 
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6.2.1 Immunisation schedule 
The protective efficacy of PotD and PotF was tested in the murine model of B. melitensis 
infection. Groups of 10 female Balb/C mice (9 - 11 weeks old) were inoculated with 10 pg 
protein adjuvanted with 12.5 pg ISCOMs and 6.25 pg CpG administered intramuscularly three 
times at three week intervals. Two positive control groups were included in this study; to assess 
B. melitensis Rev. 1 protection after 60 days specifically, both groups of mice were immunised 
with a single sub-cutaneous dose of approximately 2x105 B. melitensis Rev. 1 at either 30 days 
(Rev. 1 30) or 60 days before challenge (Rev. 1 60). Negative control groups of mice immunised 
with PBS or ISCOMs and CpG adjuvant only were also included. Sixty days after the final 
protein inoculation all mice were challenged with 1.41x104 of CFU B. melitensis 16M via the 
intraperitoneal route. Fifteen days after challenge all mice were culled and splenic colonisation 
assays were performed as previously described (section 2.5.4). 
6.2.2 An evaluation of protective efficacy of PotD and PotF over 60 days 
The protection provided by PotD and PotF in this experiment (figure 6.1) differs considerably 
from that observed in the previous experiment (Chapter 4, figure 4.18, page 120). Results show 
good protection induced by both Rev. 1 30 and Rev. 1 60 and, as expected, no protection from 
the PBS inoculated mice. However, there is no protection elicited by PotD (-0.28 PU) and PotF 
(0.48 PU) in this study. Increasing the time to challenge has reduced the protective effect of the 
adjuvant although, in this study, administration of the adjuvant alone caused significant variation 
in splenic Brucella load and has produced the highest PU of all the experimental groups. 
6.3 An evaluation of adjuvants for PotD 
Adjuvants are used to enhance the immune response to an antigen. There are different types of 
adjuvant designed to increase or prolong the immune response to an antigen, and the adjuvant 
used in these studies previously have been ISCOMs and CpGs. As mice immunised with 
ISCOMs and CpGs has controlled Brucella infection, confirmation of the protection afforded by 
PotD and PotF proteins administered alongside the ISCOMs and CpG has proven difficult. It is 
possible that the use of an alternative adjuvant may enable clarification or improvement of the 
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protective efficacy of these proteins. Here PotD protein was evaluated in combination with a 
range of adjuvants for its protective efficacy against brucellosis. 
6.3.1 Immunisation schedule 
The efficacy of PotD administered with different adjuvants was tested in the murine model of B. 
melitensis infection. Groups of six female Balb/C mice (9 - 11 weeks old) were inoculated with 
10 pg of PotD protein along with one of five different adjuvants in a total volume of 100 pl PBS. 
The adjuvants used were: 12.5 pg ISCOMs, 6.25 pg CpG, 12.5 pg ISCOMs and 6.25 pg CpG, 
20% v/v Alhydrogel (aluminium hydroxide) or a 50% v/v emulsion of Incomplete Freund's 
Adjuvant. Mice were inoculated three times at three weekly intervals via the intramuscular route. 
A positive control group was immunised with a single dose of 2x105 CFU of B. melitensis Rev. 1 
and negative controls groups were inoculated with either 100 pl PBS or adjuvant only. After final 
inoculation mice were left for 30 days before being challenged with 3.6x104 CFU of B. melitensis 
16M administered via the intraperitoneal route. Fifteen days after challenge all mice were culled 
and splenic colonisation assays were performed to determine the B. melitensis 16M load. 
6.3.2 Evaluation of protective efficacy of PotD with different adjuvants 
Figure 6.2 shows the protection afforded by PotD when administered alone or with adjuvants. 
No protection was elicited by PotD alone (-0.25 PU) or when administered with any of the 
adjuvants. The lack of protection elicited by PotD administered with ISCOMs and CpGs is 
surprising since this experiment followed the same inoculation schedule as in Chapter 4, when 
PotD and PotF were initially identified as vaccine candidates. There is also minimal protection 
observed from the mice administered with ISCOMS and CpG (0.58 PU). 
6.4 Evaluation of PotD and PotF protection by DNA vaccination 
Due to the variation observed in protection elicited by PotD and PotF as protein vaccine 
candidates, an alternative method of delivering PotD and PotF as DNA vaccines was evaluated. 
DNA vaccination involves the direct injection of a DNA plasmid encoding the vaccine candidate 
of interest, into a host. The plasmid is taken up by host cells, which produce the protein via 
transcription and translational mechanisms. Once produced, the protein is presented to the 
immune system. DNA vaccination has recently undergone a resurgence in popularity and, due 
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to improvements in molecular techniques and DNA vaccine understanding, they are becoming 
more effective at inducing strong immune responses. In recent years four DNA vaccines have 
been licensed for use in animals, covering a range of targets including West Nile virus [71] in 
horses and Melanomas [25] in dogs. The licensing of DNA vaccines represents a significant 
advancement their development. Along with the four currently licensed DNA vaccines there are 
over 90 different phase Ito phase III clinical trials ongoing [177]. The licensing of DNA vaccines 
for use in animals is of significant relevance to the Brucella research community, as any novel 
DNA vaccine produced against brucellosis could be potentially licensable. 
As brucellosis is the world's most prevalent zoonotic disease, controlling the disease in animals 
may be the best way to control the disease in the human population too. An effective DNA 
vaccine against brucellosis could provide a licensable product for use in endemic Brucella areas 
around the world. There have been a number of attempts to create effective DNA vaccines for 
brucellosis (section 1.6.5 and table 1.2). 
In order to improve the efficacy including PotD and PotF, DNA vaccines encoding these vaccine 
candidates were produced and evaluated in the murine model of B. melitensis infection. 
6.4.1 Construction and expression of DNA vaccines 
PotD and PotF DNA vaccines were constructed by Geneart AG (Regensburg, Germany). The 
truncated PotD and PotF genes were synthesised and inserted into the pcDNA3.1 DNA vector 
(Invitrogen Ltd, Paisley, UK and section 2.3.4, figure 6.3). The pcDNA3.1 vector was chosen as 
the DNA vaccine vector as it has been used extensively in the production of other candidate 
Brucella DNA vaccines [370,59,199]. DNA vaccines were purified using Endotoxin Free Giga 
prep kits according to manufacturer's instructions (Qiagen, UK). The DNA vaccine concentration 
was determined using A260 optical density readings. DNA purity was assessed using A260/A280 
ratios and preparations with readings of 1.8-2.0 were considered of suitable purity for further 
use. 
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Figure: 6.3: Schematic representation of pcDNA3.1 vector 
containing PotD or PotF antigen genes 
CMV promoter: Allow high level expression of the recombinant 
vaccine antigen 
Neomycin resistance cassette: Allows selection of transfectants 
in mammalian tissue culture 
pUC origin: Allows for high-copy replication in E. coli 
Ampicillin resistance cassette: Allow for selection of stable 
transfectants in E. coli 
Antigen gene 
PotD or PotF 
Human 
cytomegalovirus 
(CMV) promoter Neomycin 
resistance cassette 
Ampicillin 
resistance cassette 
pUC origin 
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Expression of PotD and PotF DNA vaccines was confirmed by transfection of COS-7 
mammalian kidney cells with the DNA vaccines and subsequent evaluation by Western blotting 
(section 2.3.4.4 and 2.4.1.2). To assess the optimal transfection and expression conditions for 
the DNA vaccines two different transfection reagents (GeneJuice® or Polyfect(@) were used. 
COS-7 cells were harvested and cultured in six well plates at a density of 4x105 cells, the plates 
were incubated overnight at 37°C and 5% CO2. COS-7 cells were transfected with a plasmid 
expressing green fluorescent protein (GFP) using either GeneJuice® or Polyfect® transfection 
reagents and DNA to transfection reagent ratios recommended in the manufacturer's 
instructions. The cells were then incubated for 24 or 48 hours, after which the expression of 
GFP was assessed using confocal microscopy (figure 6.4, section 2.6.3.1.2). The optimal 
transfection reagent and expression length (GeneJuiceO at a ratio of 3 pl to 1 pg DNA vaccine 
for 48 hours) was used to assess expression of PotD and PotF DNA vaccines. Following 
transfection of COS-7 cells with these DNA vaccine constructs, expression of both PotD and 
PotF was confirmed by Western blot (figure 6.5). Bands of approximately 39.8 kDa (PotD) and 
42.4 kDa (PotF) were observed in the experimental cell lysates, which corresponded to the 
purified PotD and PotF proteins, respectively. 
6.4.2 Immunisation schedule 
Groups of six (6-8 week old) female Balb/C mice were inoculated with four doses of 100 pg of 
DNA vaccine dissolved in 100 pl PBS at four week intervals. Two further groups of negative 
control mice were inoculated with 100 pl PBS or 100 pg of pcDNA3.1 vector. A group of six 
mice immunised with a single dose of 2x105 CFU of B. melitensis Rev. 1 was used as a positive 
control. Mice were challenged 30 days after the final inoculation with approximately 1x104 CFU 
of B. melitensis 16M via the intraperitoneal route. 
6.4.3 IFN-y production from ex-vivo splenocytes from mice immunised 
with DNA vaccines 
The DNA vaccines were initially evaluated for their immunogenicity. Specifically, three mice 
were immunised using the schedule described in section 6.4.2 but, instead of receiving a 
challenge, mice were culled and their spleens removed and the number of IFN-y producing cells 
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was quantified after stimulation with PotD and PotF antigens. IFN-y has been established as an 
important cytokine in Brucella immunology [229). Measuring the number of IFN-y producing 
cells after stimulation with PotD and PotF gives an indication of the strength of the immune 
response to these antigens. The number of IFN-y producing cells was measured by ELISPOT 
assay; mouse spleens were harvested 30 days after their final inoculation, homogenised, and 
plated out (at 5x 108 cells/ml) along with 10 pg/ml of stimulatory antigen (either PotD or PotF 
protein). Plates were incubated at 37°C, 5% CO2 for 20 hours before being developed. 
The PotD and PotF DNA vaccines induced numbers of IFN-y producing cells in mice that was 
significantly higher than the mice immunised with the pcDNA3. I control vector (p < 0.05 (figure 
6.6). However, the numbers of IFN-y producing cells was low, suggesting that the PotD and 
PotF DNA vaccines are poorly immunogenic. Although there was a low number of IFN-y 
producing cells, it does not mean that protection will not be observed against brucellosis. 
Previous work presented in Chapter 4 has shown that a high number of IFN-y producing cells 
does not necessarily correlate with a protective immune response. 
6.4.4 Evaluation of protective efficacy of PotD and PotF DNA vaccines 
Mice inoculated with four doses of 100 pg DNA vaccine at four week intervals were challenged 
30 days after their final inoculation with approximately 1x 10° CFU of B. melitensis 16M. Fifteen 
days after challenge mice were culled and splenic colonisation assays were performed (section 
2.5.4) to assess the Brucella load in the spleen. 
There was a significant difference in splenic bacterial load mice inoculated with PBS when 
compared to mice immunised with Rev. 1, showing that the Rev. 1 vaccine provided effective 
protection as expected (figure 6.7). Vaccination with PotF DNA vaccine resulted in control of the 
Brucella infection with a PU of 2.76 and an average Log1o Brucella CFU of 3.03, a significant 
reduction in Brucella burden when compared to naked pcDNA3.1 or PBS inoculated mice (p < 
0.05). The PotD DNA vaccine had a PU of 2.08 which indicates a reduction in bacterial load. 
However, this reduction was not significantly different from the negative controls (p > 0.05), due 
to the amount of variation seen within the data set. These results indicated that PotF DNA 
vaccine can be considered novel protective antigens against brucellosis. 
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Figure 6.6: IFN-y production from ex-vivo splenocytes of mice 
immunised with PotD and PotF DNA vaccines after 20 hours stimulation 
with 10 pg/mI PotD and PotF proteins. 
* Significant increase (p < 0.05, t-test) in IFN-y production from control 
mice 
Error bars represent the standard deviation of the data 
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6.5 Re - evaluation of PotD and PotF in folded structural conformation 
6.5.1 PotD and PotF protein structural analysis 
The protective efficacy of PotD and PotF proteins showed significant variation. However, the 
challenge studies presented in Chapter 4 (protective proteins) were completed with different 
batches of purified proteins to the trials completed in Chapter 6 (non-protective proteins). This 
could mean that there are qualitative differences between the batches that caused the variation 
in protection. To test this hypothesis both batches of proteins were subjected to circular 
dichroism (CD) analysis (a method that resolves the secondary structure of protein by 
measuring the differential absorption of circularly polarized light). 
The PotD and PotF proteins produced in the first batch (tested in Chapter 4) had different CD 
traces (and therefore structures) the PotD and PotF proteins produced in the second batch 
(tested in Chapter 6, figure 6.8). Specifically, there is less secondary structure in the second 
batch of protein, when compared to the folding in the first batch. These differences observed in 
the structures of the two batches of PotD and PotF proteins suggests that structural 
conformation could be important in their protective efficacy. As there was no protein left from the 
original protein batches, further batches of endotoxin-free NO and PotF proteins were 
commercially re-produced by Lionex (Germany). Circular Dichroism analysis of these proteins 
has shown that they also have a similar structural conformation to the first batch of (protective) 
protein. 
Since the variation in PotD and PotF protective efficacy may be linked to their structural 
conformation, a further experiments was undertaken to evaluate the folded PotD and PotF 
proteins. Additionally, the effect of co-administering PotD and PotF together was assessed in 
this experiment. 
6.5.2 Immunisation schedule 
Groups of 6 female Balb/C mice (six to eight week old) were inoculated with 10 pg of PotD, 10 
pg of PotF or 10 pg of PotD and 10 pg of PotF, adjuvanted with 12.5 pg ISCOMs and 6.25 pg 
CpG, via the intramuscular route. Further groups of mice were inoculated with a single sub- 
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cutaneous dose of 2x105 CFU of B. melitensis Rev. 1 as a positive control or with 100 pg PBS or 
12.5 pg ISCOMs and 6.25 pg CpG as negative controls. Three inoculations were given at three 
week intervals, and 30 days after final inoculation mice were challenged with approximately 
1x104 CFU of B. melitensis 16M via the intraperitoneal route. Fifteen days after challenge mice 
were culled and splenic colonisation assays were completed to assess the number of B. 
melitensis 16M CFU per spleen. In parallel, groups of three female Balb/C mice were inoculated 
with the proteins and controls as described above. However, instead of being challenged, 30 
days after final inoculation, mice were culled and tested for IFN-y and IL-4 production via 
ELISPOT assay. 
6.5.3 Antigen-specific humoral immune response to PotD and PotF 
The total antigen-specific IgG response was assessed in sera taken at day 58 of the vaccination 
schedule (measured by ELISA). The data generated (figure 6.9A) shows that PotF generated 
the highest total IgG of the experimental groups. Mice immunised with both PotD and PotF 
generated approximately equal amounts of PotD- and PotF-specific IgG showing that neither of 
the antigens appear to produce a dominant immune response. Interestingly, the total PotD- 
specific IgG produced by mice immunised with PotD alone was similar to that in mice 
immunised with PotD and PotF, indicating that dosing mice with both proteins may not produce 
a greater immune response overall. 
Total antigen-specific IgG1 or IgG2a antibody responses were determined to clarify the type of 
immune response generated by the PotD and PotF proteins (figure 6.9B). Comparison of 
antigen-specific IgG1 and lgG2a levels indicate that PotD induced IgGI-biased antibody 
response (indicative of Th2 type immunity), whereas all the other proteins elicited a more 
balanced immune response. Mice immunised with both PotD and PotF showed a stronger 
antibody response to PotF when assaying for the individual antibody isotypes. 
6.5.4 Comparisons of IFN-y and IL-4 production from ex-vivo splenocytes 
At 30 days post final inoculation mice were culled and their spleens were removed to evaluate 
the number of IFN-y and IL-4 producing cells following stimulation from the specific vaccine 
antigen. The spleens were homogenised through a 40 pM sieve into 5 ml of DMEM and the red 
cells 
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blood were lysed by the addition of 10 ml red cell lysis buffer (Sigma, Paisley). The cells were 
counted and the density adjusted to 5x106 cells/ml, before 100 pl of cell suspension was plated 
onto an anti-IFN-y/IL-4 coated ELISPOT plate with 100 pl of a 10 pg/ml solution of vaccine 
candidate. 
The number of IFN-y producing cells in all experimental groups was high (> 550 IFN-y 
producing cells per 5x105 cells/ml) and significantly greater than the number generated by mice 
inoculated with PBS or adjuvant only (p < 0.01, figure 6.10). Mice immunised with PotD 
produced the largest numbers of IFN-y producing cells (> 750 IFN-y producing cells per 5x105 
cells/ml), whereas mice immunised with PotF or the combined PotD and PotF formulation 
produced similar numbers of IFN-y producing cells (approximately 600 IFN-y producing cells per 
5x105 cells/ml). 
The number of IL-4 producing cells within all groups was significantly higher than the number 
generated in mice inoculated with PBS or adjuvant only (p < 0.05). Again, the highest number of 
IL-4 producing cells was observed in mice immunised with PotD. However, in comparison to the 
number of IFN-y producing cells there was significantly lower numbers of IL-4 producing cells (p 
< 0.05). Interestingly, mice immunised with both PotD and PotF do not seem to produce any 
more IFN-y producing cells than the other groups despite receiving double the amount of protein 
during the inoculation. 
6.5.5 IFN-y production from CD4 deplete and CD8 deplete populations of 
ex-vivo splenocytes 
Cell mediated Thl type immune responses are characterised by IFN-y production. Measuring 
the number of IFN-y producing cells upon stimulation from the vaccine antigen in immunised 
mouse ex-vivo splenocytes provides an indication of the strength of the immune response 
induced by a vaccine candidate. Furthermore, separation of whole ex-vivo splenocyte cell 
populations from immunised mice into CD4* and CD8+ depleted cell populations will help define 
which cell type is responsible for PotD or PotF induced IFN-y production. 
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Mice inoculated with three doses (at thee week intervals) of 10 pg PotD or PotF, or a PotD/PotF 
combination, were culled 30 days after their final immunisation and number of IFN-y producing 
cells was measured as a memory response from their spleens via ELISPOT assay. Spleens 
were harvested and separated into CD4+ and CD8+ depleted populations using MACS 
separation columns (Miltenyi Biotech, Surry UK, section 2.6.2.4). The cell density was adjusted 
to 5x106 cells/ml before cells were plated onto an anti-IFN-y coated ELISPOT plate along with 
100 pl of 10 pg/mi stimulatory antigen. Plates were developed as described in section 2.6.2.5. 
The results of this experiment (figure 6.11) show that the CD8+ depleted cell populations 
produced significantly more IFN-y producing cells than mice inoculated with PBS or adjuvant 
only (p < 0.001) and significantly more IFN-y producing cells than CD4' depleted cell 
populations (465 to 708 IFN-y producing cells compared to 40 - 90 IFN-y producing cells per 
5x105 cells per ml, p<0.001). The CD4+ depleted cell populations did not contain significantly 
more IFN-y producing cells than PBS or adjuvant stimulated cells, indicating that the CD4' cell 
population is driving IFN-y production. In the CD8' depleted cell populations mice immunised 
with PotD or PotD/PotF combined produced the highest numbers of IFN-y producing cells (680 
and 708 IFN-y producing cells per 5x105 cells per ml). Incomparison, mice immunised with PotF 
had only an average of 465 IFN-y producing cells per 5x105 cells/ml, perhaps signifying that a 
more potent immune response was generated in mice immunised with PotD or PotD/PotF 
combined. 
6.5.6 Protective efficacy of PotD and PotF when tested in the folded 
structural conformation 
Mice inoculated with three doses (at three week intervals) of 10 pg PotD or PotF or a PotD/PotF 
combination were challenged 30 days after their final inoculation with 8.5x103 CFU of B. 
melitensis 16M. Fifteen days after challenge mice were culled and their spleens removed for 
splenic colonisation assays (section 2.5.4). The results (figure 6.12) show that mice immunised 
with Rev. 1 had significantly reduced Brucella loads (4.04 PU) in their spleens when compared 
to mice inoculated with PBS. Mice immunised with PotD (0.02 PU) or PotF (- 0.62 PU) did not 
show any significant signs of protection when compared to any of the negative control. 
However, mice immunised with 10 pg of PotD and 10 pg of PotF combined showed highly 
significant protection (p < 0.001) with a PU of 3.03. There was no significant difference the 
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protective efficacy of the PotD/PotF combined group and the mice immunised with Rev. 1, 
indicating that a similar performance was observed in both groups. 
Overall, these data suggest that 10 pg PotD and 10 pg PotF proteins in the folded conformation 
without endotoxin maybe poor protective antigens. However, administered as a 20 pg combined 
formulation they are effective protective antigens for brucellosis in the mouse model. 
6.6 Conclusions 
The aim of this chapter was to further assess the protective efficacy of PotD and PotF proteins 
in the murine model of B. melitensis infection. However, the protection afforded by PotD and 
PotF proteins is extremely variable. The protection observed from PotD and PotF proteins in 
Chapter 4 was 3.61 and 2.46 PU, respectively. In comparison, the challenge studies completed 
using PotD and PotF proteins in this chapter have elicited PU values of - 0.62 and 0.48 for PotF 
and 0.02, - 0.28 and - 0.25 for PotD. The lack of protection observed from the first study in this 
chapter trial could be due to the extended time to challenge. However, it is unlikely that the 
memory response generated from the inoculations would be so ineffective after 60 day, 
considering the levels of protection observed after 30 days (in Chapter 4). Originally the 
difference in protection observed between proteins was thought to be due to the variation 
observed in the proteins structural conformation between different batches, as discovered by 
CD analysis. When the proteins were made and tested again in the folded conformation, there 
no protective effect was elicited by the individual proteins. However, the poor protective efficacy 
of PotD and PotF in this experiment may reflect the low levels of endotoxin present in this batch 
of highly purified protein. In comparison, the PotD and PotF proteins produced in Chapter 4 
were made in-house at DSTL and therefore removal E. coli endotoxin contamination was not 
achieved as sufficient protein could not be produced to compensate for protein loss during 
endotoxin removal steps. It is possible that endotoxin (which is a potent innate immune 
stimulator via activation of TLR4) assisted in activating the immune response to the proteins in 
the original protection study. The re-assessment of endotoxin-free PotD and PotF in their folded 
conformation has shown that the proteins administered with ISCOMs and CpG gave no 
protection. However, the results from this experiment also indicated that administered together, 
PotD and PotF induce a highly significant reduction in bacterial spleen load compared to control 
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mice, highlighting that the combined vaccination approach has an application against 
brucellosis. 
Bacterial pathogens are complex prokaryotic organisms that have many different survival 
techniques, including multiple mechanisms for similar processes. PotD and PotF are both 
polyamine periplasmic binding proteins in E. coli [142], where the potFGHI system is involved in 
the specific binding and importing of putrescine. In comparison, the potABCD system 
preferentially imports spermidine, but it can also import putrescine if needed. Thus, if the 
potFGHI system is damaged or inactivated, the potABCD system might be able to compensate 
for its loss. When PotD and PotF are administered alone the generated immune response may 
be targeting one of these systems, perhaps allowing Brucella to compensate via a different 
mechanism. However, when the proteins are administered together the immune response 
should target both systems, causing a deficiency in polyamine import for the Brucella. Many of 
the more promising novel vaccine candidates developed against Brucella are also a 
combination of two antigens [47,75,199,370]. 
PotD and PotF were also tested as DNA vaccines to see if the antigens were protective when 
delivered by an alternative approach. The truncated PotD and PotF genes were inserted into 
the pcDNA3.1 DNA vaccine vector and their protective efficacy and immunogenicity was tested 
using the murine model of B. melitensis infection. The PotD and PotF DNA vaccines are poorly 
immunogenic since ex-vivo splenocytes from DNA immunised mice, when stimulated with PotD 
and PotF protein, produced very low levels of IFN-y. There was also no detectable antigen- 
specific antibody in serum removed from DNA-immunised mice. However, despite the fact that 
these DNA vaccines are poorly immunogenic, they provided some protective efficacy over a 
Brucella infection with PU of 2.08 (PotD) and 2.76 (PotF), although the protective efficacy of 
PotD was not significant when compared to the negative controls. With a 100-fold drop in 
bacterial load it is difficult to dismiss the PotD DNA vaccine as a potential DNA vaccine 
candidate without further analysis. When comparing the protective efficacy of PotD and PotF 
DNA vaccines to other DNA vaccine previously reported in the literature it is clear that they are 
very good candidates (Chapter 1, table 1.2, page 40). However, a direct comparison to other 
DNA vaccines is difficult due to differences in experimental techniques and Brucella species or 
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strains used. When comparing PotD and PotF to B. melitensis Omp25 and IaIB DNA vaccines 
(with PU of 2.54 and 2.70, respectively [59]), the data indicates that PotD and PotF are viable 
DNA vaccine candidates against B. melitensis, confirming PotD and PotF as novel sub-unit 
vaccine candidates against brucellosis. 
During the immunology studies completed in this chapter the number of IFN-y producing cells 
has been used as a measure of the strength of the immune response. This is because IFN-y 
production is a good indicator of a Th1 type immune response, which is considered the 
appropriate immune response for clearance of intracellular pathogens [292]. It has also been 
demonstrated that IFN-y production is crucial for survival of mice infected with Brucella as in its 
absence mice will die of brucellosis [229]. In both the PotD and PotF protein and DNA vaccine 
studies there have been different numbers of IFN-y producing cells generated. Mice immunised 
with PotD and PotF individually produced increased numbers of IFN-y producing cells and yet 
showed no protection, whereas mice immunised with the PotD and PotF DNA vaccine produced 
low but significant higher numbers of IFN-y producing cells and induced controlling levels of 
protection. This difference in the number of IFN-y producing cells reinforces the point that, 
although protective immunity is dependant upon the generation of IFN-y, the production of IFN-y 
alone does not always correlate with a protective immune response. A similar observation was 
made in Chapter 4 with the ZnuA vaccine candidate, where high numbers of IFN-y producing 
cells was observed and yet no protection was elicited. It has previously been demonstrated that 
other vaccine candidates are able to stimulate a strong IFN-y responses but elicit no protection 
[19,10,335]. The reason for the high immunogenicity of some of these candidates and yet their 
inability to elicit a protection is not fully understood. However, it could be that these antigens are 
not presented to the immune systems during Brucella infection or that they are not critical to 
Brucella survival, so if disabled by an immune response the Brucella are still infectious. 
The data generated in this chapter indicates that, in the correct protein formulation or as DNA 
vaccines, PotD and PotF should be considered as novel vaccine candidates against Brucella 
melitensis 16M. 
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Chapter 7- General Discussion 
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7.1 General discussion 
Brucella species are the causative agents of brucellosis and are endemic to the Middle East, 
Mexico, Asia, South America and the Mediterranean [251,130]. As brucellosis is classed as the 
world's most prevalent zoonotic disease, management of animal brucellosis is the best way to 
reduce the prevalence of human brucellosis. However, management of animal brucellosis 
requires strict control procedures and regulation of diagnostic testing, which in certain endemic 
areas is difficult to achieve. Although the use of live attenuated animal vaccines such as B. 
abortus RB51, B. melitensis Rev. 1 and B. abortus S19 is widespread in endemic areas these 
vaccines have drawbacks. Firstly, they can interfere with diagnostic testing, making it difficult to 
distinguish between vaccinated animals and naturally infected animals. Second, as these are 
live attenuated strains it has been shown that they can occasionally cause symptomatic 
infections in vaccinated animals [291,130]. Additionally these vaccines are still able to cause 
infection in humans, making their use as human vaccines impossible. It is clear from this that 
there is no vaccine for both animal and human brucellosis. The development of a novel vaccine 
against brucellosis would be of great use in endemic areas of the world. However, a new 
vaccine should ideally enable vaccinated animals to be distinguishable from naturally infected 
animals using current diagnostic tests. There should be no chance of the vaccine reverting to 
full virulence or causing infection and the vaccine should be licensable for human use. A novel 
sub-unit vaccine candidate offers the most potential to meet these criteria. 
The import and export of molecules across cell membranes is essential for bacterial survival, 
and ABC transporters are responsible for much of this movement [68]. ABC systems generally 
comprise two hydrophilic ABC domains associated with two hydrophobic membrane-spanning 
domains (inner membrane (IM) proteins). Import systems are only found in prokaryotic 
organisms and contain both ABC domains and IM domains, along with extra-cytoplasmic 
binding proteins (BP) adapted to bind the specific allocrite of that ABC system [68]. In Gram- 
negative bacteria, the BP are located in the periplasm whereas, in Gram-positive bacteria, they 
are anchored to the outer membrane of the cell via N-terminal lipid groups [261,370]. Research 
into the roles of ABC systems has indicated their potential as virulence factors or as protective 
antigens [130,316,295,112,160,115,218]. 
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The creation of inventories of all ABC systems within several genome sequenced strains of 
Brucella was described in Chapter 3. These inventories have identified potentially interesting 
differences between the Brucella species. Of the five Brucella strains studied, the four strains 
that are known to infect humans (B. melitensis, B. abortus, B. suis and occasionally B. canis) all 
have more ABC systems than B. ovis which is not known to infect humans. Some of the ABC 
systems absent in B. ovis but present in the other species have been studied in other bacterial 
species. For example, it has been demonstrated in E. coli that disruption of the CDI system 
(comprised of the FtsE, the ABC protein component, and FtsX, the inner membrane protein 
component) leads to a reduced growth capacity [286]. As B. ovis is the only Brucella strain 
studied that lacks the CDI system it is possible to theorise that it could be related to its reduced 
virulence, and therefore could be targeted in the other Brucella species as a potential virulence 
factor. 
After the completion of this work the B. melitensis 16M genome has been re-annotated. Thus, it 
is possible that this re-annotation might slightly change the ABC system inventory for B. 
melitensis 16M produced in this study. It should also be noted there that four further Brucella 
strains have been sequenced since this work was completed: B. melitensis ATCC 23475, B. 
abortus 2308, B. abortus S19 and B. suis biovar 2. It would be interesting to compile ABC 
systems inventories of these strains to see if any further differences can be identified. Among 
the newly sequenced strains is a strain from B. suis biovar 2, which is not known to cause 
disease in humans, and B. abortus S19, a vaccine strain. ABC system inventories of these 
strains would be of particular interest since they are considered less pathogenic than the wild- 
type strains and yet the reasons for this lack of pathogenicity are currently unknown. 
In this thesis the compilation of ABC system inventories of Brucella (Chapter 3) has provided a 
framework from which eight potential vaccine candidates (Chapter 4) could be selected and 
evaluated. In turn the preliminary evaluation led to further studies of the adjuvant system used 
and the protection demonstrated. Figure 7.1 summaries a schematic flow of the work in this 
thesis. This work contributes to studies in the Brucella field and in the wider field of sub-unit 
vaccine development (summarised in figure 7.2). 
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In this thesis, the ISCOMs and CpG combination used as an adjuvant in all protection studies 
has elicited a level of control over a Brucella infection. Chapter 5 attempted to understand this 
finding, highlighting that the use of ISCOMs and CpG in combination leads to a longer lasting 
immune response to a vaccine antigen than when administered separately. 
The use of CpGs as an adjuvant is well established and, although there are no directly licensed 
CpG products on the market, there have been a number of clinical trials evaluating their safety 
and efficacy [2,174,61,14,60]. Originally CpGs had a major limitation in that the phosphodiester 
backbone was extremely susceptible to nuclease breakdown, inactivating the stimulatory 
properties of the CpG [297]. Changing the phosphodiester backbone to a stronger 
phosphorothioate backbone has decreased the susceptibility to nuclease breakdown, although 
it still occurs at a reduced rate [187]. To overcome the pharmacokinetic problems associated 
with CpGs, studies are being carried out to enhance their properties, including coupling of CpG 
to a polysaccharide carrier such as a modified 0-(1-3)-D-glucan schizophyllan (SPG, an 
extracellular polysaccharide produced by the fungus Schizophyllan commune) [221], binding of 
CpG to cationic carbon nanotubes [27], packaging of CpG into fusogenic liposomes (FL, derived 
from conventional liposomes with an inactivated Sendai virus-derived accessory protein 
attached) or normal liposomes [366,354] and co-administration of CpG with polyphosphazenes 
(synthetic water-soluble, biogradable polymers) [230]. However, many of these methods 
involve modifying, coupling or packaging the CpG with other products, which might have 
implication for licensing and/or production of the CpG preparation. 
The use of dual adjuvants is not common. However, research using oil-based adjuvant systems 
with CpG has shown that the addition of CpG can enhance the immune response generated to 
vaccines [230,190]. The co-administration of ISCOMs and CpG as an adjuvant has also been 
used successfully to generate responses to vaccine antigens [130,98]. This study demonstrates 
for the first time that the combination of CpGs with ISCOMs stimulates a stronger and longer 
lasting immune response than CpG alone. The data generated shows that the administration of 
three doses of ISCOMs and CpG to mice leads to a strong immune response after the first 24 
hours, which would be expected from both of these adjuvants individually due to their 
immunostimulatory properties [173,298,7]. However, after two weeks this initial immune 
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response decreases before a further slow increase until six weeks after the final dose (Chapter 
5, section 5.3, pages 129 to 131). There is no known description of this pattern of immune 
response elicited by any other adjuvant. The ability to combine two current adjuvant 
technologies to generate a greater and longer immune response may be a particularly useful 
feature for the development of new combination adjuvants. 
Although ISCOMs and CpG have previously been used in combination as an adjuvant (130,98] 
this is the first demonstration of their use in combination with a vaccine candidate for 
brucellosis. Since this adjuvant is able to decrease the Brucella load in an immunised mouse by 
approximately 1 Log1o without the need for any other antigens, the use of ISCOMs and CpG 
adjuvant with novel vaccine candidates could help to increase their protective efficacy for 
brucellosis. For example, one of the most efficacious novel vaccine candidates against 
brucellosis in the literature is P39 (a putative periplasmic binding protein) [10]. Three doses of 
20 pg P39 protein were administered to Balb/C mice adjuvanted with 20 pg of CpG at three 
week intervals. Three weeks after their final inoculation mice were challenge with 5x104 CFU of 
B. abortus 544, and then at four weeks and eight weeks later mice were culled and the Brucella 
burden was assessed by splenic colonisation assays. The adjuvanted vaccine candidate P39 + 
CpG elicited a PU of 2.48 at four weeks and 1.21 at 8 weeks (10]. It is possible that a 
combination of ISCOMs and CpG used as an adjuvant might significantly enhance the PU value 
at four weeks, since Chapter 5 showed that mice had increased immune responses at six 
weeks post final inoculation with ISCOMs and CpG. It is possible that, at eight weeks post 
challenge, mice immunised with P39 might also have improved PU values. 
Vaccine development in the Brucella field focuses mainly on sub-unit vaccine development or 
the creation of attenuated mutants as potential vaccines. The problems associated with newly 
created attenuated mutants are similar to those of the current live attenuated vaccines so, 
unless they are well characterised and have multiple gene knockouts, then they are considered 
unlikely to be licensable for human use. Due to the limitations of attenuated vaccines the aim of 
this project was to select, produce and evaluate ABC transporter proteins as potential sub-unit 
vaccines against B. melitensis. The Brucella ABC system inventories generated in Chapter 3, 
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coupled with published literature enabled the identification of potential sub-unit vaccine 
candidates. 
The selection of the vaccine candidates was achieved through the identification of ABC 
transporter proteins with homologies to already identified ABC transporter vaccine candidates 
for other pathogens (PotD [295], PotF [130], WE [130] and OppA [316]) or ABC transporter 
proteins identified in Brucella that might be involved in virulence (Cgt [277], ZnuA [164,363], 
CydD [93] and FbpA [94]). All eight of the ABC transporter proteins were evaluated using the 
murine model of B. melitensis infection and, of these, two proteins (PotD 3.61 PU and PotF 2.51 
PU) were identified as candidate novel protective antigens against B. melitensis challenge. 
Further testing of the PotD and PotF proteins yielded results indicating that PotD (-0.28 PU and 
- 0.43 PU) and PotF (0.48 PU) might not be protective antigens when administered alone. CD 
analysis confirmed that there were structural differences between the protein batches, which 
was thought could be the reason for the differing protection results. Due to the structural 
differences of the protein batches, the PotD and PotF antigens were tested as DNA vaccines, 
the results of which indicated that both PotD and PotF DNA vaccine induced at least a 2-log 
reduction in Brucella spleen load (2.08 PU PotD DNA vaccine and 2.76 PU PotF DNA vaccine). 
Subsequently, a re-evaluation of PotD and PotF in the folded conformation revealed that, when 
administered alone, PotD and PotF induce no protective immunity (PotD 0.02 PU and PotF - 
0.62 PU) whereas, when administered as a multivalent vaccine combination, PotD and PotF 
induce significant protection (3.01 PU). 
Due to the variation observed in all the animal studies it is difficult to fully understand the 
potential of PotD and PotF as novel vaccine candidates. The variation in protective efficacy 
observed between the PotD and PotF protein experiments in Chapter 4 (protective) and Chapter 
6 (non-protective) could be attributed to the E. co/i endotoxin present in the original batches of 
protein used in Chapter 4. Endotoxin is a potent stimulator of the immune system via TLR4 
activation, which can start a non-specific inflammatory immune response. The endotoxin could 
have provided a boost to the immune response needed to induce a protective immune response 
when mice were administered the PotD and PotF proteins in Chapter 4. The intergroup variation 
observed when PotD and PotF were used as DNA vaccine could be attributed to the 
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intramuscular injections. When administering a dose of 50 pI i. m. to a mouse it is possible that a 
large proportion of the volume (< 30 pl) does not go into the muscle tissue. During DNA 
vaccination it is imperative that the DNA vaccine goes into the muscle as it needs to be taken up 
by myocytes for effective expression/presentation to occur. Without effective 
expression/presentation any immune response generated will be very weak, as seen with PotD 
and PotF DNA vaccines. Perhaps a gene gun delivery of the PotD and PotF DNA vaccine might 
increase their efficacy as it is direct inoculation into cells via the skin. The combination of 
PotD/PotF protein works well as a multivalent vaccine which is potentially due to there being 
twice as much protein present than when the proteins are administered individually. However, 
the data generated from the immune response studies did not indicate that a stronger immune 
response was being generated by immunisation with twice as much protein. The reason for the 
protection observed from the PotD/PotF combination could be due to the generation of a 
memory response to two different Brucella antigens meaning that during a Brucella infection a 
second exposure to either PotD or PotF would result is a strong memory immune response. It is 
clear that a repeat study is needed to confirm the PotD/PotF combination protection but this 
work clearly indication these proteins have potential as novel vaccine candidates to Brucella. 
This is the first example of the use of ABC transporter proteins as a novel vaccine candidates 
for brucellosis. Although there has been conflicting data generated in this study, PotD (2.08 PU) 
and PotF (2.76 PU) DNA vaccines and the PotD/PotF protein combination (3.01 PU) have been 
shown to reduce bacterial burdens after an experimental B. melitensis 16M challenge. A 
comparison of the data generated from these trials against other protein or DNA vaccine 
candidates described in the open literature (Chapter 1, table 1.1 and 1.2, pages 32 and 37) 
reveals that PotD and PotF should be considered among the best newly identified potential 
vaccine candidates against brucellosis. In fact, a comparison of the PotD/PotF protein 
combination to the other proteins tested against B. melitensis indicates that the PotD/PotF 
protein combination is the best candidate currently identified [46]. 
The PotD and PotF proteins have been identified as novel vaccine candidates for other 
pathogens, specifically S. pneumoniae (295,294] and B. pseudomallei (130]. Sub-cutaneous 
inoculation of CBA/CaHN-Brl<xd mice with three doses of 5 pg of S. pneumoniae PotD protein 
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adjuvanted with 1 mg/ml alum provided protection from experimental challenge of 104 CFU of S. 
pneumoniae WU2 [295]. More recently, the S. pneumoniae PotD was shown also elicit 
protection when administered via the intranasal route [294]. Similarly, mice inoculated via the 
intraperitoneal route with three doses of 10 pg of B. pseudomallei PotF adjuvanted with 
ISCOMs and CpG were protected from experimental challenge with 4x104 CFU of B. 
pseudomallei K96243. Thus, this study describes a third example of the use of putative 
polyamine transporters as potential sub-unit vaccines against human and animal pathogens 
[295,130], indicating that polyamine transporters could be considered globally important 
virulence factors for bacteria. 
There are four microbial polyamines, putrescine, spermidine, spermine and cadaverine, which 
are essential small molecules that have diverse functions. For example, the roles of polyamines 
include binding to RNA in conjunction with magnesium ions to stabilise higher order structures 
such as ribosomes (which increases the accuracy of codon translation during protein synthesis) 
[145] and the interactions with outer membrane porins, resulting in porin closure which 
decreases outer membrane permeability [147]. The addition of putrescine to growth media can 
also resolve virulence gene expression in Shigella flexneria mutants unable to make 
nucleosides needed for translational RNA synthesis [86]. The acquisition of polyamines by 
bacteria takes place via two main channels: de novo synthesis via the breakdown of amino 
acids L-arginine, L-ornithine, L-lysine and L-methionine or import from the environment using 
the two ABC transporters potABCD or potFGHI [296]. The de novo synthesis of polyamines in 
E. coli is complex. The synthesis of putrescine from L-arginine requires the enzymes SpeA 
(arginine decarboxylase) and SpeB (agmatine ureohydrolase). The synthesis of putrescine from 
L-ornithine requires the SpeC (ornithine decarboxylase) enzyme. Spermidine can be 
synthesised directly from putrescine using the SpeE (spermidine synthase) enzyme or from L- 
methionine using SpeD (S-adenosylmethionine decarboxylase) and MetK (methionine 
adenosyltransferase). Production of cadaverine from L-lysine uses the CadA (lysine 
decarboxylase) enzyme [312,313,296,226]. A search for these enzymes in the B. melitensis 
16M genomes (using http: //patric. vbi. vt. edu) reveals that B. melitensis 16M has only four of 
these enzymes, SpeA, SpeC, MetK and CadA, meaning B. melitensis 16M is likely to be able to 
synthesis cadaverine from L-lysine and putrescine from L-ornithine. Studies in E. coli have 
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shown that mutants in de novo synthesis grow slower than wild-type E. coli [314,126] and, 
similarly, mutants in polyamine transport systems also grow at slower rates that their wild-type 
strains in vitro [161]. These finding indicate that E. coli might depend upon both de novo 
synthesis and the transport of polyamines for optimal growth. It has also been demonstrated 
that Agrobacterium tumefaciens (a relative of Brucella in the a-proteobacteria) requires the 
potB, potH, potC and potl genes for effective virulence in dicotyledonous plants [208]. This 
indicates that Brucella might require both the de novo synthesis pathways and ABC transporter 
systems for optimal growth. Thus, when one or both of the polyamine ABC transporter systems 
in Brucella is targeted by the immune response there may be deficient import of polyamines. In 
turn, this may lead to a reduced growth rate and therefore increased susceptibility to the 
immune system. Polyamine transport systems have been identified in other human pathogens 
such as Shigella species [348,362], Salmonella species [210,211], Treponema pallidum (202], 
Yesinia pestis [80], Bacillus anthracis [270] and many others [296]. It is possible that these 
organisms have both the de novo synthesis pathways and the ABC transporter systems. It 
would be interesting to evaluate their ABC transporter proteins as vaccine candidates based on 
the findings in this study and other published literature [295,294,130]. 
7.2 Further studies with PotD and PotF proteins or DNA vaccines 
The construction and evaluation of DNA vaccine expressing PotD or PotF is described in 
Chapter 6. The basic pcDNA3.1 mammalian DNA vaccine expression vector [59,199,370] was 
used to enable protein expression in mammalian host cells. However, more advanced DNA 
vaccine vectors may be more effective at inducing strong immune responses. For example, 
DNA vaccines are being developed that enhance MHC class I or MHC class II antigen 
processing and therefore influence the type of immune response generated by DNA vaccines 
[351,184]. Targeting the DNA vaccine products to different intracellular destinations also leads 
to different MHC class processing which, in turn, leads to different types of immune response. 
For example, fusing DNA vaccine products with a signal sequence such as tissue plasminogen 
activator (TPA) [374], endosomal targeting of DNA vaccine products via LAMP-1 signalling [349] 
proteosomal targeting using murine ubiquitin A76 [74] or endoplasmic reticulum targeting [360] 
are all approaches that enhance or alter the type of immune response generated. Endosomal 
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targeting can increase MHC class II presentation leading to an increased CD4' T cell mediated 
immune response, whereas proteosomal targeting enhances entry to the degradation pathway 
leading to an increase in MHC class I presentation, therefore increasing the activity of CD8' T 
cells [351]. It is possible that developing PotD and PotF DNA vaccines that are targeted to the 
endosome may increase MHC class II presentation, leading to increased Th1 or Th2 cell 
activation which could increase cellular and humoral immune responses. In comparison, PotD 
and PotF DNA vaccines targeted to the proteosome might increase MHC I presentation, which 
increases the CD8+ T cell activation and therefore killing of infected cells. Both of these 
strategies could lead to an increased immune response, in turn leading to an improved 
protective efficacy. 
Another approach to increasing the protective efficacy of the PotD and PotF DNA vaccines 
would be to construct a multivalent DNA vaccine encoding both the PotD and PotF genes. Luo 
et al. created a divalent DNA vaccine for brucellosis encoding two known partially protective 
antigens, L7/L12 and Omp16 [199). In their study mice immunised intramuscularly with three 
doses of 100 pg of L7/L12, Omp16 or L7/12-Omp16 DNA vaccines all had significantly less 
Brucella in their spleens at four weeks after challenge. Importantly, mice immunised with the 
divalent L7/L12-Ompl6 DNA vaccine showed greater protection than mice dosed with the 
individual DNA vaccines. However, the creation of divalent DNA vaccines can be complicated 
and some studies have shown that simply inoculating with a mixture of DNA vaccines encoding 
different antigens can also achieve increased levels of protective efficacy. For example, Yu et 
al. mixed three DNA vaccines encoding the partially protective antigens L7/L12 (1.26 PU) [176J, 
superoxide dismutase (SOD, 1.52 PU) [227] and a 31 kDa Brucel/a protein (BCSP31,1.30 PU) 
[50], and achieved 3.58 PU against experimental B. abortus 2308 challenge. This indicates that 
a divalent DNA vaccine or a mixture of the PotD and PotF DNA vaccines might be more 
effective than the DNA vaccines administered separately. This may correlate to the finding that 
when PotD and PotF proteins are administered together, high levels of protection against 
brucellosis are observed. 
Due to the variation observed in some of the animal studies in this work further studies would 
include a repeat evaluation of the PotD/PotF combined protein vaccine candidate to confirm its 
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protective efficacy. Subsequently, studies could aim to optimise/improve the protective efficacy 
of the PotD/PotF combined vaccine. There are several examples of novel multivalent sub-unit 
vaccines described [33,141,209,318,373], including the novel plague vaccine comprising the F1 
and V antigens of Y. pestis [321]. Approaches used to increase the protective efficacy of the F1 
and V antigens could be transferred to PotD and PotF to improve upon their protective efficacy. 
One of the methods used to optimise the protective efficacy of the vaccine was to evaluate 
different adjuvants including Incomplete Freunds adjuvant [352], the Ribi adjuvant system [91] 
and Alhydrogel [353]. However, for the Y. pestis vaccine, the choice of adjuvant had no effect 
on its protective efficacy, and therefore Alhydrogel was chosen as it is the only widely licensed 
adjuvant for human use. Although the use of different adjuvants was initiated in Chapter 6 
(using the PotD and PotF proteins in the incorrect conformational), and it would be useful to 
repeat this study with the PotD/PotF protein combination vaccine. Another approach that could 
be advantageous for the PotD and PotF vaccine candidates would be a DNA vaccine prime, 
protein boost study. The data in this study has shown that both the PotD and PotF DNA 
vaccines and the PotD and PotF proteins have potential as novel vaccine candidates. If 
administered in a prime boost strategy this might increase the protective efficacy observed from 
the DNA vaccines or proteins when inoculated individually. 
Another vaccine technology that would be interesting to explore with PotD and PotF would be 
the creation of a Salmonella-based delivery system. This approach offers a number of 
advantages. Firstly, Salmonella-based delivery systems can be administered orally (a natural 
route of infection for both Salmonella and Brucella). Second, since this type of vaccine uses live 
attenuated bacterial strains of Salmonella for expression of heterologous antigens, cellular 
immune response can be induced. Additionally, there are live attenuated strains of Salmonella 
typhi being developed for use as oral vaccine delivery systems, meaning that the development 
of safe licensable Salmonella vaccines is possible [116,111]. This approach has been shown to 
work with other well developed vaccine antigens, including the Protective Antigen (PA) of B. 
anthracis [309] and the F1 and V antigens of Y. pestis [38,320]. 
Using the approaches described above it may be possible to improve the protective efficacy 
elicited by PotD or PotF based vaccines. Subsequently, an assessment of optimised vaccine 
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candidates in different models of infection could be possible. Animal models of infection with 
injected or aerosolised Brucella have been developed making it possible to test vaccines 
against infection by different routes [156,2991. This would be important in the development of a 
PotD and PotF vaccine, as it would be desirable to achieve protection via different natural 
infection routes. In addition to B. melitensis, it would also be important to test the efficacy of the 
vaccines against the other economically important species of Brucella such as B. abortus and B. 
suis. A further goal for any developed vaccine candidate would be to test its protective efficacy 
in a larger natural brucellosis host such as the goat [89,157). 
Once a sub-unit vaccine has been developed for brucellosis then the search for accurate 
correlates of protection could start. A correlate of protection is a measurable sign of immunity to 
a pathogen. For example, immunisation with the PA vaccine for anthrax elicits a strong antibody 
response, and measurement of the concentration and neutralisation titre of the antibody 
produced provides a measure of the protection that an individual may have (2711. As Brucella 
are intracellular pathogens, antibody responses are likely not to be useful as a correlate of 
protection, as cellular response are likely to contribute to the protection against brucellosis. 
The cytokine IFN-y is often used as a measure of the immune response to vaccine candidates 
for brucellosis because IFN-y is critical in the Brucella immune response [229]. Although the 
presence of IFN-y is important in brucellosis, this work confirms other studies that show that the 
presence of IFN-y alone does not serve as a correlate of protection 159,19.101. Paranavitana et 
al. have studied cytokine and chemokine profiles of mice orally immunised with Brucella in 
search of a correlate of protection for brucellosis and, although their data showed an interesting 
range of cytokines and chemokines are generated, no clear correlates of protection were found 
[254]. A novel approach that could be used to create a fingerprint of a protective immune 
response to brucellosis would be microarray technology. Using a whole mouse genome 
microarray [45] to profile the genes that are switched on or off during a protective immune 
response might provide a way of finding an accurate correlate of protection. Studies to profile 
the genes that are activated in mouse J774A. 1 and RAW264.7 macrophages upon infection 
with Brucella represent a start for this type of protective profile (95,133). The search for a 
correlate of protection for a disease like brucellosis might be extremely difficult due to its 
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complex nature. It may be appropriate, therefore, to initiate correlate of protection studies once 
a next generation sub-unit vaccine has been developed that provides consistent protection. 
In summary, this work has identified the first known putative ABC transporter proteins (PotD and 
PotF) as novel vaccine candidates for B. melitensis 16M. It has also reinforced the idea that 
polyamines and polyamine transporters might have roles in bacterial virulence and 
pathogenicity [296,295,294,130] and are targets for vaccine development. Additionally, this 
work has evaluated a combination adjuvant in ISCOMs and CpG that could prove to be a more 
effective vaccine adjuvant for intracellular pathogens. Overall, there are a number of further 
studies that should be completed with PotD and PotF to fully understand their protective 
efficacy, but this work describes the first step in exploiting them as potential sub-unit vaccines 
for Brucella. 
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ABC system families/subfamilies found in Brucella species and their respective function 
Name Descri tion and Function Family Sub-Famil p 
Exporters (Predicted and Experimental) 
HMT Mitochondrial and bacterial transporters II 
CHV Beta 1---2 Gulcan export 
DPL, Drugs, Peptides, MDL Mitochondrial and bacterial transporters I 
Lipids LIP Lipid A or I cero hos holi id export 
PRT Proteases, Li ases S-Layer protein export 
CYD Cytochrome bd biogenesis 
CCM Cytochrome C biogenesis 
CLS 
Capsular polysaccharide, lipopolysaccharide and teichoic 
acids 
FAE Fatty Acid Export 
Importers 
DLM D- L-Methionine and derivatives 
CBY CBU Cobalt uptake, putative 
MKL Related to MOI family but unknown substrate 
YHBG Related to HAA family, but unknown substrate 
CDI Cell division 
MET Metals 
MOS Monosaccharides 
MOI Mineral and Organic ions 
PAO Polar amino acids and Opines 
HAA Hydrophobic amino acids and amides 
OSP Oli osaccharides and polyols 
OPN Oli oe tides and Nickel 
OTCN Osmoprotectants Taurine Cyanate and Nitrate 
ISVH Iron-Siderophores VitaminB-12 and Hemin 
Cellular Process (Experimental) 
ISB Iron-sulphur centre biogenesis 
ART, Antibiotic 
resistance and 
translation regulation 
REG Translation regulation 
UVR DNA repair and dru resistance 
Unknown 
DRI Drug resistance YHIH Drug resistance, putative , , bacteriocin and 
lantibiotic immunity NOS Possible nitrous oxide reduction 
NO Unclassified Systems 
0228 Unknown 
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